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Abstract
Survivors of acute myocardial infarction (MI) have a high risk of developing chronic
heart failure (CHF). In human CHF there is evidence that plasma levels of the potent
vasoconstrictor peptide, endothelin (ET)-l and its precursor big ET-1 are increased,
correlate positively with disease severity, and may be important predictors of
outcome. The aims of this thesis were to investigate the heart as a source of ET-1
synthesis and to investigate the role of the cardiac ET-1 system during scar formation
in the early stage post-MI and also during progression of CHF in a rat model. MI in
the rat was induced by surgical ligation of the left anterior descending coronary
artery. The myocardial ET system was investigated using immunohistochemical and
in situ hybridisation techniques.
In the normal heart, immunoreactive ET-1 was identified in the vascular endothelium
and myoendothelial cells in the myocardium. Staining for ET-1 was intense and
uniform in cardiomyocytes throughout the myocardium. In situ hybridisation
confirmed that sites of preproET-1 mRNA expression coincided with sites of
immunoreactive ET-1. These results indicate that the myocardium has the capacity to
endogenously produce ET-1 in both myoendothelial cells and cardiomyocytes.
Investigation of ET-1 immunoreactivity during scar formation 2, 7 and 14 days post-
MI indicated an early transient increase in ET-1 in the infarct, which peaks at 7 days.
At this time point, ET-1 could be localised to proliferating fibroblasts, infiltrating
inflammatory cells and in the endothelia of newly forming vessels, suggesting a role
for ET-1 in scar formation early post-MI.
Though increased ET-1 staining could be localised at a cellular level in the
developing infarct, further studies were needed to identify whether ET-1 was
beneficial or detrimental during scar formation. Therefore, the effect on early stage
scar formation of an ETa/b receptor antagonist (A-182086) fed to rats immediately
after coronary artery ligation surgery and for the duration (2, 7 or 14 days) of the
study was investigated. In rats treated with antagonist, viable myocardial content of
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the infarcted region was significantly greater at both 7 and 14 days post-MI
compared to untreated rats. The salvaged myocardium also demonstrated a vascular
supply and ET-1 immunoreactivity similar to that observed in normal viable
myocardium from sham-operated rats.
In rat hearts 5 and 12 weeks post-MI, the area of infarction induced by coronary
artery ligation had formed a fibrosed scar. ET-1 staining was located uniformly in all
non-infarcted areas of the heart, but only in the few remaining viable myocytes in the
infarcted region. PreproET-1 mRNA expression matched ET-1
immunohistochemical visualisation in all areas of the heart. ETa receptor expression
was similar in the non-infarcted areas of post-MI rat hearts compared to that in areas
from age-matched sham-operated rat hearts. However, ETb receptor expression and
ETb immunoreactivity were increased in the non-infarcted areas of rat hearts at 12
weeks but not 5 weeks post MI and co-localised with an increase in the
transcriptional growth factor ERK.
These results suggest that the heart has the capacity to endogenously produce ET-1
and that changes in the ET-1 system occur at different stages post-MI. Furthermore,
these changes may be detrimental to acute myocardial cell survival post-MI, and in
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1.1 Anatomy and physiology of the normal working heart
The heart and blood vessels comprise the circulation system whose basic function is
to pump blood and provide adequate flow to the various organs in the body, thereby
maintaining oxygen and substrates while removing metabolites and other materials.
The wall of the heart is split into three layers, the inner endocardium which consists
of simple squamous epithelium and a layer of connective tissue; the middle layer,
myocardium, which contains a layer of cardiac muscle, and finally the outer
pericardium, a two layered serous membrane enclosing the whole heart (reviewed by
MacKenna & Calander, 1997). The myocardium consists ofmany different groups of
cells including 'working' myocardial cells, specialised 'conducting' cells, and
vascular and connective tissue. Working cells predominantly consist of cardiac
myocytes, which occupy 75% of the myocardial space. The individual ventricular
myocytes that account for more than half of the heart's weight are roughly
cylindrical in shape and measure about 10-25pm in diameter and about 50-100pm in
length (Moody et al., 1990). Those in the atrium are smaller, being less than 10pm in
diameter and about 20pm in length. Although there are many different cell types in
the heart, it is the ventricular myocytes that, by their contraction, propel blood
around the heart.
A collagen network, composed largely of type I and III fibrillar collagens, is found in
the extracellular space of the myocardium (Weber et al., 1994). Collagen fibres
course through the myocardium surrounding and grouping muscle fibres into
bundles. Collagen also surrounds individual myocytes connecting them to one
another and to their neighbouring capillaries. Support and alignment of myocytes,
blood vessels and lymphatic vessels relative to one another preserve myocardial
thickness and architecture. The network also prevents cardiac myocyte slippage and
myocytes from overstretching, while being the basis for diastolic myocardial
stiffness and adding tensile strength to the myocardium to prevent rupture. Overall,
the collagen network preserves architecture and stiffness of the myocardium, and the
geometry of ventricular chambers would be weakened without it.
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Other components of cardiac connective tissue include fibroblasts, which are
mesenchymal cells that potentially produce components of the extracellular matrix
including collagen and fibronectin. The matrix metalloproteases include various
enzymes (such as collagenase) that break down all the types of collagen as well as
other components of the extracellular matrix including laminin, fibronectin and other
glycoproteins. The balance between the synthesis of extracellular matrix collagen by
various growth factors and neurohormonal peptides versus degradation by the
metalloproteases has important implications for the mechanical properties and hence
the function of the myocardium.
Vascular smooth muscle cells are found in epicardial and intramyocardial coronary
arteries and are different in shape and function from striated myocardial cells. These
cells are adapted to much slower rates of contraction and relaxation and to the
maintenance of sustained tonic contractions. Their major function directly on the
heart is to maintain coronary vascular tone while indirectly, through regulation of
peripheral vascular resistance, controlling the resistance against which the heart
pumps out blood. Vascular smooth muscle cells, like endothelial cells and
fibroblasts, are capable of re-entering the cell cycle and can therefore undergo
mitosis and hyperplastic growth. On the other hand, adult cardiomyocytes are
thought to be terminally differentiated and, therefore, do not proliferate (Weber &
Brilla, 1991).
Because work production and energy requirement of the heart vary so much from
rest to exercise, there must be some system of variable oxygen delivery to the
myocardium. Blood reaches the cardiac myocytes via the coronary circulation. Two
major coronary arteries run from the base of the aorta to the left and right ventricles,
respectively, before giving off branches that run down the surface of the heart toward
the apex. The major branch of the left coronary artery, which supplies the left
ventricle, is the left anterior descending coronary artery (Figure 1.1).
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Figure 1.1 Diagram ofheart showing the major coronary vessels that supply blood

















The control of the myocardial oxygen supply lies in the coronary arterioles, which
keep branching until the very small, thinned-walled capillaries are formed. It is here
that transfer of oxygen from oxygenated arterial blood to the myocardial tissues
occurs. Endothelial cells in the atrial and ventricular myocardium form the lining of
both coronary vessels and the fine coronary capillary network that runs thoughout the
myocardium, these endothelial cells being termed myoendothelial cells. At the level
of the coronary microvasculature, there is close contact between endothelial cells and
cardiac myocytes throughout the heart, with no cardiac myocyte being more than 2-
3pm from a coronary vasculature endothelial cell.
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1.1.1 The Cardiac Cycle
The interrelationship amongst electrical, mechanical and valvular events during one
complete heartbeat is referred to as the cardiac cycle. The rhythmicity of cardiac
muscle contraction is normally controlled by the electrical activity of the heart
initiated by pacemaker cells in the specialised myocardial cells of the conducting
system. In a normal human heart, action potentials originate at a rate of about 100 per
minute in the sino-atrial node, located in the right atrium near the entrance of the
superior vena cava. From there they are conducted along the plasma membrane from
one atrial cell to another via three conducting pathways causing both atria to contract
almost simultaneously. The pathways merge at the next node, the atrioventricular
(AV) node, which is located in the atrioventricular fibrous ring on the right side of
the atrial septum. The AV node is the only electrical pathway from atria to ventricles
through the insulating fibrous ring. From the AV node action potentials travel at
speeds of lm/s in the Purkinje fibres of the bundle of His along the right and left
branches down the ventricular septum. Excitation reaches all parts of both ventricles
rapidly causing an increase in myocyte intracellular calcium concentration in the
vicinity of the sarcoplasmic reticulum (SR). This leads to the release of large
amounts of calcium from the SR that reacts with the contractile proteins of the
myofibrils causing contraction.
1.1.2 Neurohormonal regulation in the normal heart.
1.1.2.1 Control ofheart rate
The heart rate of a resting adult human is 50-100 beats/minute while in small
mammals it is faster (e.g. rat, 400-500 beats/minute). Autonomic control of the heart
is split into two components, the parasympathetic nervous system, which decreases
heart rate and the sympathetic nervous system, which increases heart rate. The
parasympathetic fibres to the heart are carried by the vagus nerve. Parasympathetic
nerve terminals act by releasing the neurotransmitter acetylcholine, which binds to
muscarinic receptors, leading to a fall in intracellular cyclic 3',5'-adenosine
monophosphate (cAMP) and reduced activation of sodium channels involved in
5
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propagation of the depolarising inward pacemaker current. Unlike the
parasympathetic fibres, sympathetic fibres richly innervate ventricular muscle as well
as the atria and electrical system. The sympathetic nerve terminals act by releasing
the neurotransmitter noradrenaline. Noradrenaline binds to (3j-adrenoreceptors on the
pacemaker cell membrane increasing intracellular cAMP, and over the course of
several beats this leads to an increase in firing rate.
1.1.2.2 Control ofstroke volume
Changes in the force of contraction can be produced by a variety of factors, but two
are dominant under most physiological conditions: (1) changes in end-diastolic
volume, that is, the volume of blood in the ventricles just before contraction; and (2)
changes in the magnitude of sympathetic nervous system input to the ventricles. The
relationship between stroke volume and end-diastolic volume is known as Starling's
law of the heart. This law states that an increase in venous return automatically
forces an increase in cardiac output by increasing end-diastolic volume and hence
stroke volume {Figure 1.2). As normal cardiac muscle is stretched, contractile force
continuously rises to reach a maximum, but further stretch causes no decline in
contractile force.
Figure 1.2 The Frank-Starling curve under normal conditions (red), and under
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Stimulation by the sympathetic nerves (via noradrenaline) increases ventricular
contractility. The Frank-Starling mechanism still applies, but during nerve
stimulation the stroke volume is greater at any given end-diastolic ventricular
volume. Therefore, increased contractility leads to a more complete ejection of the
end-diastolic ventricular volume.
1.1.3 Autocrine and paracrine modulation of myocardial function
The contribution of endogenous angiotensin (Ang) II to the physiological regulation
of cardiac contractile function remains uncertain, though a locally active renin-
angiotensin system is now known to be present within the human and animal heart
(reviewed by Danser et al., 1999) and is involved in disease states such as left
ventricular hypertrophy and congestive heart failure (Lijnen. & Petrov, 1999; Kim &
Iwao, 2000). Ang II is formed from Ang I by the activity of two major enzymes,
angiotensin converting enzyme (ACE) and heart chymase (Urata et al., 1991). ACE
present in endothelial cells and cardiac myocytes in the heart (Hokimoto et al., 1996;
Paul et al., 1996) also has kininase activity, thus modulating local levels of
bradykinin as well as Ang I and II. Sacrolemmal receptors for Ang II are present on
cardiac myocytes (Sadoshima & Izumo, 1993). Ang II is a direct positive inotrope
and also facilitates sympathetic nervous influences on the heart (Paul et al., 1992).
The biological effects of bradykinin (BK) are mediated through specific receptors,
classified as BKi and BK2. BK2 mediates most of the known cardiovascular effects
of kinins. Activation of the receptor stimulates endogenous nitric oxide synthase
(NOS), thus increasing levels of the vasodilator factor nitric oxide (NO) and
counteracting the effects of Ang II. Both BK2 receptors (Minshall et al., 1995) and
NOS activity have been detected in cardiac myocytes (Stein et al., 1996), and an
intact kallikrein/kinin system has been found in the heart (Nolly et al., 1997).
Literature (reviewed by Nambi et al., 1992) suggests that a normally functioning
BK2 receptor is needed for the maintenance of normal blood pressure homeostasis
and that inactivation of the receptor could contribute to the development of
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hypertension by leaving the activity of endogenous vasoconstrictor agents
unopposed.
The family of natriuretic peptides which include atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) are both expressed in the heart, with alterations
occurring during development and in disease states (reviewed by Forssmann et al.,
1998). Atrial cells store and release ANP, which has powerful effects on the kidney,
stimulating sodium and water excretion, and the vasculature mediating
vasorelaxation. Release of ANP occurs in response to stretching of the atria by
increased central venous pressure, signalling volume overload of the circulation.
Unlike ANP, produced by the atria, BNP is mainly synthesised and released into the
circulation by the left ventricle and is therefore influenced by stimuli involving this
cardiac chamber, such as an increase in arterial pressure, left ventricular hypertrophy
and dilation. Both peptides exert their effects by combining with membrane receptors
on vascular endothelial cells leading to generation of cyclic 3',5'guanosine
monophoshpate (cGMP) and vasorelaxation, similar to the pathway activated by NO.
Plasma BNP levels are very low in healthy subjects, and respond modestly, but
significantly to physiological stimuli such as changes in posture or sodium intake (La
Villa et al., 1995).
Effects of endothelin-1 on the heart will be discussed in Section 1.2.5.2.
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1.2 The Endothelin Family
1.2.1 Discovery and Background
Past experiments on isolated arteries and veins have shown that either hypoxia
(Rubanyi & Vanhoutte, 1985) or anoxia (Demay, & Vanhoutte 1983; Detar & Bohr,
1972) could induce endothelium-dependent contractions. In 1985, Hickey et al.
demonstrated that a culture medium of bovine aortic endothelial cells triggered a
slowly developing and long lasting contraction of isolated pig arteries, which could
not be attributed to any known vasoconstrictor mediators and was peptidergic in
nature. A subsequent study confirmed this observation (Gillespie et al., 1986).
In 1988, Yanagisawa et al. reported that this endothelium-derived factor, one of the
most potent constrictors described to date, was a 21 amino acid peptide, which they
termed endothelin (ET; (Yanagisawa et al., 1988)). The EC50 value of the
vasoconstrictor activity of ET-1 in porcine coronary artery measured by Yanagisawa
et al. (1988) was 3xlO"'°M. This value is about 100-fold more potent than that of
Ang II, which was the most potent vasoconstrictor peptide until that time.
Subsequent studies have shown that ET-1 isolated from endothelial cells is one of a
family of isopeptides (Figure 1.3), all of which are formed through a three-step
processing pathway from their respective precursor peptides (.Figure 1.4) that share
high sequence homology, but are encoded by distinct genes. Four isopeptides (ET-1,
ET-11.31, ET-2 and ET-3) have now been identified in the ET family; predicted by
three separate genes, of which ET-1 is the most potent in the cardiovascular system.
ET-1 was primarily identified in endothelial cells, though later studies have also
identified ET-1 in rat (Giaid et al., 1991), human (Giaid et al., 1995) and porcine
(Tonnessen et al., 1995) cardiomyocytes and in vitro studies have established
stimulated production of ET-1 in smooth muscle cells under pathological conditions
(Hanehira et al., 1997).
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Figure 1.3 Structures of the three human endothelin peptides and Sarafotoxin S6c.
The shaded circles indicate the amino acids that differ from that ofendothelin-1. The
lines indicate disulphide bridges linking cysteine amino acids between residues 1 &









It is now also clear that the ET isopeptides share a close structural similarity to the
sarafotoxins (SRTXs; see Figure 1.3), peptides isolated from the venom of the Israeli
burrowing asp Atractaspis engaddensis (Kloog et al., 1988). The ETs and the SRTXs
act through common receptors to evoke a multitude of effects. Isoforms of SRTX
have also been utilised extensively as tools for the characterisation of ET receptors
(Sokolovsky, 1994). Though there are four identified isopeptides in the ET family,
studies in this thesis will investigate the actions of the ET-1 peptide only.
1.2.2 Regulation of ET-1 synthesis
Extracellular factors can influence ET-1 generation both positively and negatively
through a series of intracellular mediators that modulate gene transcription.
PreproET-1 mRNA expression can be activated in endothelial cells and
cardiomyocytes in response to such stimuli as hypoxia (Hu et al., 1998), growth
factors (Battistini et al., 1993), cytokines (Molet et al., 2000), thrombin (Golden et
al., 1998), Ang II, vasopressin and noradrenaline (Imai, T. et al., 1992; Hanehira, T.
et al., 1997; McEwan, P.E. et al., 2000).
Several recent studies also suggest that activation of ET-1 is associated with a
deficiency of the NO pathway. Kourembanas et al. (1997) demonstrated that
suppression of baseline NO levels in vitro using a NOS inhibitor in endothelial cells
from normotensive rats led to a 3-fold increase in baseline ET-1 levels. Increased
ET-1 gene expression was further demonstrated via blocking of endogenous NO
using a NOS inhibitor in hypertensive rats in vivo (Tharaux et al., 1999).
Interestingly, shear stress has been shown to induce a sustained suppression,
preceded by an early transient upregulation, in ET-1 gene expression in endothelial
cells (Malek et al., 1999). Stimulation of cGMP-mediated inhibition of
phosphatidylinositol metabolism has been implicated in inhibition of ET-1 synthesis
by heparin (Yokokawa et al., 1993), atrial and brain natriuretic peptides (Hanehira et
al., 1997) and by the prostanoids prostaglandin E2 and prostacyclin (Prins et al.,
1994). There are several regulatory pathways through which external factors can
activate intracellular ET-1 gene expression (Figure 1.4). The human ET-1 gene
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Figure 1.4 Schematic pathway illustrating ET-1 synthesis. Modified from Miyauchi






















contains five exons that encode preproET-1. Several regulatory elements are found in
the 5' region of the ET-1 gene: motifs of the consensus binding sequence for the
transcription factor nuclear factor (NF)-l (Gronostajski, 1987), and sequences highly
homologous to the octanucleotide consensus AP-l/Jun-binding site (Inoue et al.,
1989). The presence of an AP-l/Jun-binding site in the 5'-flanking region could
explain the rapid induction of ET-1 as demonstrated following treatment of
endothelial cells with the protein kinase (PK) C activator phorbol ester (reviewed by
Miyauchi & Masaki, 1999).
ET-1 mRNA released from the nucleus into the cytoplasm, translates a 212 amino
acid polypeptide termed preproET-1. PreproET-1 is cleaved by a signal peptidase to
produce proET-1 which is further cleaved by a furin-like enzyme at two recognition
sequences (Lys52-Arg53 and Arg90-Arg91), resulting in the 38 amino acid peptide
big ET-1. The mature ET-1 is then generated through an unusual proteolytic cleavage
between Trp21-Val22 of big ET-1 by another endopeptidase endothelin-converting
enzyme (ECE; ET-1 synthesis pathway reviewed by Miyauchi & Masaki, (1999)).
This hypothesis was supported by the presence of big ET-1 and its carboxyl terminal
fragment in the conditioned medium of endothelial cells, indicating that all of the
biosynthetic stages can occur within the endothelial cell (Emori et al., 1989).
Big ET-1 is several orders of magnitude less active than ET-1 for displacement of
binding to ET receptors and also in stimulating vascular constriction in vitro (Hirata
et al., 1990; Lai et al., 1998). The conversion of big ET-1 to ET-1 is essential for
biological activity, because the pressor action of big ET-1 is almost completely
inhibited by a relatively large dose of phosphoramidon, an inhibitor of ECE
(Matsumura et al., 1990, Haynes & Webb, 1994). Because of the difference in
activity between ET-1 and big ET-1, inhibition of ECE has been proposed as a
possible therapeutic intervention on the actions of ET-1.
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ECE was first purified to homogeneity from rat lung (Takahashi et al., 1993).
Cloning of the rat, human and bovine cDNAs to ECE-1 rapidly followed (Ikura, T. et
al., 1994; Schmidt, M. et al., 1994; Shimada, K. et al., 1994) with ECE-1 being
identified as a zinc metallopeptidase related to neutral endopeptidase (Turner &
Murphy, 1995). ECE-1 is a type-II integral membrane protein composed of 754 or of
758 amino acids, with a large C-terminal domain containing the enzymatic active site
and a short N-terminal cytoplasmic tail, and has been shown to be localised on the
cell surface as well as intracellularly (Barnes et al., 1996; Russell et al., 1998).
Variability of the ECE-1 short N-terminal domain is responsible for the existence of
different isoforms (ECE-la, ECE-lb and ECE-lc) which cleave big ETs with
identical efficiency but differ with respect to their subcellular localisation (Schweizer
et al., 1997). The existence of these isoforms in the human is the direct consequence
of the presence of independent promoters on the ECE-1 gene (Valdenaire et al.,
1995; Orzechowski et al., 1997). Furthermore, a recent study has reported the
existence of a fourth novel human ECE-1 isoform, ECE-Id, with its own
independent promoter region on the ECE gene and which is expressed on the cell
surface (Valdenaire et al., 1999). ECE-la is in addition strongly expressed at the
plasma membrane, which is not the case for ECE-lb, which is almost exclusively
intracellular. ECE-lc is moderately expressed at the cell surface.
A second ECE subtype termed ECE-2 has also been cloned (Emoto & Yanagisawa,
1995). This is also a Type II integral membrane protein composed of 787 amino
acids, but unlike ECE-1 has an acidic pH optimum. ECE-1 is widely distributed, but
not found in neurons and glia in the brain, which are known to produce mature ETs
(Xu et al., 1994). ECE-2, in contrast, seems to be most abundantly expressed in
neural tissues (Emoto & Yanagisawa, 1995). Two isoforms of ECE-2 have recently
been isolated and may have different intracellular targeting and subcellular
localisations (Nakahara et al., 1999). The recently reported targeted disruption of the
ECE-1 gene in mice, however, indicates that ECE-1 is the main enzyme responsible
for the transformation of big ETs to ETs (Yanagisawa et al., 1998).
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Early evidence suggested that the conversion of big ET-1 to ET-1 in vivo occurred
via ECE present on the plasma membrane. For example, Fukuroda et al. (1990)
demonstrated that the conversion of big ET-1 to ET-1 in isolated blood vessels was
dependent on an intact endothelium. The current consensus though, is that
endogenous big ET-1 is most likely to be converted during its transit through
intracellular constitutive and regulated secretory pathways, especially within the
Golgi apparatus (Corder & Barker, 1999). This conclusion is consistent with
immunohistochemical staining for ET-1 and big ET-1 in the cytoplasm of endothelial
cells and the reported ability of a low density intracellular fraction to convert big ET-
1 to the mature peptide (Gui et al., 1993; Harrison et al., 1995). Additionally, ET-1,
big ET-1 and ECE have been located in vesicles within endothelial cells suggesting
that these subcellular compartments are an important site for processing of big ET-1
by ECE (Harrison et al., 1995; Ozaka et al., 1997; Russell et al., 1998). There are
therefore two suggested secretory pathways in the secretion of ET-1: a constitutive
pathway controlled at the level of protein synthesis and involves basal release of ET-
1, and a regulated pathway involving rapid, stimulated degranulation of ET




The diverse biological functions exerted by ET-1 predicted the existence of more
than one ET receptor. Two cDNAs that encode ET receptors were cloned from rat
(Arai et al., 1990) and bovine (Sakurai et al., 1990) lungs, with further ET receptor
cDNA cloned from rats (Lin et al., 1991), pigs (Elshourbagy et al., 1992), and
humans (Sakamoto et al., 1991; Hosoda et al., 1992). These receptors could be
classified into two groups, according to the relative binding affinities of the ET and
SRTX isopeptides for the receptors. The order of affinity for the first receptor type,
designated ETa, was ET-1>ET-2»ET-3>SRTX S6b. The second receptor type,
designated ETB, showed equal affinity for ET-1, ET-2 and ET-3 (Sakurai et al.,
1991).
Screening of amphibian cDNA libraries has revealed the existence of two other
receptor clones, though neither has been detected yet in the mammalian genome.
Emori et al. (1990) initially demonstrated an alternative ET-3 preferring receptor
subtype. This receptor was subsequently cloned from Xenopus dermal melanophores
and was termed the ETc receptor (Kame et al., 1993). The second, cloned from
Xenopus heart, was termed ETax because of its high affinity for ET-1, like the ETa
receptor (Kumar et al., 1994).
The ETa and ETB receptor genes located on chromosome 4 and 13 respectively, have
similar structural organisation, suggesting that they originated from the same
ancestral gene. Amongst the ET receptors, the 7 transmembrane domains and
cytoplasmic loops of the receptors are highly conserved, but the N-terminal and other
extracellular domains exhibit differences in both length and amino acid sequences.
ET receptors can be divided into two distinct parts, one involved in ligand receptor
binding comprising of transmembrane domains I, II, III and VII; the other
comprising transmembrane domains IV, V and VI that determine isopeptide
selectivity (reviewed by Gray & Webb, 1996).
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In situ hybridisation and northern blotting techniques have revealed quite different
distributions of the two receptors. The ETa receptor is predominantly expressed in
vascular smooth muscle, including aorta, coronary vessels and renal arterioles, but
also in bronchial smooth muscle, myocardium and the adrenal and pituitary gland
(Arai et al., 1990; Hori et al., 1992; Shibata et al., 1997; Maxwell et al., 1998). The
ETb receptor is most abundant in vascular endothelial cells and this might account in
part for the substantial levels of ETb receptor mRNA found in the brain, lung,
kidney, stomach, liver, intestine and adrenal glands (Hori et al., 1992; Elshourbagy et
al., 1993; Mathison & Israel, 1998).
ET receptors have been detected within the heart in various cells. Both ETA and ETB
receptors were located on human and rat cardiomyocytes (Molenaar et al., 1993;
Kelso et al., 1996), fibroblasts (Katwa et al., 1993) and within the coronary
vasculature (Opgaard et al., 1996). There is also evidence of different ratios of ET
receptors for specific cell types in the heart. Adult rat cardiomyocytes were found to
express predominantly ETA receptors (>90%); in contrast, both ETA and ETB
receptor subtypes were nearly equally represented on cardiac fibroblasts (Fareh et al.,
1996). However, the overall ratio of ETA to ETB receptors in the normal rat heart has
been reported to be around 90:10 (Sargent et al., 1994; Sakai et al., 1996a), though
this ratio may change with the progression of some diseases.
ET receptor expression can be influenced by various factors including Ang II,
cytokines, insulin and steroids (Nambi et al., 1992; Kanno et al., 1993; McDonald et
al., 1995; Uddman et al., 1999). Changes in ET receptor expression have been
demonstrated in various pathological conditions including ET receptor upregulation
in the rabbit diabetic kidney (Khan et al., 1999), the porcine coronary artery after
restenosis (Katwa et al., 1999), and in the lung and heart of the rat model of chronic
hypoxic pulmonary hypertension (Li et al., 1994). ETB receptor downregulation has
been reported in the aorta of DOCA-salt hypertensive rats (Bokil et al., 1999).
Additionally, prolonged exposure of cultured smooth muscle cells (Hirata et al.,
1988) and Swiss 3T3 cells (Devesly et al., 1990) to ET-1 in vitro caused a marked
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decrease in ET-1 binding sites, indicating that ET receptors can be down-regulated
by ET-1 itself.
The development of potent and selective ET receptor agonists and antagonists (Table
1.1) has allowed the functional role of ET-1 to be more clearly defined (Allcock et
al., 1993; Bonvallet et al., 1993; Karaki et al., 1993).
Table 1.1 List of some of the main ET receptor agonists and antagonists in
experimental use.
Receptor ETa ETb
ET potency order ET-1>ET-2>ET-3 ET-1=ET-2=ET-3













The findings of the above agonist and antagonist studies are consistent with the view
that constriction of vascular smooth muscle is mediated predominantly by ETa
receptors (.Figure 1.5) and that constriction is modified by release of relaxing factors
from the endothelium through stimulation of ETb receptors (Figure 1.5). However,
successive studies showed that in vivo pressor responses produced by ET-1 could not
be inhibited completely by ETA receptor antagonists (Cristol et al., 1993; McMurdo
et al., 1993). ETb receptor mRNA has been detected in both the medial smooth
muscle of human arteries (Davenport et al., 1993; Maguire et al., 1994) and in
cultured smooth muscle cells (Batra et al., 1993). Furthermore, ETb receptor agonists
have been shown to evoke constriction in vitro (Sumner et al., 1992; Shetty et al.,
1993; Gray et al., 1995) and pressor responses in vivo (Clozel et al., 1992; Haynes et
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al., 1995a). These studies indicated that ETB receptors are present on vascular
smooth muscle cells where they mediate constriction (Figure 1.5). In addition,
Mickley et al. (1997) demonstrated the relative role of ETB-mediated
vasoconstriction in rat small mesenteric arteries is greater when the ETA-mediated
effect is blocked, suggesting the presence of a possible 'crosstalk' mechanism





Figure 1.5 Diagrammatic representation of the actions ofET-1 via ETb receptors on
the endothelium and via ETa and ETb receptors on the vascular smooth muscle.
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Additionally, use ofET receptor antagonists have suggested the presence of subtypes
of the ETa and ETb receptor populations (Sudjarwo et al., 1994; Douglas et al.,
1994). These authors proposed a subclassification based on the sensitivity of
vasoconstrictor and vasodilator responses to BQ-123 and PD 142893. ETA receptors
could further be subclassified into ETAi and ETA2 receptors, based on the
susceptibility to an ETA receptor antagonist BQ-123, in which ETAJ is sensitive to
and ETA2 is resistant to BQ-123 (Sudjarwo et al., 1994). The ETB receptor was also
subclassified as an ETBi receptor, which mediates mainly vasorelaxation through the
19
Chapter 1
release of nitric oxide and is inhibited by PD 142893 and bosentan, and the ETb2
receptor, which mediates direct vasoconstriction of veins and is inhibited by SB
209670 and BQ-788 (Douglas et al., 1994).
Generally, activation of both ETa receptors and ETb receptors on vascular smooth
muscle cells (Force, 1998) and cardiomyocytes (Sugden & Bogoyevitch, 1996) by
ET-1 leads to a biphasic increase in intracellular calcium (Ca2+). In the first phase,
ET-1 binds to the ETa/b receptors at the cell surface activating a pertussis toxin-
insensitive G-protein, which in turn stimulates phospholipase C (PLC). Hydrolysis of
phosphatidylinositol by PLC generates inositol triphosphate (IP3) and diacylglycerol
(DAG), both of which function as second messengers transducing information from
the surface of the cell to the interior. IP3 is a fast-acting mediator that binds to a
receptor on the sarcoplasmic reticulum and triggers the release of Ca2+ from
intracellular stores. After the release of Ca2+, a second phase is initiated in which
Ca2+ moves into the cell from the extracellular space (Berridge, 1993), and it is this
sustained elevation in intracellular Ca2+ that is responsible for increases in cell
contractility. DAG activates PKC that sensitises the contractile proteins to Ca2+ via
phosphorylation (Sunako et al., 1989; Takanashi & Endoh, 1991). The increase in
intracellular pH enhances the contractility of the cell, again via sensitisation of the
contractile proteins via Ca2+.
A recent interesting study has also indicated a role for ET-1 in stimulating ANP
release in rat cardiomyocytes in vitro through ETA receptor-mediated activation of
cAMP. Rebsamen et al. (1997) further demonstrated that in these cells calcium
mobilisation from intracellular stores and stimulation of cAMP production
represented two cellular events linked to two different G proteins that are coupled to
one receptor, the ETa receptor.
ETb receptors on endothelial cells in the heart stimulate a similar PLC-mediated
intracellular pathway to that of ETA and ETB receptors on cardiomyocytes, but in
endothelial cells the outcome is the release of a physiological endothelial-derived
relaxing factor NO. Stimulation of ETb receptors at the cell surface by ET-1 activates
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a pertussis toxin-insensitive G-protein, which through a series of intracellular
processes (as described above) leads to an influx of Ca2+ and an increase in
intracellular Ca2+ levels. The enzyme NOS, which is central to NO biosynthesis is
controlled by intracellular Ca2+/calmodulin. A Ca2+/calmodulin complex forms as a
result of Ca2+ influx into the cell, which then binds to NOS; the resulting activated
NOS leading to production and release ofNO from endothelial cells.
Upon production, NO diffuses freely through the endothelial cell to cardiomyocytes
where, depending on its concentration, it has biphasic contractile effects on cardiac
tissue. High levels of NO induce large increases in cGMP (Ignarro, 1989). Raised
cGMP levels has actions on myosin light chain kinase, PKG, phosphodiesterases and
ion channels resulting in reduced intracellular Ca2+ (Moncada & Higgs, 1991) and a
negative inotropic effect mediated by a PKG-dependent reduction in myofilament
responsiveness to Ca2+. Conversely, low levels of NO increase cAMP in part by a
novel cGMP-independent activation of adenylyl cyclase and induces a positive
contractile response (Kojda et al., 1996; VilaPetroff et al., 1999).
1.2.4 Clearance and Degradation of Endothelin
The observation that concentrations of circulating ET-1 were increased by a mixed
ETa/ETb receptor antagonist (Loffler et al, 1991) or by a selective ETB receptor
antagonist (Fukuroda et al., 1994), but not by ETA receptor antagonists, was
suggestive of a role for ETb receptors in the clearance of ET-1. ETB receptors were
also shown to be completely and exclusively responsible for pulmonary ET-1
removal in the dog in vivo, with a half-life of plasma ET-1 of 3-5 minutes (Dupuis et
al, 1996). As observed with other vasoconstrictor substances, internalisation of the
endothelin receptor complex is believed to be the mechanism for down regulation
and clearance (Resink et al., 1990a). After internalisation, the ligand-receptor
complex is thought to be sequestered into lysosomes, which the acidic environment
promotes ligand dissociation (Hirata et al., 1988). Bremnes et al. (2000) recently
reported a similar possible mechanism for the clearance of plasma ET-1 by
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demonstrating that ETA and ETb receptor subtypes were targeted to different
intracellular routes after ET stimulation. Whereas the internalised ETA receptor was
recycled to the cell surface, the ETb receptor followed an arrestin- and
dynamin/clathrin pathway to intracellular lysosomes whereupon they were degraded.
1.2.5 Physiological actions of Endothelin in the cardiovascular system
1.2.5.1 Vascular Tone
In view of the multiple cardiovascular actions of ET-1 and the fact it is one of the
most potent vasoconstrictor peptides known, there has been much interest in its
contribution to basal vascular tone. The physiological importance of endogenous ET-
1 in the maintenance of basal vascular tone and blood pressure in humans has been
demonstrated by local (Haynes & Webb, 1994) and systemic (Etaynes et al., 1996)
vasodilation in response to inhibitors of the ET system. More recently, Spratt et al.
(1999) demonstrated that systemic blockade of the ETA receptor, using BQ-123,
inhibited agonist-induced vasoconstriction and decreased peripheral vascular
resistance, suggesting that ETA-mediated vascular tone contributes to the
maintenance of basal systemic vascular resistance and blood pressure. Furthermore,
in the forearm vasculature, there was a similar threshold for inhibition of
vasoconstriction to both exogenously administered and endogenously generated ET-
1. ET-1 mediated local and systemic vasoconstriction was also demonstrated using a
specific ETa receptor antagonist BMS 193884 given to human subjects, with orally
administered antagonist effects still evident 24 hours later (Strachan et al., 1999).
The sustained vasoconstrictor effects of ET-1 are predominantly mediated by the
ETa receptor, although vascular smooth muscle ETb receptors may also contribute to
ET-1 mediated vasoconstriction in animals (Clozel et al., 1992) and humans (Haynes
et al., 1995b) in vivo. However, Strachan et al. (1999) recently demonstrated that
systemic administration of the ETb receptor selective antagonist, BQ-788, causes
substantial systemic vasoconstriction associated with a reduction in heart rate and
cardiac index, suggesting that the overall balance of effects of endogenous ET-1 at
the vascular ETb receptor favours vasodilatation. Through these ET receptor
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antagonist studies, it is now acknowledged that ET-1 has a role to play in mediating
vascular tone under physiological conditions through its receptors on both smooth
muscle (ETa and ETb) and endothelial cells (ETb).
1.2.5.2 Effects on the Heart
It is now established that the precursors of ET-1, ECE, ET-1 itself and its receptors
are all present in the heart. Synthesis of ET-1 peptide has been reported in cultured
neonatal rat cardiac myocytes (Suzuki et al., 1993) and ischaemic porcine cardiac
myocytes in vivo (Tonnessen et al., 1995). ET-1 immunoreactivity and preproET-1
mRNA expression has also been identified in endothelial cells throughout human
hearts (Plumpton et al., 1996) and in endothelial cells and cardiomyocytes in human
transplanted heart tissue (Giaid et al., 1995). Furthermore, ECE immunoreactivity
has been reported in endocardial endothelial cells of the heart (Davenport et al.,
1998).
Specific sarcolemmal receptors for ET-1 are present on cardiac myocytes isolated
from mammalian (Hirata et al., 1989; Ono et al., 1995) and human hearts (Moody et
al., 1990). Both ETA and ETb receptors have been identified on cardiac myocytes
(Molenaar et al., 1993; Ono et al., 1995) and are coupled to multiple subcellular
signalling pathways including stimulation of phosphoinositide hydrolysis, activation
of arachidonic acid metabolism, and G-protein mediated inhibition of adenylyl
cyclase (Hilal-Dandan et al., 1992; Clerk & Sugden, 1997).
ETa and ETb receptor antagonists have been shown to increase and decrease
coronary flow respectively in isolated perfused rat hearts indicating the presence of
both ET receptors on the coronary vasculature, and suggesting an indirect effect of
ET-1 on cardiac muscle through modulation of coronary artery tone (Wang et al.,
1994). Systemically administered ETA selective receptor antagonist BQ-123 in
healthy human subjects was reported to increase heart rate and cardiac index (Spratt
et al., 1999) indicating a role for ET-1 through the ETA receptor in control of basal
cardiac parameters. Furthermore, infusion of the ETA selective antagonist BQ-123 in
healthy volunteers, caused a significant reduction in left ventricular dP/dt, with no
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effect on relaxation suggesting that endogenous ET-1 may have a physiological role,
contributing to cardiac output (MacCarthy et al., 2000).
Shortly after ET-1 had been identified as an endothelium derived vasoconstrictor,
Ishikawa and colleagues (Ishikawa et al., 1988) also reported that ET-1 had a potent
inotropic activity in guinea pig atrial strips. Subsequent studies have demonstrated
positive inotropic effects of ET-1 in both perfused rat heart (Kusumoto et al., 1996)
and human atrial myocardium (Meyer et al., 1996) in vitro. Interestingly, MacCarthy
et al. (2000) demonstrated a small positive inotropic effect of exogenously
administered ET-1 in normal human hearts in vivo, but a negative inotropic effect in
heart failure, which may be due to differences in intracellular signalling or to excess
ET-mediated vasoconstriction in the heart failure group. However, the effect of
endogenous ET-1 on intrinsic contractile function of the failing human heart remains
unknown.
In separate studies, both anti- and pro-arrhythmic effects have been suggested for
ET-1. In isolated ventricular myocytes, ET-1 acting through ETA receptors inhibited
PKA and protected the ventricle against arrhythmias (James et al., 1994). However,
ET-1 has been reported to induce arrhythmic contractions in human isolated atrial
tissue, which did not appear to be mediated by the ETA receptor (Burrell et al.,
2000). Also, infusion of ET-1 through coronary vessels in isolated perfused rat and
guinea pig hearts led to an increase in coronary perfusion pressure, where at peak
pressure, ventricular arrhythmias were observed (Ercan et al., 1996). Paradoxically,
low dose of the ETA receptor antagonist BQ-123 have been found to reduce the
incidence of arrhythmias in the rat model of ischaemia, but a high dose of BQ-123 is
pro-arrhythmic (Garjani et al., 1995). However, at these higher doses, BQ-123 may
no longer be ETA specific. Furthermore, Sharif et al. (1998) demonstrated that ET-1
released endogenously during ischaemia is arrhythmogenic, whereas exogenous
application of ET-1 under certain conditions is anti-arrhythmogenic.
Growth effects of ET-1 on the heart are discussed in section 1.2.6
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1.2.5.3 Actions on the Kidney
The ETs are produced by, bind to, and induce biological responses in a wide variety
of renal cell types (Kohan, 1997). While ET-1 is primarily implicated in regulating
cell contraction or proliferation (Wang et al., 1994; Nitta et al., 1995) in the
vasculature and mesangium, it serves a different function in the tubule. ET-1 may
function as an autocrine inhibitor of water reabsorption in the collecting ducts
(Tomita et al., 1990; 1993). The peptide has a more complex effect on sodium
reabsorption in the nephron; however, it is likely that the predominant effect on the
proximal tubule, cortical collecting tubule and inner medullary collecting duct is to
promote sodium excretion (Zeidel et al., 1989; Tomita et al., 1993; Ling, 1994). It is
therefore apparent that ET-1 subserves opposite functions in the renal tubule and
vasculature. In the vasculature, the peptide primarily reduces renal blood flow and
glomerular filtration rate, thereby promoting sodium and water retention.
Conversely, ET-1 appears to function as a diuretic and natriuretic agent in the
nephron. Though there is abundant data indicating the potential of ET-1 in modifying
renal hemodynamics and urinary salt and water excretion, it is still unclear if the
peptide influences renal function under normal conditions.
Numerous studies indicate that ET-1 is involved in the pathogenesis of a broad
spectrum of renal diseases including ischaemic renal failure, inflammatory
glomerular nephritis and endotoxemia. ET-1 may also mediate, in part, excessive
extracellular matrix accumulation and fibrosis occurring in chronic renal failure and
diabetes mellitus (reviewed by Kohan et al., 1997). Several clinical studies have
indicated that in patients with systemic hypertension, progressive proteinureic
nephropathies, or acute and chronic renal dysfunction due to cyclosporin A therapy,
the endothelin pathway is activated, as previously observed in experimental animals.
Continuing pre-clinical observations suggest strongly that ET antagonists are likely





ETs have been shown to play a pivotal role in the control of various endocrine and
neuroendocrine tissues. The presence of ETs has been demonstrated in the porcine
(Nunez et al., 1990), rat (Sakurai et al., 1991) and human (Imai et al., 1992) adrenal
gland. In vitro studies performed in several animal models have shown that ETs are
potent stimulators of corticosteroid secretion. In rat, ET-1 caused a dose-dependent
increase in both corticosterone and aldosterone secretion in vitro (Elinson et al.,
1991; Belloni et al., 1995). Furthermore, ET-1 has been shown to regulate secretion
of arginine vasopressin (AVP) and atrial natriuretic peptide (ANP) from the adrenal
medulla. Macchi et al. (1999) demonstrated ET-1 to stimulate release of AVP and
ANP from rat adrenal medulla fragments in vitro, with ET-1 acting exclusively via
the ETa receptor subtype.
ET-1 has also been found to exert multifaceted effects on the renin-angiotensin-
aldosterone system (RAAS), such as dose dependently inhibiting renal renin
production, directly stimulating aldosterone production from the adrenocortical zona
glomerulosa and promoting growth of the adrenal cortex (reviewed by Rossi et al.,
1999). The observation that, despite this inhibitory effect on renin, ET-1 was found
to markedly stimulate aldosterone secretion both in animals (via ETB receptors) and
in humans (via ETA and ETB receptors) suggests a direct effect of the peptide on the
adrenal cortex.
It has been hypothesised that Ang II, the active peptide of the RAAS, affects the
synthesis ofET-1, which in turn can influence the RAAS by acting at different steps.
Herizi et al. (1998) demonstrated that bosentan entirely prevented the exogenous
effects of a ten day infusion of Ang II (200ng/kg/min) including development of
hypertension, the reduction of renal blood flow and a marked increase in heart
weight. Furthermore, bosentan was found to exert a hypotensive effect in addition to
that of the AT| receptor antagonist losartan in a canine model of hypertension
(Massart et al., 1998).
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An animal model that lends itself to the investigation of the interactions between the
RAAS and ET systems in vivo is the TGR(mREN-2)27 rat. In this model, the
introduction of the Ren-2 gene, encoding for renin, causes severe hypertension,
associated with overexpression of the transgene in many tissues with ensuing
enhanced endogenous production of Ang II in tissues with low plasma renin activity
(Ganten et al., 1991). It has been reported that aortic responsiveness to ET-1
followed changes that closely paralleled those of systolic blood pressure in these
animals, thereby suggesting a role for ET-1 in this form of renin-dependent
hypertension (Cargnelli et al., 1998). However, administration of the non-selective
ET receptor antagonist bosentan did not have either a blood pressure lowering effect
or any effectiveness in preventing left ventricular and vascular hypertrophy in male
TGR(mREN-2)27 rats. The reasons why ET-1 may take part in hypertension induced
by exogenously administered Ang II, but not in the models with an enhanced
endogenous production ofAng II, are unclear at present.
In summary, there are several interactions between the RAAS and the ET system,
which may have relevant effects on blood pressure and on hypertension-related
complications. However, the question of whether or not they are also relevant in
humans in the clinical setting and have therapeutic implications needs further
investigation.
1.2.5.5 Interactions with the Nervous System
Specific distribution of ET within the central nervous system (CNS) has been
demonstrated in many areas of the brain as well as the spinal cord (Kuwaki et al.,
1994). This extensive distribution suggests different roles for the ET system in CNS
regulation of multiple physiological events including a role for the ET system in
CNS regulation of cardiovascular function (Kuwaki et al., 1995). With regard to the
peripheral nervous system, ET receptors are found distributed in superior cervical
and nodose ganglia as well as the carotid body, implicating an additional
cardiovascular regulatory role by influencing both systemic arterial baroreceptor and
chemoreceptor reflexes (reviewed by Mortensen, 1999).
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ET-1 has emerged as an important growth factor and as a substance with an
obligatory role in normal tissue development and differentiation. Evidence indicating
this comes from studies using mice in which the ability to synthesise ET-1, ETa or
ETb receptors has been knocked out. In ET-1 gene knockout mice (Kurihara et al.,
1994), the homozygotes die at birth with abnormalities in craniofacial tissues and
other organs that make breathing impossible. These malformations are also seen in
ETa receptor knockout mice (Yanagisawa et al., 1998), indicating that endogenous
ET synthesis leading to ETa receptor activation is essential for normal development
and survival. In contrast, gene targeting of ETB receptor synthesis gives rise to mice
that suffer from aganglionic megacolon, as seen in Hirschsprung's disease (Hosoda
et al., 1994). It is therefore evident that ET-1 and ET receptor genes are critical to
normal development.
ET-1 is also an important regulator of mitogenesis influencing DNA synthesis, the
expression of protooncogenes, cell proliferation and hypertrophy. ET-1 has been
shown to regulate DNA synthesis in various cell types such as bovine brain capillary
endothelial cells (Vigne et al., 1990), rat kidney fibroblasts (Yeh et al., 1991),
cultured neonatal rat cardiomyocytes (Ito et al., 1991) and rat vascular smooth
muscle cells (VSMC; Rosen et al., 1999). ET-1 also promoted VSMC proliferation
(Peiro et al., 1995) and induced hypertrophy of adult rat cardiac myocytes in vitro
(Mullan et al., 1997).
In vertebrates, the actions of many stimuli resulting in proliferative or hypertrophic
growth converge on a set of cellular kinase cascades that are collectively called the
mitogen-activated protein (MAP) kinase cascades (Force & Bonventre, 1998). Of the
three MAP kinase cascades, the extracellular regulated kinase (ERK) cascade is
critical to the mitogenic response, to cellular differentiation and, in some cells, to
induction of hypertrophy. The other two MAP kinase cascades (the stress activated
protein kinase / janus kinase cascade and the p38 cascade) are activated by cellular
stress and cytokines. Growth factor stimulation (i.e. ET-1) of G-protein-coupled
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surface receptors on cardiomyocytes leads to activation of internal signal
transduction pathways and eventual activation of ERK. During prolonged activation,
a portion of the ERK protein translocates to the nucleus (Gonzalez et al., 1993;
Lenormand et al., 1993), and promotes cell hypertrophy by activating c-jun proto-
oncogene expression (Davis, 1995). C-jun has been demonstrated to be an important
growth factor in the myocardium (Schunkert et al., 1991).
ET-1 has also been shown to co-operate with other growth factors in a synergistic
fashion to enhance mitogenesis of fibroblasts and VSMCs in vitro (Weissberg et al.,
1990; Yeh et al., 1991, Hafizi et al., 1999). Bonin et al. (1993) reported that pre-
treatment of human smooth muscle cells with either endothelial growth factor (EGF)
or basic fibroblast growth factor (bFGF) produces significant increases in ET-1
binding to these cells without any significant change in kj. A further interesting
study by Hafizi et al. (1996) demonstrated pronounced synergy between ET-1 and
three polypeptide growth factors, platelet derived growth factor (PDGF), bFGF and
EGF, in co-stimulation of DNA synthesis in quiescent human cultured coronary
artery smooth muscle cells. Since ETs themselves have been reported to elicit
relatively weak mitotic responses (Battistini et al., 1993), the synergistic effect
between ET-1 and other growth factors may suggest a mechanism by which ET-1




1.3.1 Aetiology of heart failure
Heart failure is somewhat difficult to define though it can be simply thought of as a
clinical syndrome typified by an inability of the heart to meet the metabolic needs of
the body and is recognised by a characteristic pattern of haemodynamic, renal, neural
and hormonal responses.
Heart failure has, due to an increased ageing population, become more prevalent in
recent years. There are almost 4.8 million people in the US with congestive heart
failure (CHF), with this figure expected to reach 10 million by the year 2007 (Rich,
1997). More than $56 billion is spent annually on the treatment and management of
heart failure, 70% of which covers the hospitalization of patients. However, mortality
rates from CHF continue to be high, with a 6-year mortality rate secondary to heart
failure of 84% in men and 77% in women (Croft et al., 1999). There is therefore a
need to develop innovative solutions and new treatments to keep this growing
population out of hospital and improve overall survival.
In practice, heart failure may be diagnosed whenever a patient with significant heart
disease develops the signs or symptoms of a low cardiac output, pulmonary
congestion and systemic venous congestion. The cardiac output is a function of the
preload (the volume and pressure of blood in the ventricle at the end of diastole), the
afterload (the arterial resistance) and myocardial contractility. Starling's Law states
that the more myocardial fibres are stretched (the end-diastolic fibre length), the
greater the force of the ensuing contraction (see section 1.1.2.2). In heart failure,
however, the curve moves to the right and becomes much flatter (Figure 1.6).
Because of reduced contractility due to loss of contractile tissue, a given amount of
work is only achieved with a greater end-diastolic fibre length. The reduced
physiological limits of the myocardium and increased end-diastolic filling pressure
leads to an overall lower cardiac output with increases in filling pressure.
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Figure 1.6. The Frank-Starling curve for a normal heart (red), and during heart
failure (blue).
100 200 300
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There are many mechanisms for myocardial failure (Table 1.2) including pressure
overload, volume overload, and reduced ventricular contractility. In each case,
through different mechanisms, the myocardium attempts to compensate for the
primary defect before the stages of overt myocardial failure develop.
In response to pressure overload, for example, via aortic stenosis or sustained severe
hypertension, left ventricular (LV) pressure must increase to overcome the resistance
to the ejection of blood. The mechanism for the increase at the cellular level is
probably a stretch-induced increase in force of contraction (inotropy), controlled by
mechanoreceptors. The result is that the LV systolic pressure increases, the
obstruction to the outflow of blood is overcome, and cardiac output is maintained.
The disadvantage of this mode of adaptation is that the LV wall stress is greatly
increased, which may lead to LV dilation via increased transmural wall pressure,
causing further increased wall stress. However, exposed to a sustained pressure load,
the myocardium adapts via hypertrophy, and the wall becomes thicker. The result of
hypertrophy is that the abnormally increased wall stress is reduced so that systolic
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function at rest is normal. However, such compensatory hypertrophy is gained at the
cost of greater susceptibility to ischaemia and abnormal diastolic function.
The initial event in volume overload may be, for example, valvular regurgitation of
either the mitral valve or the aortic valve. To deal with this volume load, there are
both changes in the loading conditions and in ventricular size. First, the volume load
means that the preload increases and the heart is functioning at the length limit of the
Frank-Starling curve. Second, some increase in chamber volume may be attained by
slippage of cells. The result is enhanced diastolic filling and decreased LV stiffness
(Zile et al., 1993), so that diastolic function improves rather than deteriorates as in
pressure overload. Nonetheless, as chamber size increases, so must wall tension. The
consequence is some hypertrophy, which allows the LV cavity to regain a normal
wall stress by modest and proportional LV hypertrophy.
Where reduced ventricular contractility occurs, the dysfunction may be global
(myocarditis or dilated cardiomyopathy) or regional (myocardial infarction, MI). In
Western countries, coronary artery disease (CAD) is by far the main cause of heart
failure due to left ventricular dysfunction, with dilated cardiomyopathy being much
less common (McMurray et al., 1992). CAD most often results from atherosclerosis,
where fatty streak formation on the inside wall of the artery leads to formation of a
plaque. The initial stage consists of an asymptomatic period during which non¬
obstructive plaque is formed with further progression depending on its associated
risk factors. The second stage, however, consists of a rapid thrombogenesis due to
plaque rupture exposing thrombogenic components such as collagen, platelets and
tissue thromboplastin, which promote platelet aggregation, fibrin formation, and
development of occlusive or near occlusive thrombus (Falk, E. et al., 1996). CAD
and its complications (including arrhythmia, angina pectoris and MI) are among the
leading causes of death in the UK.
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1.3.2 Acute phase after myocardial infarction
A left ventricular MI (for example secondary to coronary artery disease) starts a
chain of events in the myocardium that aim to compensate for decreased contractility
and cardiac output (Figure 1.7). The size of the MI is influenced by the localisation
of the coronary artery occlusion, duration of ischaemia, left ventricular oxygen
consumption during ischaemia and collateral blood flow (Maroko et al., 1971;
Schaper & Pasyk, 1976).
Initially, impaired coronary blood flow and oxygen supply to the affected area of
myocardium produces extensive biochemical and morphological changes in the
myocardial cells (Poole-Wilson, 1989). These changes, depending on the duration of
ischaemia, result in widespread abnormalities of cardiac contraction, relaxation,
electrical repolarisation and to varying degrees of myocardial damage. Acute
deprivation of oxygen delivery to myocardial cells will, after 10-15 seconds, cause a
reduction in oxygen tension and high-energy phosphates such as creatine phosphate
and adenosine triphosphate. Myocardial metabolism changes from normally being
aerobic to an anaerobic state. The activation of anaerobic glycolysis and the
formation of lactate result in the reduction of intracellular pH (Peiper, et al., 1980)
and the subsequent accumulation of CO2 and lactic acid in the interstitium. A
prolonged period of ischaemia, myofibrillar oedema, reduced glycogen content and
accumulation of lactic acid finally results in signs of irreversible myocardial cell
damage and death.
There is evidence that apoptosis is a major source of myocyte cell death in the
irreversibly injured myocardium (in both animals and humans), followed by necrosis
at later time points (Kajstura et al., 1996; Olivetti et al., 1997; Buja & Entman,
1998). Apoptosis has been reported in the rat to begin within the first 2 hours after
MI, where activation of an endogenous endonuclease results in endonucleolysis and
the removal of apoptotic bodies by neighbouring cells without initiation of an
inflammatory response (reviewed by Anversa et al., 1998). Hallmarks of apoptosis
include cell shrinkage, membrane blebbing, chromatin condensation, and DNA
fragmentation (MacLellan & Schneider, 1997).
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Figure 1.7 Flow diagram (including approximate time scale) of responses to a MI in
the rat heart.
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35
Chapter 1
Where apoptosis is thought of as controlled physiological cell death, necrosis can be
termed non-physiological cell death. Cell necrosis also commences 2-4 hours after
MI and is characterised by an immediate loss of plasma membrane integrity,
mitochondrial alterations, stimulation of an inflammatory cell infiltration
(Darzynkiewicz et al., 1992). Kajstura et al. (1996) reported a 2.4 fold increase in
myocyte apoptosis in the infarcted portion of the rat wall 2 to 4.5 hours after
coronary artery ligation, with levels decreasing after 1 day. Also, necrotic myocyte
cell death increased continuously from 2 hours to 1 day but was markedly attenuated
at 7 days.
Necrotic cells in the infarcted area release a number of substances (i.e. tumour
necrosis factor (TNF)-a, interleukin-1, complement) that act as chemoattractants to
inflammatory cells, thereby initiating an inflammatory response (Ono et al., 1998).
The traditional interpretation of inflammatory cells is that they function as a
protective response to infection by ingesting and destroying infectious agents or
scavenging dead tissue, thus paving the way for repair of the damaged site (Iverson,
1989). Neutrophils primarily enter the infected area where they interact directly with
necrotic tissue and release toxic components such as neutrophil proteases and
reactive oxygen species, which have cytotoxic effects on the surrounding tissue
(Entman et al., 1990). Soon after, macrophages and lymphocytes infiltrate the
myocardium starting a process which catabolises and disposes of dead myocytes.
The process of degradation and clearance of necrotic tissue is followed by formation
of a scar composed principally of collagen. Fibroblasts are attracted to the site of
injury where they convert to myofibroblasts. Through a complex series ofmolecular
events that includes expression of immediate early response genes (e.g. c-fos, c-jun
and erg-1) and activation of multiple second messenger systems, which act
synergistically to induce mitosis, these cells proliferate and lay down fibrillar
collagen that replace lost myocytes (Weber, 1997). Myofibroblasts are central to
fibrogenesis at sites of repair, synthesising type III and then type I collagen, the
major fibrillar collagens that contribute fibrous tissue (Weber et al., 1988; Bishop et
al., 1990). Northern blot and in situ hybridisation analyses have shown an increase in
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type III procollagen mRNA at the infarct site by day 2 post-MI in the rat, reaching a
peak at day 21 and declining thereafter (Cleutjens et al., 1995). Type I procollagen
increased at day 4 and remained elevated at week 4 at the site of the infarct
(Cleutjens et al., 1995). Myofibroblasts also contain actin filaments, which may
enable these cells to reorganise the scar and hence be responsible for scar contraction
(Whittaker, 1997).
Myofibroblasts express receptors for Ang II, transforming growth factor (TGF)-(3i,
and endothelins, which permit their response to these regulatory molecules. TGF-Pi
has numerous actions on the extracellular matrix including chemotaxis, phenotype
transformation, and proliferation of fibroblasts and scar tissue remodelling (Singer, et
al., 1986; Desmouliere, et al., 1993). Macrophages, clustered at sites of tissue injury,
are a likely source of TGF-Pi (Riches, 1996) that may be important to the appearance
of the myofibroblast phenotype (Desmouliere et al., 1993). Depending on the
species, the entire process of scar formation is completed within weeks to months
(Fishbein, et al., 1978).
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1.3.3 Adaptive changes in the heart after myocardial infarction
An acute MI, particularly one that is large and transmural, can also produce long-
term alterations in the topology of both the infarcted and non-infarcted regions of the
ventricle. The structural remodelling of the left ventricle after MI is a time-dependent
process involving both the region of necrosis and the residual normal myocardium
(Pfeffer & Braunwald, 1990).
Early post-infarction, regions of hypoxic necrosis may become over-stretched during
ventricular contraction due to increased systolic tension of the viable myocardium
and with sufficient repetition, this process leads to permanent structural changes in
the ventricle (Michel et al., 1995). The non-contracting infarcted region undergoing
stretch and stress relaxation shows an overall thinning and dilation, the thinning a
consequence of slippage between muscle bundles resulting in a reduction in the
number ofmyocytes across the infarcted region. The morphological consequences of
this repetitive stretching of the myocardium during systole has being termed 'infarct
expansion' and is associated with an elongation of the contractile zone with further
distortion of the ventricular shape and increase in ventricular filling volume (Swan,
1993).
Later post-infarct, an overlapping phase of fibroblast proliferation and collagen
deposition continues and completes the formation of scar tissue, wherein the
remaining viable myocytes within the infarcted region are realigned and attached in a
dense collagen matrix, providing resistance to further stretching (Vracko et al.,
1989). The fibroblast proliferation and collagen deposition is responsible for a
decreased compliance in the infarcted area compared to the remaining functional
myocardium in the non-infarcted areas (Pfeffer, 1995). To compensate for loss in
wall contractility and overall dysfunction in the infarcted area of myocardium, the
heart undergoes important morphological processes such as ventricular remodelling
and hypertrophy in areas away from the infarct.
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Post infarct remodelling is a regional process that progresses from adjacent non-
infarcted regions to involve the entire left ventricle as further contractile units
become exposed to the damaging effects of mechanical overload and/or humoral
over stimulation (Sakai et al., 1998). Analysis of cell signalling mechanisms shows
that stretch activates multiple signal transduction pathways, similar to those activated
by growth factors (Swynghedauw, 1999). The hypertrophic response is characterised
by increased cardiomyocyte cell volume, proliferation of non-myocyte cells (mainly
fibroblasts), activation of myosin light chain 2, skeletal a-actin and P-myosin heavy
chain (Rumberger, 1994). The ventricular enlargement process leads to restoration of
pump function without concomitant increases in filling pressure (McKay et al.,
1986).
The downside of the initial compensation which uses the altered geometry
(enlargement) to restore stroke volume is that architectural changes create greater
loading conditions on the viable myocardium that promote further enlargement,
hypertrophy and dysfunction. Therefore, although appropriate myocardial
hypertrophy of the surviving myocardium compensates for myocardial loss in the
infarcted area, excessive hypertrophy of the myocardium is believed to be
maladaptive and to be associated in part with dysfunction of the surviving
myocardium (Sakai et al., 1998). The transition from compensated to decompensated
heart failure is also likely to be related to the overexpression of neurohormones and
peptides such as noradrenaline, Ang II, ET-1, and pro-inflammatory cytokines (Piano
et al., 1998).
These pathological developments of decompensated heart failure translate into
distinct, if overlapping, stages in clinical presentation and can be classified according
to the New York Heart Association (NYHA) scaling system. This classification was
first proposed in 1964, and updated in 1973. Patients are categorised as NYHA Class
I, II, II or IV (Table 1.3). Classes II, III and IV are regarded as mild, moderate and




Table 1.3 NYHA grading ofsymptoms.
Class Symptoms
I Cardiac disease but without resulting limitation ofphysical activity.
II Cardiac disease but with slight limitation ofphysical activity, comfortable at rest.
Ordinary physical activity results in fatigue, palpitation, dyspnoea or anginal pain.
III Cardiac disease resulting in marked limitation of physical activity but comfortable
at rest.
Less than ordinary physical activity causes fatigue, dyspnoea or anginal pain.
IV Cardiac disease resulting in the inability to perform any physical activity without
discomfort, often discomfort at rest.
If any physical activity is undertaken, discomfort is increased.
1.3.4 Neurohormonal systems activated during heart failure
The body responds in a number of ways to the changes affected by a MI and are
largely designed to compensate for reduced flow of blood to the body. Two sets of
neurohormones with opposing effects are activated in CHF. The vasoconstrictor
hormones including noradrenaline, Ang II, and AVP are anti-diuretic and, generally,
have growth promoting properties. The vasodilator hormones (including the
natriuretic peptides), on the other hand, are natriuretic, diuretic and have
antimitogenic properties.
1.3.4.1 Increased adrenergic activity
In heart failure, decreased cardiac output leads to a number of adaptive mechanisms
including activation of the sympathetic nervous system. Augmented sympathetic
activity in heart failure is initially beneficial, increasing cardiac output (via activation
of Pi adrenoreceptors in the heart) and redistributing blood flow from the splanchnic
area to the heart and skeletal muscles. In addition, renal vasoconstriction leads to salt
and water retention, which may help to improve the perfusion of vital organs.
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However, sustained sympathetic stimulation, as seen in heart failure, activates the
RAAS and other neurohormones leading to progressive salt and water retention,
vasoconstriction, oedema and increased pre- and afterload (reviewed by Ferrari et al.,
1998). The increase of adrenergic drive is characterised by decreased baroreceptor
sensitivity, increased plasma noradrenaline levels, cardiac noradrenaline spillover
and desensitisation of postsynaptic P-adrenoreceptor signal transduction.
Furthermore, heightened activity of the adrenergic nervous system also leads to
stimulation of myocardial ai-adrenoreceptors, which may cause hypertrophy, re-
expression of fetal genes (Bishorpic et al., 1987), and the induction of peptide
growth factors (Takahashi et al., 1994).
1.3.4.2 The renin-angiotensin-aldosterone system
A decrease in blood pressure in normal subjects will release renin, an enzyme
involved in the Ang II synthesis pathway. In CHF, both a low renal perfusion
pressure and increased P-adrenergic stimulation contribute to increased renin release.
The result is an Ang II mediated vasoconstriction to add to that mediated by the
activated sympathetic nervous system. Ang II directly constricts the peripheral
vessels and enhances the degree of sympathetic activation, while also evoking the
release of aldosterone, leading to an overall increase in body fluid volume as well as
retention of sodium and water. An increased circulating blood volume thus supports
the maintenance of the cardiovascular homeostasis. However, continued activation of
the RAAS leads to excessive elevation of systemic vascular resistance, increased
volume retention precipitating oedema, increased preload and overall increased
workload of the heart.
Previous studies propose the existence of a tissue-based RAAS, which suggests that
Ang II can be produced locally and thus also act locally as a vasoactivator. All of the
necessary components of the RAAS are present in several organs and tissues,
including the vasculature, heart, and kidneys. In myocardium from animals with
experimental heart failure, there is increased expression of ACE (Hirsch et al., 1991;
Schunkert et al., 1990) and angiotensinogen (Lindpaintner et al., 1993). Although
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cardiac renin mRNA expression is extremely low, renin activity is readily detectable
in the heart (Vonlutterotti et al., 1994). In contrast to renin, angiotensinogen appears
to be synthesised locally within the myocardium. Under normal physiological
conditions, cardiac angiotensinogen levels are low. However, in rats with chronic
pressure overload and in rats with left ventricular failure early after coronary artery
ligation, cardiac angiotensinogen gene expression is upregulated (reviewed by
Wollert & Drexler, 1999).
Angiotensin receptor (AT) expression has been shown to change in both animal
studies and human heart failure. Nio et al. (1995) reported upregulated ATi and AT2
receptor mRNA expression in the infarcted and noninfarcted portions of the left
ventricle after coronary artery ligation in the rat. However, several groups
investigating receptor expression in human heart failure have reported reduced AT 1
receptor density while AT2 receptor density remained unaltered (Asano et al., 1997;
Haywood et al., 1997).
Several observations suggest that a direct effect of Ang II on cardiac AT receptors
may play a central role in modifying the structure and function of the myocardium in
patients with heart failure by acting on a variety of cell types to promote cell growth
and alter gene expression. In cardiac myocytes and fibroblasts obtained from the
neonatal rat, Ang II caused myocyte hypertrophy and fibroblast proliferation
associated with the expression of several early response genes (c-fos, c-jun, and c-
myc), angiotensinogen and the peptide growth factor, TGF-Pi (Sadoshima & Izumo,
1993; Crawford et al., 1994). Ang II has also been reported to induce expression of
fetal genes encoding atrial natriuretic factor and a-skeletal actin in myocytes
(Sadoshima & Izumo, 1993). Furthermore, a study investigating the influence of
chronic Ang II infusion in vivo on expression of preproET-1, ETa and ETb receptor
mRNA in the rat heart, showed upregulation of ET-1 synthesis in the myocardium, as
well as modification of ET receptor expression in the presence of selective ATi
blockade, suggesting a role for the AT2 receptor in regulating expression of the




AVP belongs to a family of vasoactive and mitogenic peptides and has multiple
actions including inhibition of diuresis, contraction of vascular smooth muscle,
trophic actions and platelet aggregation (reviewed by Burrell et al., 2000). Recently,
de novo synthesis of AVP has been identified in the rat heart (Hupf et al., 1999),
suggesting that the peripheral and central AVP systems may exist as separate
independent systems.
The precise role of AVP in the pathophysiology of cardiovascular disease is
controversial. However, circulating levels of AVP are elevated in heart failure
(Naitoh et al., 1998) and in low-renin hypertension (Bakris et al., 1997). In CHF,
AVP may contribute to water retention and hyponatraemia through effects at the
renal V2 receptor and to increased peripheral resistance through potent constrictor
actions at the Via receptor. Therefore, the recent availability of orally active non-
peptide vasopressin receptor antagonists may allow AVP receptor antagonism to be
considered as a therapeutic option in cardiovascular disease.
1.3.4.4.Atrial and brain natriuretic peptides
The natriuretic peptides, including ANP and BNP, are upregulated in heart failure
and counteract neurohormones that induce vasoconstriction and fluid retention. ANP
induces both diuretic activities via inhibition of aldosterone secretion and
vasodilation through inhibition of noradrenaline release from terminal neurons
(reviewed by Stein et al., 1996). In addition there is evidence that the natriuretic
peptides may directly inhibit fibroblast and vascular smooth muscle hypertrophy and
interstitial fibrosis (Itoh et al., 1990; Cao & Gardner, 1995). However, increased
levels of natriuretic peptides in CHF are overcome by the drives toward
vasoconstriction and sodium retention resulting from RAAS activation. In addition,
the atrial stretch receptors involved in the secretion of ANP become downgraded,
and vascular ANP receptors decrease their sensitivity to circulating ANP stimulation
(Ferrari & Agnoletti, 1989; Matsumoto et al., 1999).
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1.3.5 Current clinical treatments
1.3.5.1 Diuretics
Diuretics are generally prescribed for all patients with heart failure who have
evidence of fluid retention, such as pulmonary congestion, raised jugular venous
pressure, or peripheral oedema. The increased diuresis and consequent reduction of
the expanded blood volume is accompanied by improvement in cardiac pumping
performance due to the reduction in preload and afterload. However, in using
diuretics, specific attention needs to be directed towards prevention of side effects
that include electrolyte imbalances, activation of neurohormonal systems,
hypotension, and interaction with other drugs (for example hyperkalaemia) when
using potassium sparing diuretics in combination with ACE inhibitors.
1.3.5.2 ACE inhibitors andAng II receptor antagonists
ACE inhibitors block the conversion of Ang I to Ang II and prevent the degradation
of BK by ACE. They therefore alter the balance between the vasoconstrictive, salt
retaining, and hypertrophic properties of Ang II and the vasodilatory and natriuretic
properties of BK. In large randomised clinical trials, ACE inhibitors have been
shown to improve ventricular function, prolong survival and reduce the need for
hospital admissions in patients with heart failure (reviewed by Lonn & McKelvie,
2000). Adverse effects of ACE inhibitors such as hypotension, syncope,
hyperkalaemia, and renal insufficiency can occur, with careful initiation of treatment
and subsequent regular monitoring required. Furthermore, a non-productive cough
may develop in some patients via an ACE inhibitor-mediated increase in bradykinin.
Ang II receptor antagonists (ARAs) can be used as an alternative to ACE-inhibitors
when side effects (such as cough) are encountered. The effects of Ang II are
mediated through two receptors; clinically available ARAs block only the ATi
receptor, but unopposed stimulation of AT2 receptor by Ang II may be beneficial
through AT2 mediated potentiation of the kinin pathway and increased NO
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generation (Liu et al., 1997; Carey et al., 2000). Studies comparing the effects of
ACE-inhibitors against ARAs show ARAs to be as effective as, but not superior to
long-lasting ACE inhibitors in reducing morbidity and mortality (Dickstein et al,
1995; Lang et al., 1997). In current clinical practice, ARAs may be deemed an
alternative to ACE inhibition for treatment of CHF when class specific side effects
such as cough (due to increased circulating bradykinin) are encountered, but ACE-
inhibitors remain the agents of choice.
1.3.5.3 Vasodilators
The term 'vasodilators' encompasses a wide range of different pharmacological
groups, which have widely diverse activities in the peripheral and central
circulations. These range from the early ai-adrenoreceptor antagonists through such
groups as the direct acting peripheral vasodilators, nitrates, hydralazine and
minoxidil. Also included are the slow calcium antagonists which only dilate the
systemic arteriolar resistance vessels; atrial natriuretic peptidase inhibitors with
combined arteriolar and venodilator activities, and potassium channel activators with
similar combined vasodilator effects.
It has become increasingly common to combine vasodilators such as nitrates or
hydralazine with other treatments such as ACE inhibitors. This further enhances
cardiac index while reducing pre- and afterload. However, as blood pressure and
renal perfusion pressure decline, sodium and water retention may worsen. Thus a
delicate balance between optimising systemic hemodynamics and maintaining renal
perfusion needs to be achieved (reviewed by Schrier et al., 2000).
1.3.5.4 /3-blockers
The primary site of action of P-adrenoreceptor antagonists is thought to be a decrease
in renin release form the kidney. P-adrenoreceptor antagonists act by inhibiting the
activation of P-adrenoreceptors, thereby preventing the deleterious actions of chronic
increased adrenergic stimulation on the failing heart that include an increase in heart
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rate, contractility, and atrio-ventricular conduction. Recently, randomised controlled
trails have shown the benefits of P-adrenoreceptor antagonists on cardiac function,
symptoms, exercise performance and survival. The Second Cardiac Insufficiency
Bisoprolol Study (CIBIS-II) found a 34% reduction in mortality and a 20% decrease
in the risk of admissions to hospital in those treated with the selective Pi
adrenoreceptor antagonist bisprolol over a mean period of 1.3 years (Lechat et al.,
1999). Carvedilol, a non-selective P-adrenoreceptor antagonist, also possessing
peripheral vasodilating activity due to «i adrenoreacptor antagonism, showed lower
mortality rates in two separate studies (Packer et al., 1996; MacMahon et al., 1997).
Several other trials of P-adrenoreceptor antagonists in heart failure also showed
improvement in survival, cardiac function and symptoms in treated patients (Lechat
et al., 1998). However, major side effects such as hypotension, fluid retention, and
bradyarrythmias are often related to use of P-adrenoreceptor antagonists.
Furthermore, caution is warranted in the initiation and titration of therapy, as
symptoms of CHF may transiently worsen.
1.3.5.5 Positive inotropes
Digitalis glycosides have many properties including mild positive inotropy, increased
delivery of sodium to the distal tubules leading to suppression of renin secretion from
the kidneys, and parasympathetic activation with resultant increased vagal tone.
When atrial fibrillation is present in patients with heart failure cardiac glycosides are
clearly indicated to lower ventricular response rates. The Digitalis Investigation
Group's large study found that digoxin was associated with a sympathomimetic
improvement in patients with CHF. But although there was a reduction in the
combined end-points of admission, there was no significant improvement in overall
survival (Perry et al., 1997).
A major pharmacotherapeutic drawback of digitalis is its narrow dose-response
relationship so that the fixed dose selected in order to avoid toxicity often falls short
of the effective therapeutic range. Side effects such as cardiac arrhythmias, nausea
and neurological complaints are commonly associated with digoxin toxicity.
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1.3.6 Endothelin & heart failure
Activation of the ET system, like that of the sympathetic and renin-angiotensin
systems, is part of the neural, hormonal and cytokine response of the body to CHF.
Patients with CHF have higher plasma ET-1 concentrations (in the vasoactive range
5-40 pmol/L) than healthy individuals (Naruse et al., 1991; McMurray et al., 1992).
However, elevated plasma ET-1 is characteristic of severe CHF and not
asymptomatic or mild cases, with plasma ET-1 levels being found to increase only in
the latter stages of CHF when accompanied by renal failure or pulmonary
congestion. Wei et al. (1994) reported plasma increases only in patients with
moderate (NYHA class III) or severe (NYHA class IV) CHF compared with healthy
individuals with asymptomatic (NYHA class I) or mild (NYHA class II) CHF.
Measurement of plasma big ET-1 has been recommended as a better marker of CHF,
with levels being found to correlate with right atrial pressure, left ventricular ejection
fraction and NYHA classification of CHF (Pacher et al., 1993). Furthermore, in a
study involving patients with advanced CHF, plasma big ET-1 was strongly related
to survival and seemed to predict 1-year mortality better than did haemodynamic
variables and concentrations of atrial natriuretic factor, an established prognostic
marker ofCHF (Pacher et al., 1996).
Although the source of elevated plasma ET levels in established CHF is unclear, at
least two mechanisms may be responsible. The first possibility is increased
production of ET-1. Studies in vitro showed increased ET-1 secretion by the
endothelium in the presence of Ang II or AVP (Resink et al., 1990b; Emori et al.,
1991). With both AVP and Ang II being elevated in CHF, these may serve as stimuli
for ET-1 production (Rubanyi & Polokoff, 1994). In addition to increased
production, decreased clearance of ET-1 from the circulation may also occur during
CHF. Cavero et al. (1990) found that after infusion of the same concentration of ET-
1, a 3-fold or greater increase in plasma immunoreactive ET-1 occurred in dogs with
CHF when compared to healthy controls indicating, at least in this animal model,
clearance of ET-1 was decreased. Although impaired renal function and decreased
clearance may be involved in generating high plasma ET-1 levels, increased plasma
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levels of big ET-1 (Pacher et al., 1993) suggest that increased synthesis may also
contribute.
A number of reports have investigated the expression and distribution of the ET-1
system in human heart failure. ET-1 mRNA expression and immunoreactive ET-1
have been demonstrated in endothelial cells of human cardiac tissue from patients
with ischaemic heart disease and idiopathic dilated cardiomyopathy (Plumpton et al.,
1996). Giaid et al. (1995) showed ET-1 immunoreactivity and preproET-1 mRNA
expression localised to vascular and endocardial endothelial cells, as well as to
cardiomyocytes in endomyocardial biopsy specimens of transplanted hearts from
end-stage heart failure patients. Cardiac myofibres in the immediate vicinity of
replacement granulation tissue and fibrosis showed the most intense immunostaining
for ET-1 and hybridisation signals for preproET-1 mRNA. However, another human
study located ET-1 immunoreactivity of similar intensities in ventricular
myocardium from both healthy hearts and from failing hearts of patients with severe
CHF (Wei etal., 1994).
Animal models of experimental heart failure have now been designed to further
address questions that are difficult to answer in human studies in vivo. Most humans
with heart failure present in the later stages, thus animal models can be particularly
useful as they allow study in the early stages. Advantages include the ability to study
the natural history of the syndrome free from the continuous effects of treatment, to
carry out experimental procedures not possible in humans, and to test new treatments
before their safety is established in humans. Reviews of animal models of heart
failure have all generally concluded that no one animal model can mimic the pattern
of human heart failure. An ideal model should have a common human counterpart
and should closely mimic heart failure in humans. Studies investigating the aetiology
of heart failure have reported coronary heart disease (Parameshwar et al., 1992), and
ischaemic heart disease (Smith, 1985; Andersson et al., 1993) as major contributors
to the development of heart failure.
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Many different models have been developed and most are useful in evaluating
particular aspects of failure and can provide information not available in the clinic
(Doggrell & Brown, 1998). Various models have been used to produce MI in
mammals. Coronary ligation has been employed in dogs, but animals that survived
the procedure developed small infarcts with only minor haemodynamic abnormalities
(Hood et al., 1967). The most widely studied MI model is that produced by coronary
artery ligation in the rat (Selye et al., 1960). Animals with large infarcts (>46% of the
whole LV) had increased LV diastolic pressure and LV dysfunction (Pfeffer et al.,
1979). The popularity of the model also stems from the fact that it is the only model
of heart failure caused by IHD (reviewed by Arnolda et al., 1999). Furthermore,
responses to treatment in this model have in some instances being confirmed in
humans with heart failure, particularly in the case of ACE inhibitors (The
CONSENSUS Trial Study Group, 1987; Pfeffer et al., 1988). The rat model of heart
failure involving coronary artery occlusion by ligation was used in the investigations
of this thesis.
Evidence of a role for ET-1 in the development of experimental CHF is more
prominent. In both dog (Margulies et al., 1990) and rat (Sakai et al., 1996a)
experimental models of CHF, circulating plasma levels of ET-1 have been shown to
be elevated. In CHF induced by pressure overload in the rat, preproET-1 mRNA and
ET-1 content were elevated in the hypertrophied left ventricles (Yorikane et al.,
1993). Increased preproET-1 mRNA, ET-1 content, and ET receptor density were
also demonstrated in the left ventricle 3 weeks after coronary artery ligation in CHF
rats (Sakai et al., 1996b), though this group did not attempt to localise the cellular
sites of overexpression. Furthermore, myocardial ET-1 mRNA levels were shown to
be increased after 1 week in dogs induced with congestive heart failure by rapid
ventricular pacing (Margulies et al., 1990).
Questions remain as to how, and more specifically when, and where the myocardial
ET-1 system may be upregulated during the development of CHF. ET-1 could
contribute towards dysfunction through stimulation of myocardial hypertrophy and
ventricular remodelling that occur in response to a myocardial infarction. ET-1 has
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been shown to exert hypertrophic effects directly in vitro in ventricular
cardiomyocytes isolated from hearts of adult rabbits (Mullan et al., 1997). ET-1 also
stimulated both a and (3-myosin heavy chain gene expression in an isolated neonatal
rat myocardial cell culture system (Wang et al., 1992).
ET receptor number and/or sensitivity may play an important role in the actions of
ET-1 during the progression of CE1F. Cannan et al. (1996) showed an attenuated
coronary vasoconstrictor response to ET-1 with an enhanced vasoconstrictor
response to SRTX S6c, suggesting an alteration in coronary ET receptor sensitivity
in a dog experimental model of CHF. Another study found a selective increase in
expression of ET-1 and the ETA receptor subtype in the hypertrophied myocardium
of the aorto-venacaval fistula rat (Brown et al., 1995).
Understanding the actions of the ET system during heart failure has been further
aided by the development of many compounds that block ET receptors or ET-
specific enzymes. The ETA receptor antagonist BQ-123 and the ECE inhibitor
phosphoramidon were shown to cause arterial vasodilatation when infused into the
forearm circulation of patients with stable CHF who were already receiving
treatment with a loop diuretic and a maximal dosage of ACE inhibitor (Love et al.,
1994). In comparison with healthy volunteers, BQ-123 induced vasodilatation tended
to be reduced and phosphoramidon-induced vasodilatation increased in patients with
CHF, consistent with upregulation of ETe-mediated vasoconstriction. Furthermore,
an interesting study by Sakai et al. (1996b) found that administration of the ETA
receptor antagonist BQ-123 (10 days after ligation) to rats for 12 weeks during the
development of severe CHF markedly increased survival, while improving left
ventricular dysfunction and preventing ventricular remodelling.
However, many studies are now investigating the actions of mixed endothelin
antagonists. Infusion of the combined ETA/ETB receptor antagonist bosentan for 2
hours (lOOmg followed 1 hour later by 200mg) in a group of 24 patients with CHF
significantly lowered pulmonary arterial blood pressure and vascular resistance and
increased the cardiac index (Kaddoura & Poole-Wilson, 1996). Administration of
50
Chapter 1
bosentan to patients with severe CHF also produced sustained systemic, pulmonary
and peripheral venous vasodilatation, and improved cardiac performance, without
causing reflex tachycardia (Kiowski et al., 1995). These studies have established that
ET-1 exerts measurable haemodynamic effects in heart failure. However the
haemodynamic effect of antagonists has so far been modest, and improved effects
may depend on timing of administration and bioavailability of antagonist used.
Although a significant increase in plasma ET-1 levels has been reported in the early
phase of acute MI in patients (Nakamura et al., 1993; Stewart et al., 1991), evidence
that ET-1 plays a role in determination ofmyocardial infarct size following coronary
artery occlusion is controversial (Watanabe et al., 1991; Grover et al., 1993; Hide et
al., 1995). Antagonist studies have been conducted mainly in acute models of
ischaemia and reperfusion. This model, depending on the timing of reperfusion after
coronary artery occlusion, produces animal models with varying degrees of
myocardial damage. This is different to the model used in the present study, in which
irreversible occlusion leads to major myocardial damage in the affected area with
blood flow re-entering the infarct, in the initial stages, most probably via collateral
flow (Maxwell et al., 1987). Grover et al. (1993) indicated a significant reduction in
infarct size after administration of the ETa receptor antagonist BQ-123 into the left
circumflex artery, 90 minutes after left coronary artery occlusion and reperfusion. A
further study found a monoclonal antibody to ET-1 (AwETN40) reduced infarct size
by 38% when administered 5 minutes after induction of coronary artery occlusion for
1 hour (Watanabe et al., 1991). Additionally, another study showed a 0.3nM/kg
injection of ET-1 reduced myocardial infarct size by activation of ATP-sensitive
potassium channels in a rabbit model of myocardial ischaemia and reperfusion (Hide
et al., 1995). Also, intracoronary infusion of the ETA receptor antagonist FR139317
increased infarct size in the dog, suggesting that endogenous ET-1 may have
cardioprotective effects (Velasco et al., 1993). ET-1 has been shown in vitro to
promote fibroblast proliferation (Takuwa et al., 1989) and increased synthesis of
collagen (Guarda et al., 1993); therefore ET-1 may be involved in the processes of
scar formation following MI. However, whether myocardial tissue levels of ET-1
change post-MI, and if so, where these changes specifically occur, is not known.
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1.4 General Aims of Study
Although evidence of an ET-1 system has been reported in the normal heart
(Molenaar et al., 1993; Plumpton et al., 1993), little is known about the specific
cellular distribution of ET-1 and its receptors throughout the myocardium.
Furthermore, it has been demonstrated that ET-1 levels in the heart increase post-MI,
though it is unclear how, when and where these changes occur. Possible mechanisms
may involve increased uptake of ET-1 by the heart into the myocardium from
circulating plasma, or the myocardium itself may synthesise increased amounts of
ET-1 locally due to increased workload and stress induced by a MI. Furthermore, if
increased levels of ET-1 peptide are synthesised in the heart early after MI or during
development of CHF, it is not clear in which specific cells of the heart these
increases are localised.
ETa/ETb receptor expression may also change post-MI, though it is unclear which
areas of the myocardium and what cells may be specifically affected. There is
evidence that antagonist treatment may be important in controlling the ET-1
mediated effects during CHF. It is not known, however, if blocking ET receptors in
the early stage after onset ofMI is beneficial or detrimental to scar formation.
This thesis set out to investigate the following hypothesis:
1. A local myocardial ET-1 system is present in the healthy hearts of rats.
2. Changes occur in the myocardial ET-1 system that contribute to structural
changes in the early stage post-MI and during the progression ofCHF.
The main aims of this thesis were therefore to characterise the ET-1 system in
healthy hearts of rats, and then to investigate the ET-1 system during the
development ofCHF following MI with reference to ET-1 peptide, preproET-1, ETA,
and ETb mRNA expression. Also, a major aim was to investigate any possible
correlation between the ET-1 system and myocardial hypertrophy, fibrosis and
vascular remodelling during progression of CHF.
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With previous studies reporting an increase in plasma ET-1 in the acute phase ofMI,
a further study was conducted to characterise early stage scar formation following
left ventricular MI induced by coronary artery ligation in the rat, with reference to
changes in myocardial ET-1 peptide levels. The effect of an ET-1 mixed receptor








This chapter details the experimental techniques that are referred to in more than one
results chapter. All experiments were performed using the appropriate level of safety
as prescribed in the Control of Substances Hazardous to Health regulations. All
animal work was carried out in accordance with the Animals (Scientific Procedures)
Act (1986).
2.1 Coronary artery ligation surgery
Male Wistar rats (250+5g, Charles River, UK) were subjected to ligation of the
proximal portion of the left coronary artery and infarction of the left ventricular free
wall according to the method of Selye et al. (1960) and modified by Pfeffer et al.
(1979). Rats were allowed access to normal rat chow and water ad libitum, for at
least 2 days after arrival prior to surgery.
On the day of surgery, the rat was weighed immediately before operation, then
anaesthetised by injection ofNa pentobarbital (60mg/kg i.p.; Sagatal, Rhone Merieux
Ltd., Essex, UK). The front right area of the rat's chest was shaved and cleaned with
70% alcohol. The rat was then placed on a thermostatically controlled heating pad
for surgery and intubated (1.5mm diameter plastic cannula, Portex Ltd., UK) via the
mouth with the aid of a guide wire.
Mechanical ventilation (room air mixed with 100% O2) was achieved by use of a
small rodent ventilator (Harvard Apparatus Ltd., Kent, UK) at a rate of 60
cycles/minute and a tidal volume of lml/lOOg body weight. Autoclaved instruments
were used to cut a 2cm long area of the skin parallel to the direction of the ribs. The
underlying muscle layers were gently separated using blunt scissors and held in
position by smooth metal clips, revealing the rib cage. A left thoracotomy was
performed between the fourth and fifth ribs exposing the inner chest cavity. To avoid
damage to the lungs during surgery, the left lung was collapsed by folding a small
square of sterilised gauze and using it to cover the lung, which was then gently
pushed downward and away from the heart. The pericardium was then cut and the
heart gently and rapidly exteriorised by gentle application of pressure to the thorax.
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A 1Omm round bodied needle (Ethicon® Ltd, Edinburgh, UK) was passed around the
proximal left coronary artery. The heart was subsequently returned to its position in
the thorax, and the ligature left untied for 10 minutes to permit recovery from initial
trauma. The ligature was then tied and the chest incision left open for a further 15
minutes to allow manual manipulation of the heart during any subsequent
arrhythmias that occurred after myocardial infarction (MI); usually between 7 and 14
minutes after MI.
Before closing the ribcage, a 0.75mm diameter plastic cannula (Portex) was placed in
the chest cavity, and the small square of sterilised gauze retaining the lung removed.
The rib cage was then closed by gently squeezing the chest cavity to remove air
before inserting 2 stitches of suture (16mm round bodied needle, Ethicon); the
remaining muscle was released back over the ribcage and the skin closed with 4
stitches of suture (25mm round bodied needle, Ethicon). The plastic cannula in the
chest cavity was connected to a 1ml syringe and used to extract any remaining air
from the chest after closure, then gently removed. The rat was then taken off the
ventilator and, when spontaneous ventilation was re-established, placed on a heated
pad and exposed to 100% O2 during recovery from anaesthesia. The tracheal cannula
was removed upon initial signs of recovery from anaesthesia after which rats were
returned to their cages. All rats were given buprenorphine hydrochloride
(Vetergesic®, 0.24mg/kg; Redcut & Colman, UK) subcutaneously upon recovery
from anaesthetic and again the following morning for analgesia. Sham-operated rats
were subjected to the same protocol, except the ligature was not tied, but pulled
through under the coronary artery.
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After the allocated period of ligation or sham-operation, the rats were anaesthetised
by injection of Na pentobarbital (60mg/kg i.p.). The left carotid artery was located,
dissected free of extraneous tissue and cannulated with either a polyethylene fluid
filled catheter attached to a pressure transducer (Senso Noras Ltd., Horten, Norway),
or a pressure transducer-tipped catheter (Model SPR-407, Millar Instruments, Texas,
USA), attached to a MacLab (version 3.4/e) system (AD Instruments, Hastings UK).
The catheter was fed via the left carotid artery and aorta into the left ventricle where
left ventricular end-diastolic pressure (LVEDP) was measured and analysed on an
Apple Mac computer (model LC 475).
Figure 2.1 A sample pressure-transducer reading from within the carotid artery
(CA) recording arterial blood pressure, and within the left ventricle (LV) recording
left ventricular end-diastolic pressure (L VEDP).
Pressure
(mmHg)




The initial part of the trace (Figure 2.1) displays arterial blood pressure in the carotid
artery, from which mean arterial blood (MAP) pressure can be measured. As the
catheter enters the left ventricle the trace becomes larger, and now indicates left
ventricular end systolic pressure. An LVEDP value was measured by calculating the
average pressure reading from the troughs of 20 pressure spikes along the LVEDP
trace.
Following haemodynamic measurements, the rat was exsanguinated via a needle
(1mm diameter, Microlance®, Becton Dickinson, Ireland) placed in the dorsal aorta
and an ~8ml blood sample collected into a 10ml syringe pre-rinsed with heparin (100
U/ml final concentration, Multiparin®, CP Pharmaceuticals, Wrexham, UK). The
blood was aliquoted into pre-chilled test tubes containing 50pl of 10mmol/l
ethylenediaminetetraacetic acid (EDTA; Sigma, UK) and immediately centrifuged
(2000g, 4°C, 20 minutes). Plasma was aliquoted from each sample and stored at -
70°C for future plasma ET-1 and big ET-1 analysis. The heart, lungs and kidneys
were excised, rinsed in ice-cooled physiological saline, then individually weighed.
The heart was cut apex to base so that each section encompassed both left and right
ventricle. All samples were placed in 10% neutral buffered formalin solution (Sigma,
UK) for 24hrs fixation. The next day, heart sections were further processed and wax
embedded. As the tissue fixative (10% formalin) is in aqueous solution, the water has
to be removed in order to embed the tissue in paraffin wax. This was achieved by
immersion in increasing strengths of ethanol, and is known as dehydration. Since
alcohol and wax are not miscible, the alcohol must be replaced by a wax solvent, and
as the majority of wax solvents have the effect of raising the refractive index of
tissue, which make them appear clear, this stage has become known as clearing. The
heart was finally embedded in wax, while the rest of the organs and tissue were
stored at -70°C for future analysis.
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2.2.1 LDH (lactate dehydrogenase) assay for confirmation of successful CAL
During periods of hypoxia or induced cellular damage, cells can still produce ATP
via anaerobic glycolysis. Glucose is broken down to pyruvate via the following
reaction:
Glucose + NAD+ + 2ADP ► Pyruvate + NADH + 2ATP
This reaction does not last long as cellular levels of NAD+ become depleted.
However, the cell regenerates NAD+ by the following reaction:
Pyruvate + NADH + H+——► Lactate + NAD+
LDH is an enzyme that catalyses this final reaction of anaerobic glycolysis, namely
the reduction of pyruvate to lactate. It is an NADH-linked dehydrogenase and
consists of four subunits. There are two kinds of subunit designated M and H. In
human skeletal muscle the homogeneous tetramer of M4 type predominates and in
the heart the H4 tetramer is the predominant form (Apps et al., 1992). Other
heterogeneous forms such as M3H, M2H2 and MH3 occur in blood serum.
A very sensitive clinical test for heart disease is based on the existence of the various
isozymic forms of this enzyme. The relative amounts of H4 and MH3 isozymes in
blood serum increase dramatically after myocardial infarction compared with normal
serum. A commercial LDH assay kit (LDH, Boehringer Mannheim, UK) allowed in-
lab spectrophotometrical measurement of LDH enzyme levels from plasma samples
removed from rats two hours after ligation operation, thereby determining whether a
successful ligation had been performed. The basis of the kit utilises the reaction
whereby LDH catalyses the reduction of NADH, whose rate of reduction correlates
with concentration of LDH present. NADH reduction results in a decrease in
absorption at 340nm wavelength, allowing LDH concentration to be indicated over a
set time period (Apps et al., 1992).
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Briefly, a tail-tip blood sample was collected directly into prechilled test tubes
containing EDTA (10mmol/l final concentration), kept on ice and centrifuged at
2000# for 20 minutes at 4°C. Plasma was extracted into test tubes and heated to
27°C. From the LDH assay kit, one reagent tablet was added to 3ml of
buffer/substrate and also heated to 27°C (end concentration in reagent solution:
phosphate buffer: 50mmol/l, pH 7.5; pyruvate: 0.6mmol/l; NADH: 0.18mmol/l).
1,5ml of buffer was then placed in a spectrophotometer set to 340nm wavelength and
the reading set to zero. To initiate the reaction, 50pl of plasma was added to the
1.5ml buffer and the spectrophotometer reading taken immediately. Further readings
were taken at 1-minute intervals for 3 minutes and the average reading was
calculated over the time period. An average reading of at least 3 times greater than
that found in plasma from a corresponding sham-op rat indicated a successful
ligation.
2.2.2 Measurement of plasma ET-1 / big ET-1.
ET-1 and big ET-1 were measured using an in-house radioimmunoassay (RIA)
technique (Hand et al., 1999) and performed with the assistance ofMr. Neil Johnston
at the Clinical Pharmacology Unit, Western General Hospital, Edinburgh.
2.2.2.1 Introduction
RIA is a well validated technique used to measure any antigenic component present
in a liquid sample. Similar to immunohistochemistry, this technique utilises specific
antibodies (Abs) raised against the antigenic substance in question, followed by the
addition of radiolabeled antigen (Ag). The radiolabeled, precipitated Ag/Ab
complexes are then measured in a gamma counter. Therefore, the higher the
concentrations of endogenous antigen, the lower the amount of bound radiolabeled
antigen and the subsequent radiation counts. For this thesis, both ET-1 and big ET-1
levels were measured in plasma samples from rats undergoing either coronary artery
ligation surgery or sham-operation to ascertain whether there was increased
circulating production of the peptide. Increased circulating levels of ET-1 and big
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ET-1 have been demonstrated in both human and animal studies (see section 1.3.6).
However, it is important to delineate between the two forms of the peptide, since it
may help in demonstrating whether there is an upregulation of the production of ET,
or reduced clearance and elimination of the mature peptide, in CHF. In order to
answer this question, primary, polyclonal antibodies raised in rabbits against human
ET-1 and big ET-1 (Peninsula Labs, USA) were used. These antibodies have a 100%
reactivity with rat ET-1 and big ET-1. Furthermore, The ET-1 Ab had a cross
reactivity with big ET-1 of 10%, and the big ET-1 Ab had a cross reactivity with ET-
1 of 8%.
There are two main components to the measurement of ET-1 or big ET-1 from the
plasma samples in the RIA technique. These are, the extraction of either ET-1 or big
ET-1 from the sample, and subsequent RIA of the extracts.
2.2.2.2 Extraction technique
An ~8ml blood sample was collected as previously described (Section 2.2). ET-1 and
big ET-1 had to be extracted from the plasma samples due to the extremely low
circulating levels of these peptides. The peptides were extracted using Cis 200mg
Bond Elut Extraction Cartridges (Varian Sample Preparation Products, Switzerland).
These cartridges are internally coated with a silica sorbent that consists of an
octadecyl carbon matrix with high affinity for peptide molecules containing polar
groups, such as ET-1 and big ET-1.
Prior to extraction of the sample, the extraction columns had to be activated to obtain
the correct conditions for the extraction of either ET-1 or big ET-1. For ET-1 and big
ET-1 extraction, 3ml of 100% methanol (BDH-Merck, UK) was added to the column
and allowed to flow through. The columns were washed with deionised water, and
then brought to pH 5.5, by the addition of 2ml of 10% acetic acid (BDH-Merck,
UK). After thawing, the plasma samples were acidified with 20% acetic acid (1:1
v/v; 2.5ml:2.5ml), added to the column for extraction and left to flow through by
gravity. The column was washed with 2ml of 10% acetic acid to remove any
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unwanted proteins, followed by 3ml of ethyl acetate (BDH-Merck, UK) to remove
any unwanted lipids, from the column. To elute the ET-1 fraction from the extraction
columns, collection tubes were placed under the extraction columns, and 1.5ml of
elution buffer (80% methanol / 20% 0.05M ammonium bicarbonate solution; BDH-
Merck, UK) was added to the columns and allowed to flow through by gravity.
Following the collection of the eluted ET-1 or big ET-1 extracts, the elutes were
dried down under nitrogen (British Oxygen Company, UK) in a water bath at 37°C.
The dried elutes were reconstituted with 0.25ml assay buffer, and stored at -40°C
until assay (generally the next day). Previous validation studies in the laboratory
have demonstrated that the extraction/recovery rate is 89% for the ET-1 protocol and
91% for the big ET-1 methodology (Hand et al., 1999).
2.2.2.3 Standard curves
The standard concentrations used in the ET-1 and big ET-1 RIAs were as follows.
The stock concentration of ET-1 (Peninsula Labs, USA) was 64pg/ml. Serial 1:1
dilutions using assay buffer were performed, giving concentrations of 32pg/ml (S32),
16pg/ml (SI6), 8pg/ml (S8), 4pg/ml (S4), 2pg/ml (S2) and lpg/ml (SI). The stock
concentration of big ET-1 (Peninsula Laboratories, UK) was 128pg/ml (S^g). as for
the ET-1 standard curve, serial 1:1 dilutions using assay buffer gave standards of S64,
S32, S 16, Ss, S4, S2, Si and S0.5.
Duplicates of lOOpl of each sample and standard were assayed. Furthermore, 3 other
control tubes were made up and assayed. These were the 'Blank', which contained
195 195
only assay buffer solution, I-ET-1 or I-big ET-1 and Amerlex™ donkey anti-
rabbit antibody (Amersham Life Sciences Ltd., UK); a 'Reference' tube which
125 125
contained assay buffer solution, primary Ab, I-ET-1 or I-big ET-1; and
125




2.2.2.4 ET-1 RIA protocol
After thawing of the ET-1 extracts, lOOpl of the primary anti-human ET-1 Ab
(1:20,000; Peninsula Laboratories, UK) was added to lOOpl of sample, standard and
reference tube (but not the blank or total tubes), vortexed and left to incubate at room
temperature for 4 hours. The ET-1 Ab had previously been diluted 1:20 in 0. 1%
Triton-X (BDH-Merck) in assay buffer solution. Following incubation, lOOpl of 125I-
ET-1, which is diluted to contain 7500 cpm, was added to the samples, standards,
reference, blank and total counts tubes, vortexed and allowed to incubate overnight at
4°C.
1 9 S
In order to separate out the Ag/Ab complexes from the unbound I-ET-1, 200pl of
Amerlex™ was added to all tubes, except the total tube, vortexed and incubated for
30 minutes at room temperature. Amerlex™ is a separation reagent, which consists
of magnetic polymer beads coated with donkey, anti-rabbit IgG, which binds to the
bound Ag/Ab complex. The separation of the free and bound fractions were carried
out using a magnetic separator and centrifugation at 4°C allowing the beads to
migrate to the base of the tube, taking with them any bound, labelled complex. The
• • 1 9 S
unwanted supernatant containing any unbound I-ET-1, as well as any other
substances present in the sample, was aspirated off and the resulting pellets were
counted for radioactivity in the Gamma counter (Wallac, Finland). The standard
curves were plotted using an automatic sigmoid plot line (spline) programme within
the counter, and the levels of ET-1 present in each sample calculated from the
standard curve.
2.2.2.5 Big ET-1 RIA protocol
A similar methodology to the ET-1 RIA was used for measurement of big ET-1
levels. However, lOOpl of rabbit anti-human big ET-1 Ab (Peninsula Laboratories,
UK) was added to the relevant tubes and samples and left to incubate overnight at
I 9 S •
room temperature. lOOpl of I-big ET-1 was added on the second day of the assay.
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After overnight incubation at 4°C, 200pl of Amerlex™ was added to each tube
(except the Total), and the rest of the protocol performed as for the ET-1 RIA.
2.2.3 General Staining
2.2.3.1 van Gieson's collagen stain
Wax embedded hearts were sectioned at 3 pm and floated out on a water bath set at
48°C. Sections were then placed on TESPA (3-Aminopropyltriethoxy-saline; Sigma,
UK) - coated slides (see Appendix) and allowed to adhere overnight in an oven at
37°C. For collagen staining, sections were initially dewaxed through xylene and
rehydrated through 100, 90 and 70% alcohol solutions before being placed in water
for 15 minutes. Sections were then dipped in Celestine Blue nuclear stain for 2
minutes, immersed in van Gieson's stain for 3 minutes, then dehydrated through 70,
90 and 100% alcohol solutions and xylene before being mounted in DePeX mounting
medium (BDH Laboratory Supplies, UK).
2.2.3.2 Haematoxylin and eosin stain
3pm tissue sections were dewaxed and rehydrated as described above. Sections were
then immersed in haematoxylin (Harris', BDH, UK) for 3 minutes, and rinsed briefly
in distilled water before being immersed in 1% eosin (BDH, UK) for 5 minutes.
Finally, sections were dehydrated through 70, 90 and 100% alcohol solutions and
xylene before being mounted in DePeX mounting medium.
2.2.3.3 Neutrophil stain
Neutrophils were detected in myocardial granulation tissue using a diagnostic kit that
highlights Naphthol AS-D Chloroacetate Esterase (Sigma, UK), an enzyme that is
present in, and usually considered specific for, cells of granulocytic lineage. Briefly,
3 pm tissue sections were dewaxed and rehydrated as described above. Sections were
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then incubated with napthol AS-D chloroacetate in the presence of freshly formed
diazonium salt protected from light for 30 minutes at 37°C. Enzymatic hydrolysis of
ester linkages liberates free napthol compounds. These couple with the diazonium
salt, forming highly colored (purple) deposits at sites of enzymatic activity. Finally,
sections were covered with mounting medium (Aquamount Improved, BDH, UK)
and placed in coverslips.
2.2.3.4 Apoptosis Assay
Apoptotic cells were detected using a DeadEnd™ Colometric Apoptosis Detection
System (Promega, UK), which end-labels the fragmented DNA of apoptotic cells
using a modified in situ nick end-labelling (TUNEL) assay. Biotinylated nucleotide
was incorporated at the 3'-OH DNA ends using the enzyme Terminal
deoxynucleotidyl Transferase (TdT). Horseradish-peroxidase-labelled strepavidin
was then bound to these biotinylated nucleotides, which were detected using the
peroxidase substrate hydrogen peroxide and the stable chromagen diaminobenzidine
(DAB). Apoptotic nuclei appeared brown. The procedure was carried out with the
assistance ofMr. David O' Regan.
2.2.4 Measurement of infarct parameters
Sections from hearts stained with van Gieson's collagen stain were used to measure
different parameters of the infarct including infarct size, thickness and myocardial /
collagen ratio of the infarct. Infarct size was measured as previously described by
Mulder et al. (1997). Briefly, sections were placed under a CCD video camera
module (Sony, UK) attached to a microscope with a x20 lens, and an image of the
heart brought up on computer as shown below {Figure 2.2).
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Figure 2.2 Scanned image of a longitudinal section of heart, which is used for
measuring infarctparameters. Key: LV, left ventricle; RV, right ventricle, S, septum;
INF, area of infarction.
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The endocardial and epicardial circumferences of the infarcted tissue and of the left
ventricle were determined with image analysis software (Zeiss Kontron 300 image
analysis package, Image Associates, Thame, UK). Infarct size was calculated as:
[endocardial +epicardial circumference of the infarcted free left ventricle (mm)]
[endocardial +epicardial circumference of the whole free left ventricle (mm)]
and expressed as a percentage. Infarct thickness was measured by randomly selecting
4 points along the length of the infarct and calculating an average value in mm.
Myocardial / collagen content of the infarct was also measured in the infarct wall of
van Gieson stained sections. This was achieved by identifying areas of collagen and
myocardium in the infarct zone using the light microscope and measuring these areas
using the image analysis equipment. The area of each was measured (in mm2) and
the ratio ofmyocardium to collagen calculated. All sections from different MI groups
within the same study were examined blinded, with heart numbers and corresponding
group reserved from the investigator until the analysis was complete.
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2.3 Antagonist administration protocol
An experimental protocol was designed to administer an endothelin ETa/ETb
receptor antagonist, A-l82086 (kind gift from Abbott Laboratories, Illinois, USA) to
groups of rats that had undergone coronary artery ligation or sham-operation. The
following initial experiments were performed to investigate if rats would drink water
containing A-l82086. Also, experiments were performed to show whether rats would
assimilate the antagonist and, finally, if a concentration of 15mg/kg rat/day
(recommended by Abbott Laboratories) was sufficient to block both ETa and ETb
dependent responses to ET-1.
2.3.1 Drinking Water Pilot Study
Initial studies indicated that a 250g rat drinks on average 35 ml of water per day
{Table 2.1).
Table 2.1 Average volume ofwater consumed by a ratper day.
Rat weight Volume Overall amount Average Average
No. (g) H20 drunk (ml) volume volume/
given day 1 day 2 consumed (ml) weight
1 250 50 ml 34 34 34 0.136
2 232 50 ml 34 33 33.5 0.144
3 212 50 ml 28 28 28 0.132




Therefore, a rat ofXg weight will drink 0.135X ml/day (35ml/250g - 0.135ml/g rat).
Rats were to receive 15mg/kg/day of antagonist; therefore a 250g rat receives
3.75mg/day. Antagonist was subsequently added to the drinking water at a
concentration of: 3.75mg day"1/35ml day"1 = 0.1071mg/ml.
Rats were individually caged and allowed free access to the water throughout the
study, which lasted either 2 or 7 days. After each 24-hour period, the amount of
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water drunk from each bottle was measured to allow assessment of water, and
therefore antagonist, consumption per rat.
2.3.1.1 Protocol to test uptake of A-182086 into rat and effective blocking of
receptors.
After an allocated time of 2 or 7 days, rats (n=2 per group) were anaesthetised by
injection of Na pentobarbital (60mg/kg i.p.). The left carotid artery was located,
dissected free of extraneous tissue and cannulated with a pressure transducer-tipped
catheter (Model SPR-407, size 2F, Millar®, Texas, USA), attached to a MacLab
(version 3.4/e) system (AD Instruments, Hastings UK). A further 0.75mm diameter
cannula was inserted into the right jugular vein and used to administer 0.05ml bolus
doses of endothelin-1 (ET-1) at concentrations of O.lnM, 0.3nM and InM (made up
in 0.9% saline). Changes in arterial blood pressure were recorded on an Apple Mac
computer (model LC 475) and analysed for the effect ofET receptor antagonism.
2.3.1.2 Resultsfrom drinking waterpilot study
Those rats not exposed to A-182086 (control, n=2) produced a dose response to ET-1
which consisted of an initial ETB receptor-mediated vasodilation followed by a
prolonged ETa receptor-mediated vasoconstriction (Figure 2.3.). Both vasodilator
and vasoconstrictor responses were more pronounced at the higher ET-1
concentrations. In rats allowed free access to drinking water containing A-182086
(15mg/kg) the ETb receptor-mediated vasodilation response was substantially
reduced after 7 days {Figure 2.4), but only partially blocked after 2 days (not shown).
However, ETA mediated vasoconstriction was not affected at either time point.
These results suggested that a higher concentration of antagonist would be needed to
block both receptors at both time points, therefore a concentration of 30mg/kg was
used as indicated by Abbott as being in the high dose range for blocking both ET
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Figure 2.3 Dose responses to ET-1 (0.1, 0.3 and l.OnM i.v.) in an anaesthetised









Figure 2.4 Response to O.lnM ET-1 in an anaesthetised rat after exposure to A-
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receptor types in rats. Also, due to the relative difficulty in measuring and assessing
drinking levels (and therefore antagonist consumption), a simpler protocol was
designed to assess the feasibility of drug administration in food.
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2.3.2 Milupa Pilot Study
This protocol involved supplementing the normal diet with a mixed cereal feed
(Milupa® mixed cereal baby feed, Seven Seas, UK) administered as a paste (5g +
9ml water) containing a precise amount of drug calculated for each rat. The rats were
maintained on a restricted diet throughout the experiment to ensure that all food
given to them, and therefore the complete drug dose, was ingested.
Rats were brought into the animal house and left for 2 days (day 0, day 1) to recover
from travel prior to surgery and fed under normal animal in-house conditions. On
day 2, rats were weighed, then started on a restricted diet of 5g Milupa for the next
24 hrs. On day 3, rats were re-weighed (should be between 80-90% of initial weight),
then given 5g Milupa with added drug and 5g of standard pellet chow (total food
weight =T0g). The drug was administered at a concentration of 30mg/kg/day to each
individually caged rat in the 2 groups and was added daily to the Milupa only e.g. (a
250g rat would receive 7.5mg ofA-182086 in the Milupa).
From day 4 onwards, rats were re-weighed, and given the same drug/Milupa dose. If
a rat had gained or lost more than 4g in weight over previous 24 hrs, then the amount
of standard pellet chow added was adjusted by decreasing or increasing the amount
given by 0.5g accordingly. This procedure was continued until the rat had finished
the dosing time cycle. Time cycles of 2 and 7 days were used for this pilot
experiment, after which rats were sacrificed and underwent a similar ET-1 dose
response protocol to those rats undergoing the drinking water study.
2.3.2.1 Resultsfrom Milupa pilot study.
An ET-1 dose response in rats (n=2) after 2 days antagonist (30mg/kg/day) treatment
in food showed ETB-mediated vasodilation to be completely blocked, but ETA-
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The lack of complete antagonism of the ETA receptor-mediated response may have
been due to the length of time between final drug consumption (28-30 hours) and
dose response experiment (the following day.). Therefore it was suggested that rats
from both groups would receive a further supplement of Milupa plus antagonist on
the morning of the day of sacrifice. Dose response experiments were then carried out
approximately 3 hours after Milupa plus antagonist consumption. Responses to both
ETa and ETB receptors were now shown to be completely blocked (Figure 2.6).
Figure 2.6 The response to O.lnM ET-1 (i.v.) in an anaesthetised rat from the 2 day
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Therefore, these pilot studies indicated that the most efficient method of drug
administration was in food with an antagonist concentration of 30mg/kg/day showing
effective blockade of both ETA and ETe-mediated responses. Also, all animals
undergoing operation and antagonist treatment would be fed their first supplement of
A-182086 upon recovery after operation and subsequent doses each morning up until
the day of sacrifice.
2.3.3 Protocol used for rats undergoing coronary artery ligation (CAL) plus
antagonist administration study
The following protocol was therefore used for administering A-182086 to the groups
of rats used in this experiment. Initially, rats (200-225g) were brought into the animal
house and fed under normal animal house conditions and given free access to water.
After 2 days, the restricted diet protocol was followed to maintain individual rat
weights at 250±5g throughout the protocol, thereby allowing a constant drug dose of
7.5mg/day to be administered.
On the day of surgery, CAL was performed as described previously and the rat
allowed to recover. Upon recovery, approximately 2-3 hrs after ligation, a tail-tip
blood sample was taken for measurement of plasma LDH levels using a commercial
assay kit (LDH, Boehringer Mannheim, UK). This was performed to assess the level
of damage to the heart and therefore an indication of a successful ligation. Rats that
had an LDH level at least 3-fold greater than sham-op levels were deemed to have a
successful ligation and were continued in the study (see section 2.3.1 for more
detailed discussion). Both sham-op and CAL rats were then randomly allocated to
receive antagonist with Milupa 'paste'. Rats undergoing antagonist treatment were
therefore given 5g Milupa paste with added drug upon recovery. Those rats not
undergoing antagonist treatment received 5g Milupa paste only.
The following morning (day 1) rats were again weighed, then given 5g Milupa (with
drug mixed in for those rats undergoing antagonist treatment) and 5g of standard
pellet chow (total food weight =10g). Therefore, rats undergoing antagonist
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treatment received 2 drug doses within the first 24 hrs after CAL. The original
schedule of feeding once every 24 hours was continued again on day 2 (with the
weight of chow fixed accordingly with changing weight of the rat) and continued for
a period of 2, 7 or 14 days whereupon the rats were sacrificed. For each group of
CAL and sham-op rats undergoing antagonist treatment, there was an equal group,
which went without. Overall, there were 12 groups in this study (Table 2.2).
Table 2.2 Number ofanimals allocated to each of the 12 groups in the study. Rats
were sacrificed at 2, 7 or 14 days after sham-operation (Sham-op) or coronary
artery ligation (CAL). A = antagonist (30mg/kg rat/day in food).
Group Sham-op CAL Sham-op + A CAL+A Total
2 day 8 8 6 6 28
7 day 8 8 7 7 30
14 day 8 8 7 8 31




2.4.1 Background to Immunohistochemistry
Immunohistochemistry (IHC) is a technique for identifying cellular or tissue
constituents (antigens) by means of antigen-antibody interactions, the site of the
antibody binding being identified either by direct labelling of the antibody, or by use
of a secondary labelling method. Antibodies are formed in the humoral immune
system by plasma cells. Immunoglobulin (Ig) G, the commonest and most frequently
used antibody for immunohistochemistry, is composed of two pairs of light and
heavy polypeptide chains linked by disulphide bonds to form a Y shaped structure.
The terminal regions of each arm vary in amino-acid sequence and this variability
provides specificity for a particular epitope and enables the antibody to bind
specifically to the antigen against which it was raised.
The primary reagents in IHC are antibodies (polyclonal and monoclonal) and lectins.
Immunising a host animal with a purified specific molecule (immunogen) bearing the
antigen of interest produces polyclonal antibodies. It is likely that the animal will
produce many clones of plasma cells with each clone producing an antibody with a
slightly different specificity to the variety of epitopes present on the immunogen (De
Mey & Moeremans, 1986). Some of these antibodies may cross-react with other
molecules and will need to be removed by absorption with the appropriate antigen.
In 1975, Kohler and Milstein developed the procedure for generating monoclonal
antibodies. This technique involves fusing activated B cells (source of antibodies)
with myeloma cells in culture. The result is a clone of antibody producing cells,
which continue to grow and divide in culture. By careful screening, hybrids
producing antibodies of interest without cross-reactivity to other molecules can be
chosen for further cloning. The end result is a supply of one pure antibody with
known specificity. The advantage of monoclonal antibodies is their absolute
specificity for a single sequence or 'epitope' on the antigen molecule.
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Lectins are sugar-binding proteins or glycoproteins of non-immune origin which are
derived from both plants and animals. Most lectins studied are multimeric, consisting
of non-covalently associated subunits. It is this multimeric structure which gives
lectins their ability to agglutinate cells or form precipitates with glycoconjugates in a
manner similar to antigen-antibody interactions. Since virtually all biological
membranes and cell walls contain glycoconjugates, all living organisms can be
studied with lectins. They can be labelled in similar ways to antibodies or identified
by using lectin-specific antibodies as secondary reagents.
Enzymes are the most widely used labels in immunohistochemistry and incubation
with a chromogen using a standard histochemical method produces a stable, coloured
reaction end product suitable for light microscopy. The two most common enzyme
labelled conjugate systems used to detect antigens are the peroxidase method and the
alkaline phosphatase method. Horseradish peroxidase is the most widely used
enzyme and in combination with the most favoured chromogen, i.e. 3,3'-
diaminobenzidine tetrahydrochloride (DAB; Sigma, UK), it yields a crisp, insoluble,
stable, dark brown end product. Alkaline phosphatase is the most widely used
alternative enzyme tracer to peroxidase. New fuschin substrate produces a permanent
insoluble red product at sites of alkaline phosphatase activity.
The method used for antigen detection in this thesis is the indirect antigen technique.
Here, the primary unconjugated antibody is allowed to bind to the antigen in the
tissue section. A second tracer-conjugated antibody, raised in another animal host
and specific for the animal and immunoglobulin class of the primary antibody, is
applied to the section and allowed to bind to the primary antibody. The complex that
forms can be visualised by incubation of the section in an appropriate substrate.
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2.4.2 IHC Alkaline phosphatase protocol
Immunohistochemistry for detection of ET-1, TGF-f3i and endothelial cells was
performed on sections of cardiac ventricular tissue taken from the CAL and sham-op
groups of rats using the alkaline phosphatase method of antibody detection.
For detection of inflammatory cells, immunohistochemistry using different
antibodies directed at specific inflammatory cell surface markers such as CD lib
(Serotec Ltd., UK) or MAC 387 (NeoMarkers, CA, USA) were performed. Both the
alkaline phosphatase method and the peroxidase method were utilised, though cell
specific staining could not be accomplished. Also, changes in antibody and serum
blocking concentration or incubation periods could not improve cell specific staining.
However, the endothelial cell marker GSL I was also found to be an excellent marker
of inflammatory cells (which were easily distinguishable from endothelial cells by
their larger cell size and defined nucleus). Therefore, though GSL I was initially
acquired as a marker for endothelial cells, it was also used to highlight inflammatory
cells via the alkaline phosphatase method of antibody detection.
Wax embedded hearts were sectioned at 3gm and floated out on a water bath set at
48°C. Sections were then placed on TESPA (3-Aminopropyltriethoxy-saline; Sigma,
UK) -coated slides (see Appendix) and allowed to adhere overnight in an oven at
37°C. The following day, sections were dewaxed in xylene, rehydrated in 100, 90
and 70% alcohol solutions and placed in water for 15 minutes before being washed
in pH 7.6 phosphate buffered saline (PBS) buffer (see Appendix) for 5 minutes.
During the process of formalin fixation, antigenic sites may become masked and
treating sections with proteolytic enzymes may restore the immunoreactivity of
masked antigens. Enzymatic pre-treatment of sections is reported to enhance not only
immunohistochemical staining but also to improve the reliability and sensitivity of
immunocytochemical methods. Therefore, sections were primarily incubated in pH
7.8 tris-buffered saline (TBS; see Appendix) for 15 minutes at 37°C before being
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treated with 0.1% trypsin (made up in TBS) for 45 minutes at 37°C, these incubation
conditions giving optimum enzyme interaction.
The main cause of non-specific background staining is a non-immunological binding
of the specific immune sera by hydrophobic and electrostatic forces to certain sites
within the tissue sections. Blocking those sites that show non-specific affinity for
immunoglobulins can reduce background staining. This can be achieved by
incubating the sections in an immunoglobulin, which will not react or interfere with
the primary specific antiserum. The section is generally incubated in normal whole
serum from the species in which the secondary antibody is raised. Sections were
therefore treated with 1% serum (goat/rabbit serum diluted in PBS) for 30 minutes at
room temperature, then incubated in either 1/300 mouse anti-ET-1, 1/40 chicken
anti-TGF-Pi, or 1/500 Griffonia Simplificolia Lectin I (GSL I; for endothelial cells
and inflammatory cells) primary antibody overnight at 4°C. For negative control
sections, the primary antibody was replaced with an identical antibody, which lacked
the specific antigen recognition site.
The following morning sections were rinsed in PBS, incubated with 1/60 alkaline
phosphatase-conjugated goat anti-mouse, 1/60 rabbit anti-chicken IgG secondary
antibody, or 1/200 goat anti GST I (for endothelial cells) for 30 minutes. Sections
were then washed again in PBS for 15 minutes before addition of a tertiary antibody
(1/60 alkaline phosphatase conjugated rabbit anti-goat IgG) for GSF I. ET-1, TGF-pi
and endothelial cell immunoreactivity was detected using new fuschin substrate
(Dako Etd., UK). A red product was precipitated at sites of alkaline phosphatase
enzyme interaction 10-15 minutes after application of substrate (Figure 2.7). All
antibody concentrations and incubation times were optimised in-lab from values
recommended by the specific antibody supplier.
Sections were rinsed in distilled water for 5 minutes and secondary stained for 3
minutes using haematoxylin (Harris', BDH. UK) that highlights nuclei in purple.
Finally, sections were covered with mounting medium (Aquamount Improved, BDH,
UK) and placed on coverslips.
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2.4.3 IHC Peroxidase protocol
The peroxidase method was used to locate ETb receptor and P-myosin heavy chain
(MHC) immunoreactivity. As described previously, wax embedded heart sections cut
longitudinally to a thickness of 3pm were dewaxed in xylene, rehydrated in 100, 90
and 70% alcohol solutions and placed in water for 15 minutes. Peroxidase is present
in some normal and neoplastic tissues, e.g. leucocytes and erythrocytes. Pre¬
incubation of sections in 0.3% hydrogen peroxide solution for 10 minutes at room
temperature produces an almost complete abolition of endogenous peroxidase
activity, without affecting the immunoreactivity of antigens. After incubating
sections in hydrogen peroxide, sections were washed in PBS buffer for 5 minutes.
Sections were then trypsinised (as described previously) at 37°C for 45 minutes,
before application of a goat or rabbit blocker (plus addition of 4 drops of biotin per
ml of blocker) for 30 minutes at room temperature. Unbound biotin was added to




The avidin-biotin technique of indirect antibody binding is used for detection in this
method (Hsu et al., 1981). Avidin (molecular weight 67kdal) is a glycoprotein of egg
white and is composed of four sub-units, which form a tertiary structure possessing
four biotin-binding hydrophobic pockets. Biotin is a vitamin that forms the
coenzyme or prosthetic group of several enzymes that transfer carboxyl groups. It is
possible to conjugate proteins and other large molecules with biotin. The method to
make use of avidin and biotin for immunohistochemical detection of antigens relies
on the strong affinity of avidin for biotin and consists of four stages separated by
washes. The first step involves addition of the primary antibody, which is unlabelled
and dilute. Sections were incubated in either 1/200 mouse anti-P-MHC or 1/300
sheep anti-ETn primary antibody made up in PBS (with addition of 4 drops of avidin
per ml of antibody solution) and left overnight at 4°C. Avidin was added to block
sites of non-specific binding of avidin-peroxidase bound biotin at later time points in
the procedure.
The second step involves addition of a secondary antibody that is biotinylated with a
large number of biotin molecules. Goat anti-mouse biotinylated IgG (1/150) for P-
MHC or donkey anti-sheep biotinylated IgG (1/150) for ETb was added to the
respective sections for 30 minutes. The third step involved using a reagent that is a
complex of avidin (strepavidin) with peroxidase labelled biotin. Avidin has an
isoelectric point of 10, which may cause it to bind to charged sites in the tissue and
lead to non-specific binding. Therefore Strepavidin (a microbial protein that contains
no carbohydrate and has a more neutral isoelectric point of 7; thus less prone to
attachment through charged binding sites) is used instead. After addition of the
biotinylated secondary antibody, sections were incubated in the strepavidin biotin
complex (Strep-ABC; Strep-ABC kit, Dako Ltd, UK) for 30 minutes (.Figure 2.8).
Strep-ABC consists of strepavidin and biotin-peroxidase which when incubated
together for 30 minutes form an enormous cross-linked molecule
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In preparation of Strep-ABC, excess strepavidin in the mixture ensures that some
strepavidin binding sites will be free to combine with the biotin on the secondary
antibody. The strepavidin/biotin-peroxidase complex is added to the sections leading
to binding of the complex to the secondary antibody and overall amplification of the
peroxidase enzyme signal that can be highlighted by incubation in DAB for 20
minutes yielding a strong brown colour. Sections were finally washed in distilled
water; secondary stained using haematoxylin (Harris', BDH, UK), then finally
dehydrated through 70, 90 and 100% alcohol solutions and xylene before being
mounted in DePeX mounting medium (Sigma, UK).
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2.5 In Situ hybridisation
2.5.1 Background
The technique of in situ hybridisation enables the precise localisation and
identification of polynucleic acids within the cell while preserving tissue
morphology. It involves the hybridisation of a labelled nucleic acid "probe" with a
specific nucleic acid within a tissue section "target". In situ hybridisation was first
described in 1969 (Gall & Pardue, 1969; John & Birnstiel, 1969) for the detection of
multiple copy ribosomal RNA genes. Since then the technique has become well
established for the identification and localisation of both DNA and RNA within cell
and tissue preparations (Coghlan et al., 1985; Singer et al., 1986; Warford, 1988).
In situ has two main advantages over other molecular biology techniques: precise
anatomical localisation and high sensitivity. It also extends immunohistochemical
results by addressing the issue of whether a positively staining cell has synthesised
the detected protein or acquired it by means of uptake from the extracellular space. In
studies in this thesis, detection of both ET-1 protein immunoreactivity and preproET-
1 mRNA in a particular cell would provide strong evidence that the cell is the site of
synthesis.
In spite of the high sensitivity and wide application of in situ hybridisation
techniques originally developed using radioactive probes, problems were associated
with safety measures required, limited shelf life, and extensive time necessary for
autoradiography (around 6 weeks). However, current methods now available
involving nucleic acid probes with a stable non-radioactive label overcome the major
obstacles that restricted the application of in situ. Advantages include identification
of cellular localisation of the probe by using wax embedded sections and a much
shorter overall protocol duration of 4-5 days. The in situ method performed in this
thesis involved a non-radioactive digoxygenin (DIG) labelled probe, which was




2.5.2 Probe synthesis & labelling
Riboprobes for detection of preproET-1, ETA and ETB were produced in our
laboratory by Dr. Pauline McEwan. Briefly, plasmids (a gift received from Dr.
Olivier Valdenaire, Hoffmann-La Roche Ltd., Basel, Switzerland) containing the
cloned cDNA fragments of preproET-1, ETA or ETB in pCR II vector (Stratagene
Ltd., CA, USA) were used to transform E.Coli. Ampicillin resistant cell cultures
were grown up in LB media (Life Technologies Ltd., UK). The cells were then lysed
and supercoiled DNA isolated and linearised using a specific restriction enzyme for
the antisense or sense cDNA template required (Table 2.4).
Table 2.4 List ofETProbe Vectors, Promoter enzymes andRestriction enzymes.
PreproET-1 ETa ETb
Vector pCRII pCRII pCR II
Antisense RNA SP6 T7 T7
polymerase enzyme
Restriction Enzyme EcoRV Kpn I Kpn I
Sense RNA T7 SP6 SP6
polymerase enzyme
Restriction Enzyme Kpn I EcoRV EcoRV
The linearised fragments were then phenol-chloroform extracted and ethanol
precipitated. Phenol denatures the proteins whilst ethanol precipitates them out to
leave purified DNA. The linearised plasmid was then used as a matrix to produce
labelled probe.
pCR II vector has recognition (promoter) sites for specific RNA polymerase enzymes
SP6 and T7 (Promega, Madison, WI, USA). Under appropriate reaction conditions,
the specific RNA polymerase enzyme (Table 2.4) recognises its promoter and
transcribes in either the 5'—>3' (antisense) or 3'—>5' (sense) until it reaches the site of
linearisation. The antisense strand, complementary to cellular mRNA, is an effective
hybridisation probe. The sense strand, similar in length, specific activity and base
composition to the cellular mRNA, provides a suitable control.
85
Chapter 2
The specific RNA polymerase enzyme incorporates free ribonucleotides into an
RNA transcript complementary to the cDNA insert. A DIG RNA labelling kit
(SP6/T7; Boehringer Mannheim, UK) was used to perform the probe synthesis and
labelling. The nonradioactive DIG, a steroid hapten, is used to label the RNA probes
produced. The kit included a transcription buffer, adenosine triphosphate (ATP),
cytosine triphosphate (CTP), guanine triphosphate (GTP), uracil triphosphate (UTP),
DIG-UTP (DIG is linked to the C-5 position of uridine nucleotides via a spacer arm
containing eleven carbon atoms {Figure 2.9), and SP6 or T7 polymerase.









Linearised non-denatured template was added to a mixture of nucleotides. The
mixture was then treated with DNAse (RNAse free; Boehringer Mannheim, UK)
which removed residual DNA molecules leaving behind the RNA probe. Efficiency
of labelling was verified on dot blot. Incorporation of DIG-UTP was one per 25
nucleotides. Synthesis of probes was carried out by Dr. Pauline McEwan. All probe-
labelling procedures were carried out with the assistance ofDr. Pauline McEwan.
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2.5.3 In situ protocol
In situ hybridisation was carried out as specified in an in-house protocol developed
by Dr. Pauline McEwan (McEwan et al., 1998a). Before starting the experiment, all
glassware and metal racks to be used were wrapped in tin foil and baked in an oven
for 3 hours at 200°C. All plastic pipette tips, ependorf tubes, and solutions including
diethyl pyrocarbonate-treated water (depEBO; see Appendix) and 1Ox-concentrated
PBS (pH 7.6; see Appendix) were autoclaved. Paraformaldehyde solution was made
up fresh (see Appendix) prior to each in situ experiment.
Initially, wax embedded hearts were sectioned at 3pm and floated out on a water bath
set at 48°C. Sections were then placed on TESPA-coated slides and allowed to
adhere overnight in an oven at 37°C. The following day, sections were dewaxed in
xylene, rehydrated in 100, 90 and 70% alcohol solutions (made up with depHiO) and
before being washed twice in lx-PBS buffer (made up with depHaO) for 10 minute
intervals.
2.5.4 Prehybridisation
The goal of the primary steps of an in situ hybridisation is to optimise conditions for
the hybridisation reaction. Critical to the sensitivity of the in situ technique is the
minimisation of non-specific binding. Proteins usually surround RNA target
sequences in the tissue and extensive cross-linking of these proteins during fixation
can mask the target nucleic acid site. Performing a number of pre-hybridisation
treatments can reduce the non-specific retention of probe in tissue sections and
unmask those nucleic acid sites covered by proteins. 20-30 minutes treatment with
0.2M HC1 was included, which aided the extraction of proteins and partial hydrolysis
of the target. Sections were also treated with the detergent Triton X-100 for 20




Protease treatment serves to increase target accessibility by digesting the protein that
surrounds the target nucleic acid. To digest the sample, preparations were incubated
with proteinase K in 20mM TE buffer (see Appendix) at 37°C. For formalin fixed
heart tissue, 40pg/ml for 90 minutes was found to give optimal results.
Background staining can arise from a variety of sources, from the formation of
imperfect duplexes with nonhomologous nucleic acids, from electrostatic interactions
between charged groups, and from physical entrapment in the three dimensional
lattice of the tissue section. Most in situ hybridisation protocols call for a
prehybridisation step designed to decrease background binding of the probe. The
prehybridisation mix includes bovine serum albumin (BSA) and lx-Denhardts
solution (Sigma, UK) to decrease non-specific binding to proteins; EDTA, salmon
sperm DNA and yeast tRNA were also added to decrease non-specific nucleic acid
interactions. Our prehybridisation step was carried out at the same temperature as the
hybridisation step (42-48°C), for a duration of 2 hours.
2.5.5 Hybridisation
Hybridisation is the process of RNA, or DNA, re-annealing with complementary
nucleic acids in solution just below their melting point. Our hybridisation mix
included all the components of prehybridisation mix, as well as the DIG-labelled
riboprobe and dextran sulphate. Dextran sulphate increases the rate of hybridisation
by an excluded volume effect (Wahl et al., 1979). In aqueous solutions, dextran
sulfate is strongly hydrated. Thus, macromolecules have no access to the hydrating
water, which causes an apparent increase in probe concentration and consequently
higher hybridisation rates. Because of their increased stability RNA-RNA hybrids
require higher hybridisation temperatures than DNA-RNA hybrids. Most
hybridisation mixes contain 50% formamide, so that optimal stringencies may be
obtained without the need to elevate temperatures greatly. Formamide reduces the
melting temperature of DNA-DNA and DNA-RNA duplexes in a linear fashion by
0.72°C for each percent formamide. Thus, hybridisation can be performed at 30-45°C
88
Chapter 2
with 50% formamide present in the hybridisation mixture. The rate of renaturation
decreases in the presence of formamide.
Prolonged exposure to high temperatures causes a deterioration of cell morphology
as well as loss of adherence of the section to the slide. Hybridisation was performed
in the dark to prevent ionisation of formamide being enhanced by light. Labelled
probe can hybridise non-specifically to sequences, which are partially, but not
entirely homologous to the probe sequence. Such hybrids are less stable than
perfectly matched hybrids. RNAse (DNAse free) selectively removes non-base-
paired RNA from tissue sections, so that background is greatly reduced with little
loss of signal. Post hybridisation washes in standard sodium citrate/formamide of
various concentrations and at varying temperatures were performed, which
disassociate weakly complemented hybrids. Sections were further washed in lx DIG
buffer 1 (DIG Wash & Block Buffer Kit; Boehringer Mannheim, UK) for 20 minutes
before immersion in 20% sheep blocking serum (made up in lx DIG buffer 1) for 3
hours at 24°C; this blocks non-specific binding sites of the primary antibody.
Sections were then treated with an alkaline phosphatase conjugated sheep anti-DIG
antibody (Boehringer Mannheim, UK) overnight at a concentration of 1/3000 (made
up in lx DIG buffer 1).
The following morning, sections were again brought through a series of 20 minute
washes in lx DIG buffer 1 and lx DIG buffer 3 before immersion overnight in nitro-
blue tetrazolium chloride/ 5-bromo-4-chloro-3-indolyl phosphate (NBT/BCIP; 0.1%
made up in lx Dig buffer 3) substrate (Boeringher Mannheim, UK). PreproET-1,
ETa receptor and ETb receptor mRNA were detected as dark blue dots within the
cytoplasm of cells in heart sections. Transverse sections of aorta were used as
positive controls. Negative controls were treated with RNAase prior to incubation
with antisense probes. Positive controls were treated with sense probes.
PreproET-1, ETA receptor and ETb receptor mRNA were semi-quantified in heart
sections also using the above mentioned computerised image analysis system (Image
Associates, UK). Application of a frame of known area (126,015pm2) and fixed
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magnification (x20) was made to four different areas within the LV at the infarct (MI
rats) or adjacent to the operation site (sham-operated control rats) and away from the
infarct and in four random areas in the right ventricle (RV). Two sections from each
block were cut randomly through the infarct and counted. For quantification of
mRNA, data were collected from two random, consecutive heart sections from each
animal for preproET-1, ETA receptor and ETB receptor mRNA. The intra-assay
variation was <5% for each probe and therefore, data for each probe from two
sections were pooled and averaged.
2.6 Data analyses
All in situ hybridisation data, plasma levels, organ weights, haemodynamic values
and infarct parameters were presented as mean±standard error of mean (SEM).
Measurements between groups were compared via one-way ANOVA, while
unpaired values within groups were assessed using a Student's /-test. A P value <





Localisation of endothelin during scar




There is extensive evidence in clinical studies that plasma levels of ET-l are
increased in the acute phase after myocardial infarction (MI). When compared with
healthy individuals, plasma ET-l levels were found to be significantly elevated in
patients at time of admission to hospital (Miyauchi et al., 1989) and remained
elevated for at least 2 days after MI (Lechleitner, 1993). Another study showed that
increased plasma ET-l in patients 24 hours after the onset of acute MI correlated
with higher pulmonary artery pressure and elevated pulmonary vascular resistance,
while increased levels after 72 hours correlated with increased infarct size (Setsuta,
1995).
However, increased plasma ET-l levels may be part of a systemic neurohormonal
response to MI or due to a reduction in plasma ET-l clearance. Whether increased
ET-l is synthesised de novo and produced locally in the infarcted heart in the early
stages after MI remains to be clarified. Animal studies have demonstrated increased
plasma ET-l released from pig hearts subjected to a brief period of CAL followed by
reperfusion (Tonnessen et al., 1993). Furthermore, Watanabe et al. (1991) found a
substantial increase in ET-l in cardiac tissue up to 2 days after coronary artery
ligation (CAL) and reperfusion in the rat. However, since ET-l was determined by
radioimmunoassay in plasma and tissue extracts, the histological sites of production
had not been addressed in any of these studies. Furthermore, no studies have
investigated the distribution of ET-l in the infarct during the progression of scar
formation after MI, without reperfusion intervention.
Within the developing scar many dynamic processes occur, including fibroblast
proliferation and collagen deposition, expression of growth factors (such as TGF-(3i),
new vessel formation and inflammatory cell infiltration (see section 1.3.2). In vitro
studies have shown that ET-l can regulate cardiac fibroblast function (Dawes et al.,
1996), with both ETA and ETb receptors evident on fibroblasts (Katwa et al., 1993).
Furthermore, ET-l was found to be involved in promoting endothelial cell migration
and angiogenesis in vivo (Goligorsky et al., 1999). ET-l also stimulates pro-
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inflammatory responses in macrophages, monocytes and neutrophils in both in vitro
(Cunningham et al., 1996; Ruetten et al., 1996) and in vivo studies (Filep el al.,
1995). Therefore, endogenous ET-1 may increase in the developing scar and regulate
the processes of infarct healing.
The aims of this chapter were, therefore, to characterise the main processes involved
in early stage scar formation, to investigate the specific localisation of endogenous
ET-1 peptide in the infarct, and to examine whether distribution of endogenous ET-1





All procedures were carried out as described in Chapter 2. Three study time points
after CAL in the rat were investigated, namely 2 days post-CAL, 7 days post-CAL,
and 14 days post-CAL; each with respective sham-operated groups. The developing
scar was characterised with respect to cellular content including inflammatory cell
infiltration, new vessel formation, collagen deposition, and TGF-(3i and ET-1
immunoreactivity.
3.2.1 Coronary artery ligation rat model
MI was induced by ligation of the left anterior descending coronary artery in male
Wistar rats as described in section 2.1. Upon recovery from surgery, rats were
housed individually and allowed access to normal rat chow and water ad libitum for
the duration of the study.
3.2.2 Plasma collection and tissue sampling
Either 2, 7 or 14 days after CAL or sham-operation, rats were anaesthetised
(60mg/kg Na pentobarbital i.p.) and then exsanguinated via a needle placed in the
dorsal aorta where an ~8ml blood sample was collected into a 10ml syringe pre-
rinsed with heparin. The blood was aliquoted into pre-chilled test tubes containing
50pi of 10mmol/l final concentration EDTA and immediately centrifuged (2000xg,
4°C, 20mins). Plasma was aliquoted off each sample and stored at -70°C for future
plasma ET-1 and big ET-1 analysis as described in section 2.2.2.
The heart, lungs and kidneys were excised, rinsed in ice-cooled physiological saline,
then individually weighed. The heart and kidney were cut longitudinally; a section of
the lung was also separated before all samples were placed in 10% neutral buffered
formalin solution for 24hrs fixation prior to further processing and wax embedding.
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Within the 7 day and 14 day post-CAL groups, infarct size as a percentage of the left
ventricular free wall was measured from 3pM heart sections stained with van
Gieson's collagen stain and the nucleus stained with Celestine Blue as described in
section 2.3.1.
3.2.3 General staining and immunohistochemistry
3pm wax embedded heart sections were treated with van Gieson's collagen stain
highlighting collagen, and naphthol AS-D chloroacetate esterase highlighting
neutrophils as described in section 2.3.3. Immunohistochemistry was also performed
on 3pm heart sections using antibodies to ET-1, endothelial cells (GSL I antibody),
and TGF-[3i using the alkaline phosphatase detection method as described in sections
2.4.2.
3.2.4 Statistical analysis
All results data were displayed as mean ± SEM. Unpaired measurements from CAL
and respective sham-op groups were compared using a Student's /-test. A P value <




3.3.1 Effects of coronary artery ligation
During the study period none of the sham-operated animals died. However, in the
CAL group mortality usually occurred during the 24-hour period after the ligation
procedure had been performed. The average survival 24-hour post-ligation was 68%.
Table 3.1 below summarises organ weights, plasma ET-1 and big ET-1 values, and
LV infarct sizes from the relevant groups.
Table 3.1 Table oforgan weights, plasma ET-1 and big ET-1 levels and infarct sizes.















2 day CAL 5 4.61±0.24 5.23±0.38
2 day sham 4 4.0410.12 4.5010.27
2.2910.21 16.4711.3
1.7810.17 17.3214.1
7 day CAL 6










14 day CAL 3










CAL did not significantly alter mean heart weight (HW), lung weight (LW), plasma
ET-1 or plasma big ET-1 values versus the respective sham-operated groups at any of
the 3 time points, though there was a tendency for increased plasma big ET-1 values
in CAL groups at the 2 later time points. Heart weights were expected to be higher in
the CAL groups. However, a smaller number in some of the groups may have
contributed to the non-significant values observed. Infarct size measured as a
percentage of the LV free wall was moderate in both 7 and 14-day CAL groups, with
no significant difference between the 2 groups.
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3.3.2 Histological and immunohistochemical characterisation of normal
myocardium.
The staining distribution of van Gieson's collagen stain in normal myocardium is
shown in Figure 3.1 (a). Cardiomyocytes, myoendothelial cells and vascular smooth
muscle stained yellow, whereas the collagenous adventitial layer of the vessel and
interstitial tissue collagen levels stained pink. Interstitial collagen levels were low in
normal myocardium.
ET-1 immunoreactivity was found to be diffusely distributed in the cytoplasm of
cardiomyocytes, myoendothelial cells and some vascular endothelial cells throughout
normal myocardium of the rat heart {Figure 3.1 (b)). Vascular smooth muscle cells in
the myocardium did not show ET-1 immunoreactivity. An immunohistochemical
protocol was performed using an identical IgG primary antibody that had no
recognition site for ET-1, with no staining evident in any areas of the myocardium
{Figure 3.1 (c)). Furthermore, ET-1 immunoreactivity in the myocardium of hearts
from unoperated rats was similar to that displayed in myocardium of sham-op rats
{Figure 3.1 (dj).
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Figure 3.1 Images ofnormal myocardium staining from sham-operated and unoperated
rat hearts, van Gieson's stain highlights collagen in pink and normal myocardium in
yellow, with nuclei counterstained dark blue with haematoxylin. ET-1 immunoreactivity
is shown in red, with nuclei counterstained with haematoxylin. (a) van Gieson's
collagen staining (x200 magnification); (b) ET-1 immunohistochemical staining (x400
magnification); and (c) an ET-1 negative control using a non-specific primary IgG
antibody (x200 magnification), all from sham-operated rat hearts; (d) ET-1









3.3.3 Histological and immunohistochemical characterisation of the developing
scar
3.3.3.1 2 days post-MI
Figure 3.2 (a) displays an area of the LV affected by the ligation. At 2 days, within
the infarct, there were areas of cellular necrosis identified by cells that have a
disrupted cell wall and cell morphology (Figure 3.2 (b)). There were still some
viable myocytes present (Figure 3.2 (c)), though these tended to be situated close to,
or surrounding, vessels that might still be receiving some blood supply. There was
also a marked increase in number of cells, which were most probably inflammatory
cells and proliferating fibroblasts, throughout the infarcted myocardium Figure 3.2
(d), though fibroblasts were not synthesising collagen at this time.
Within the infarct at 2 days post-CAL, areas of cell death and tissue necrosis showed
faint endothelial cell staining using GSL I {Figure 3.3 (a)), indicating a disrupted
capillary supply to the affected tissue. This was in contrast to the defined
morphology of myoendothelial cells that formed a capillary network throughout
normal myocardium {Figure 3.3 (b)). Some larger vessels that served the
myocardium of the infarcted area also showed GSL I immunoreactivity in their
endothelial cell layer (not shown). However, there was little evidence of
angiogenesis in any areas of the infarct at this time point.
As mentioned in Section 2.4.2, GSL I was also found to be an excellent marker for
inflammatory cells as well as endothelial cells. Within the infarct, many
inflammatory cells were evident, bordering and infiltrating central areas of necrosis.
The larger stained cells {Figure 3.4 (a), arrow), displaying a similar morphology to
macrophages, were distinguishable from endothelial cells by their larger size, more
rounded cell shape, and a defined circular nucleus. Furthermore, these cells were not
evident in normal myocardium.
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Figure 3.2 Images in the infarcted LVfrom hearts in the 2-day CAL group stained with
van Gieson's stain, (a) overview of the infarcted area (x50 magnification); and (b, +)
necrotic tissue ; (c, f) viable myocardium; (d, +) increased cellular content; within the






Figure 3.3 Images showing GSL I staining ofendothelial cells in red and nuclei stained
purple with haematoxylin. (a) loss of defined endothelial capillary staining within
necrotic tissue of the infarct at 2 days post-CAL (x400 magnification); (b) GSL 1
highlighting the defined morphology of endothelial cells that form a capillary network
throughout normal myocardium (xlOOO magnification).
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Figure 3.4 Inflammatory cells within the infarct at 2 days post-CAL. (a) Macrophages
(arrows) were stained red using GSL I with nuclei staining purple with haematoxylin
(xlOOO magnification); (b) Neutrophils stainedpurple with naphthol AS-D chloroacetate





Neutrophils, whose cytoplasm stained purple with naphthol AS-D chloroacetate
esterase (Figure 3.4 (b)), were evident in large numbers in the infarct and correlated
directly with areas of necrosis at the border and in central regions of the scar.
Neutrophils were also observed in some of the smaller vessels within necrotic areas
indicating that these vessels, in central areas of the scar, still received blood flow.
There was no evidence of neutrophils in the non-infarcted LV, RV or septum ofCAL
rats or in any areas of sham-op myocardium (not shown).
ET-1 immunoreactivity in the non-infarcted LV (Figure 3.5 (a)), RV and septum was
similar to that observed in sham-op myocardium. However, within the infarct, cells
undergoing necrosis showed faint ET-1 immunoreactivity {Figure 3.5 (b)). ET-1
staining was detected in macrophages {Figure 3.5 (c), filled arrowhead) and
neutrophils {Figure 3.5 (d)) within the infarct, though fibroblasts tended not to
display ET-1 immunoreactivity at this time point. {Figure 3.5 (c), open arrowhead).
Myocardium affected by the ligation showed no TGF-p( immunoreactivity at this
time point. However, viable cardiomyocytes within the infarct and those at the
border and above the infarct in the LV displayed increased TGF-Pi staining {Figure
3.6 (a)) compared to that observed in the RV and septum of CAL rats or in any areas
of sham-op myocardium {Figure 3.6 (c)). TGF-Pi staining in vascular smooth muscle
cells was not evident. Interestingly, TGF-pi immunoreactivity also correlated with
distribution of ET-1 staining in cardiomyocytes, both within the infarct and at the
border {Figure 3.6 (b)). TGF-Pi immunoreactivity in myocardium from sham-op rats
{Figure 3.6 (c), and from rats that underwent no operative procedures (not shown),
demonstrated faint cytoplasmic staining thoughout the myocardium located to
cardiomyocytes and myoendothelial cells.
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Figure 3.5 Images representative ofhearts from the 2-daypost-CAL group, (a) overview
area of infarcted LV and non-infarcted border showing ET-1 immunoreactivity (x50
magnification); (b, A) area of necrosis showing faint ET-1 staining (x400
magnification); (c, +) area of increased cell content showing ET-1 staining in
macrophages (filled arrowheads) but not in fibroblasts (open arrowheads, x400
magnification); and (d, t) neutrophils showing ET-1 immunoreactivity (xlOOO
magnification).
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Figure 3.6 Images representative ofTGF-fi/ staining (pink) in the LVofhearts from the
2-day CAL group, (a) increased TGF-fii staining in cardiomyocytes in the non-infarcted
LV, but a loss ofstaining in tissue affected by the MI (x200 magnification); (b) similar
distribution ofET-I immunoreactivity in a parallel section (x200 magnification); and (c)







3.3.1.2 7 days post-MI
At 7 days post-CAL, necrotic tissue is being cleared from within the infarct and
proliferating fibroblasts are now beginning to synthesise collagen as shown by pink
staining in Figure 3.7 (a). At this time point, synthesised collagen is an immature
type that has not formed cross-linking fibrils.
GSL I immunoreactivity was observed in the scar and could be located in the
endothelia of numerous newly forming vessels (Figure 3.7 (b)). New vessels
appeared mostly in areas undergoing repair and scar formation. These were most
evident on the outer edge of the infarct at this time point, though a few could also be
found in some central areas of necrotic tissue.
Inflammatory cells, also stained by GSL I, were highlighted in areas where necrosis,
degradation and cell clearance were still present, namely in central areas of the scar
(Figure 3.7 (c)). Macrophages (arrows), identified as large cells with a distinct
circular nucleus, were the predominant inflammatory cell in the scar at this time,
though monocytes (smaller rounded cells with a central circular nuclei), and some
neutrophils (bilobed nuclei) were also evident (not shown). GSL I also highlighted
non-specific staining of red blood cells, though these could be easily distinguished
from inflammatory cells by their smaller size and lack of a nucleus.
Increased distribution of ET-1 immunoreactivity was detected throughout the
developing scar at 7 days post-CAL {Figure 3.8 (a)). ET-1 could be localised in
remaining cardiomyocytes (not shown), but also fibroblasts {Figure 3.8 (b), open
arrowhead), numerous infiltrating inflammatory cells {Figure 3.8 (b), closed
arrowhead), and in endothelial cells of newly forming vessels {Figure 3.8 (b), dotted
arrow line). ET-1 staining in the non-infarcted LV was similar to that observed in the
RV and septum of CAL rats and in all areas of sham-op rat myocardium (data not
shown).
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Figure 3.7. Sections representative of areas within the infarct at 7 days post-CAL. (a)
collagen synthesis (pink) highlighted with van Gieson's stain (x200 magnification); (b)
angiogenesis (arrows, x400 magnification) and (c) macrophages (arrows, x400
magnification) highlighted within necrotic tissue using GSL I (red).
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Figure 3.8 Sections showing ET-1 immunoreactivity in the infarct, representative of that
found within scars in the 7-day post-CAL group, (a) Increased distribution of ET-1
immunoreactivity throughout infarct compared to that observed at 2 days post-CAL
(x200 magnification); (b) ET-1 staining could be located in fibroblasts (open
arrowheads), inflammatory cells (closed arrowheads) and in the endothelia of newly
forming vessels (dotted arrow line, xlOOO magnification).
109
Chapter 3
TGF-Pi immunoreactivity was increased in the infarct compared to 2 days and could
be located in specific cells throughout the developing scar (.Figure 3.9 (a)). These
included fibroblasts (Figure 3.9 (b), open arrowhead), inflammatory cells (Figure
3.9 (b), closed arrowhead) and in the endothelia of newly forming vessels (Figure
3.9 (b), dotted arrow line). Furthermore, TGF-Pi immunoreactivity was also evident
in those cells that displayed ET-1 immunoreactivity. Flowever, TGF-pi staining in
these cells was observed around the nuclei, with little staining of the cytoplasm. This
was in contrast to the staining found in cardiomyocytes, which was throughout the
cytoplasm. In the non-infarcted LV, TGF-pi immunoreactivity was increased
throughout the cytoplasm of cardiomyocytes at the border of the infarct, compared to
that found in the RV and septum (data not shown). Staining in the RV and septum of
CAL rats was similar to that found in sham-op rat myocardium (data not shown).
110
Figure 3.9 Sections showing TGF-fii immunoreactivity (red) within the infarct ofhearts
representative ofthe 7-day CAL group, (a) TGF-fii staining could be located around the
nucleus offibroblasts (open arrowheads) and in macrophages (closed arrowheads, x400




3.3.1.3 14 days post-MI
In those hearts in which a large MI had occurred after CAL, a thin scar was formed
after 14 days, which consisted predominantly of collagen and a few remaining areas
of viable myocytes {Figure 3.10 (a)). Deposited collagen was in the form of mature
cross-linking fibrils {Figure 3.10 (b)) distinct from that observed at 7 days, and
constitutes the main tensile component of the infarct wall.
GSL I staining was still evident in the endothelia of small vessels established
throughout the scar. These vessels could be found both on the outer edge and in
central areas of the infarct (data not shown).
Inflammatory cells were evident only in central areas of the scar where remaining
degradation and clearance of necrotic tissue still occurred {Figure 3.10 (c) arrows).
Again, the predominant inflammatory cells within the scar at this time were
macrophages.
ET-1 immunoreactivity was evident only in remaining viable cardiomyocytes
{Figure 3.10 (d)) and a few inflammatory cells in the thinned scar (not shown).
However, in those hearts where ligation resulted in a smaller MI, the formation of a
mature scar was not complete, and ET-1 immunoreactivity could still be located in
many inflammatory cells {Figure 3.10 (e), filled arrowheads) and fibroblasts {Figure
3.10 (e), open arrowheads) within the infarct. ET-1 staining in the non-infarcted LV
was similar to that observed in the RV and septum of CAL rats and also to that in
sham-op rat myocardium (not shown).
In developing scars at 14 days, TGF-Pi staining could be located in inflammatory
cells {Figure 3.10 (f), closed arrowhead), fibroblasts {Figure 3.10 (f), open
arrowhead) and in the endothelia of newly forming vessels {Figure 3.10 (f), dotted
arrow line). However, in those hearts that had a thinned scar, TGF-Pi staining was
less evident, being located in remaining inflammatory cells and a few fibroblasts (not
shown).
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Figure 3.10 Images (all from within the infarct) of heart sections representative of the
14-day CAL group, (a) van Gieson's stain (xlOO magnification) and (b) x400
magnification; (c) inflammatory cell immunoreactivity (arrowheads showing
macrophages, x200 magnification); (d) ET-1 immunoreactivity (xlOO magnification) and
(e) in fibroblasts (open arrowheads), macrophages (closed arrowheads, x400
magnification); (f) TGF-fii immunoreactivity in fibroblasts (open arrowhead),







The following table summarises the changes in detection of specific peptides and
processes involved in scar formation over the first 14 days post-MI.
Table 3.2 Detection levels of specific peptides and processes involved in scar
formation over the first 14 days post-MI. Key: Low (+), medium (++), or high
(+ ++) levels ofdetection.
Infarct
2 days 7 days 14 days
Neutrophils +++ +
Macrophages +++ ++ +
Collagen ++ +++
Angiogenesis +++ ++
ET-1 + +++ ++




Within normal myocardium, ET-1 immunoreactivity could be located to
cardiomyocytes, myoendothelial cells and some vascular endothelial cells indicating
the presence of mature ET-1 peptide is present in these cells under normal
physiological conditions. Sections of heart from sham-op rats showed similar
distribution of ET-1 immunoreactivity to that found in the hearts from male Wistar
rats that underwent no operative procedures, indicating that surgical processes did
not account for the distribution of immunoreactivity observed. At all 3 time points
post-CAL, ET-1 staining in the non-infarcted LV was of similar intensity to that in
the RV and septum and also similar to that found throughout the myocardium of
sham-op rat hearts.
Distribution of ET-1 staining observed in sham-op hearts was similar to that shown
in other studies using sham-op rat hearts compared against CAL groups (0ie et al.,
1997; Tonnessen et al., 1998). Furthermore, evidence of ET-1 staining in
cardiomyocytes has also been reported in hearts from sham-op rats in other CAL
studies (Sakai et al., 1996a; 1996b; Kobayashi et al., 1999), and in cardiomyocytes
from endocardial biopsy specimens of transplanted human hearts (Giaid et al., 1995).
However, a few studies have shown ET-1 immunoreactivity in endocardial
endothelial cells, but not in cardiomyocytes, in the human right ventricle (Plumpton
et al., 1996), fetal human hearts (Giaid et al., 1991; Wharton et al., 1991) and adult
rat hearts (Giaid et al., 1991). Interestingly, a sample of ET-1 antibody from the
Davenport laboratory was used on heart sections from the studies in this thesis, and
highlighted ET-1 immunoreactivity throughout the myocardium, similar to that
observed with our own antibody (a comparison of immunoreactivity between the two
antibodies is shown later, in Chapter 5).
Within the infarcted LV, an increased number of ET-1 immunoreactive staining cells
was found at 7 days compared to 2 days post-CAL, before remaining constant or
lowering at 14 days post-CAL depending on whether formation of a mature scar was
complete. Peak ET-1 staining occurred within the infarct at 7 days post-CAL and
could be localised to areas of granulation and remaining viable myocytes.
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Granulation tissue staining included fibroblasts, inflammatory cells, and endothelial
cells that were involved in formation of new capillaries. These findings agree with
recent studies that also showed increased ET-1 immunoreactivity in the infarcted LV
at 7 days post-CAL in the rat (0ie et al., 1997; Tonnessen et al., 1998). Furthermore,
0ie et al. (1997) demonstrated increased preproET-1 mRNA levels in the infarct
during the first 6 weeks after induction ofMI, with levels peaking at 7 days.
Interestingly, ET-1 immunoreactivity was not observed in fibroblasts at 2 days post-
CAL, but later at 7 days when these cells were synthesising collagen. Recent in vivo
studies investigating scar formation 7 days after MI in the rat have located ET-1
immunoreactivity in fibroblasts (0ie et al., 1997; Tonnessen et al., 1998). There are
some potential explanations why ET-1 may be raised in fibroblasts during scar
formation at this time. It is possible that the increased cellular ET-1
immunoreactivity observed, coinciding with a time when collagen is being
synthesised, may indicate a role for ET-1 in regulating this process. Cardiac
fibroblasts have been shown to express both ETa and ETb receptors, with ETB
receptors being predominant (Katwa et al., 1993). In vitro studies have demonstrated
that fibroblasts can synthesise ET-1 when stimulated by other cardiac vasoactive
factors (King et al., 1996; Gray et al., 1998). Furthermore, administration of ET-1 to
fibroblasts in vitro led to an 8-fold increase in type I collagen mRNA after 6 hours,
which could be completely inhibited by the protein kinase C (PKC) inhibitor
staurosporine indicating activation of an ET receptor-mediated pathway (Guarda et
al., 1993). The requirement of PKC in the ET-1 signalling pathway suggests that Gq
is an upstream mediator of this response, and cardiac fibroblasts express Gq in large
quantities (Hansen et al., 1995). In a rat model of MI, Gq was significantly
upregulated in border and scar tissue, these areas being abundant in fibroblast content
(Weber & Brilla, 1991). The fact that ET-1 is produced by, and can act on,
fibroblasts suggests both a paracrine and autocrine role for this peptide in collagen
synthesis during scar formation.
Although ET-1 has been shown to induce fibroblast proliferation in vitro (Piacentini
et al., 2000), ET-1 immunoreactivity was faint in proliferating fibroblasts at 2 days
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suggesting that it may not have a central regulatory role in this process in vivo.
Furthermore, another study using human cardiac fibroblasts in vitro showed that ET-
1, via the ETA receptor, stimulated collagen synthesis without having a mitogenic
effect on the fibroblasts themselves (Hafizi et al., 1998). However, fibroblasts also
express receptors for Ang II with stimulation of AT] receptors leading to collagen
synthesis and stimulation of AT2 receptors involved in mitogenesis (Smits et al.,
1992; Unger et al., 1998). ACE and renin expression are also increased in the infarct
after acute MI (Passier et al., 1995; Passier et al., 1996). However, the precise
interactions between Ang II or ET-1 and fibroblast proliferation and collagen
synthesis during scar formation remain to be clarified.
ET-1 has also been reported to be involved in the conversion of fibroblasts to
myofibroblasts, which are important contractile components in the developing scar.
These cells have intermediate features between those of fibroblasts and smooth
muscle cells, and may temporarily express a-smooth muscle actin (Darby et al.,
1990). Contraction of the newly formed connective tissue promotes healing by
facilitating closure of the wound margins (Villaschi & Nicosia, 1994). However, ET-
1 may only be upregulated in fibroblasts as a consequence of increased progressive
mechanical stress or increased humoral stimulation via Ang II and/or
catecholamines, with no crucial role in the processes of infarct healing.
At 2 days post-CAL, increased TGF-P 1 immunoreactivity was observed in viable
cardiomyocytes bordering the infarct and in remaining viable cardiomyocytes within
the infarct, with a loss of staining in cells affected by infarction. This finding was
similar to that reported in other studies where TGF-pi mRNA expression and/or
protein were increased in remaining viable cardiomyocytes bordering and within the
infarct, with a loss of staining in cells affected by the infarct at 1 (Casscells et al.,
1990) and 2 (Thompson et al., 1988) days after MI in the rat, suggesting a role for
TGF-P in the infarct healing process. Furthermore, TGF-Pi mRNA levels were also
significantly increased in the adjacent non-infarcted myocardium, but not in remote
non-infarcted myocardium, of rats 2 days after MI (Hanatoni, et al., 1998). Increased
TGF-P 1 immunoreactivity in the non-infarcted LV adjacent to the infarct, observed
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during scar development in the present study, indicates that TGF-P i may be activated
in response to an increase in progressive wall stress and/or workload in the remaining
myocardium. TGF-P i has been shown to promote cardiomyocyte hypertrophy in
vitro via inducing the re-expression of fetal genes (such as p-MHC), characteristic to
the expression observed in hypertrophy induced by pressure overload (Parker et ah,
1990a). However, p-MHC expression was not investigated here.
Increased TGF-Pi immunoreactivity found within the infarct at 7 days is also in
agreement with a recent study that found peak TGF-Pi mRNA expression in the
infarcts of rats 7 days post-MI (Sun et al., 2000). Other studies have also
demonstrated peak levels of both TGF-P in rat wound chambers after 7 days
(Cromack et al., 1987) and of connective tissue growth factor (a peptide selectively
induced by TGF-P) in the infarct tissue of 7 day post-MI rats (Ohnishi et al., 1998).
However, none of the above studies revealed the cellular location of TGF-Ps within
the scar at this time point, whereas the present study localised TGF-p i peptide to
endothelial cells, fibroblasts and inflammatory cells within the granulation tissue.
There is abundant information regarding the upregulation of TGF-P i during cardiac
fibrosis (Sun et al., 1998; Tomita et al., 1998). However, its regulatory role in
fibrous tissue formation and the precise mechanisms by which TGF-Pi is itself
upregulated remains unclear. Under hypoxic conditions, cultured human cardiac
fibroblasts treated with TGF-Pi synthesise collagen I (Agocha et al., 1997). TGF-Pi
also increases synthesis of a-smooth muscle actin in myofibroblasts, which as
mentioned earlier, are important in contraction of the scar during healing
(Desmouliere et al., 1993). Furthermore, TGF-P receptors are upregulated at the site
of MI and colocalise in areas with fibroblasts and macrophages at 1 week (Sun &
Ramires, 1996). In the present study, the appearance of TGF-Pi immunoreactivity
and synthesis of collagen within the infarct were both observed at 7 days but not 2
days post-CAL.
During inflammation, there is evidence that TGF-P i becomes upregulated as a
mechanism to suppress further inflammatory cell responses (Kulkarni et al., 1993).
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TGF-P can be synthesised by macrophages (Wahl et al., 1990), by B and T
lymphocytes as well as by smooth muscle cells (Kirschenlohr et al., 1993). TGF-Ps
have, therefore, been suggested to be factors that shift the healing process from
inflammation, towards fibrosis (Nicoletti & Michel, 1999). The observation of TGF-
Pi immunoreactivity in inflammatory cells at 7 days post-CAL in the present study
coincides with the time of downgrading of the inflammatory response in rat hearts
post-MI (Cleutjens et al., 1999). TGF-Pi has also been found to stimulate
angiogenesis in endothelial cells in vivo during wound healing (Fajardo et al., 1996)
and evidence of TGF-p i staining in these cells at 7 days post-CAL in the present
study may suggest a role in microvessel formation in the infarct at this time.
The predominant mechanism by which TGF-P i becomes upregulated in
inflammatory cells, fibroblasts and endothelial cells in the developing scar at this
specific time remains to be clarified. There is evidence that Ang II can stimulate
synthesis of TGF-Pi in fibroblasts (Lee et al., 1995). Ang II was also found to
stimulate cardiac myocyte hypertrophy via paracrine release of TGF-Pi from
fibroblasts (Gray et al., 1998). As previously mentioned Ang II levels are increased
in the infarct afterMI, though it is not known if ET-1 has a role in regulating TGF-P i
expression in these cells. Interactions between TGF-Pi and ET-1 have been reported
in other studies outwith the heart. TGF-p \ was found to stimulate the expression of
ET-1 mRNA by vascular endothelial cells in vitro (Kurihara et al., 1989), and
stimulate the release of ET-1 from stellate cells in the rat liver in vitro (Gabriel et al.,
1999). Alternatively, cyclosporin was found to amplify ET-1 production, which in
turn promoted the synthesis and activation of TGF-Pi in the rat kidney (Hutchinson,
1998). Interestingly, in the present study, those specific cells within the infarct at 7
days post-CAL that showed increased TGF-pi immunoreactivity also showed
elevated ET-1 immunoreactivity. However, whether ET-1 is an important regulator
of TGF-P i peptide synthesis is unclear. Equally, TGF-P i may have a regulatory role
on synthesis of ET-1 instead.
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At 2 days post-CAL, ET-1 immunoreactivity could be localised to the cytoplasm of
invading macrophages and neutrophils within the necrotic tissue. ET-1
immunoreactivity was also evident in the cytoplasm of varied inflammatory cells
within the infarct at 7 days post-CAL including macrophages, and also some
monocytes and lymphocytes. In vitro culture studies and in vivo studies in
pathological diseases have shown that inflammatory cells can synthesise and be
stimulated by ET-1 (Ehrenreich et al., 1990; Chanez et al., 1996; Cunningham et al.,
1997). However, the precise role of upregulated ET-1 in these cells is unclear. ET-1
has been shown to have both pro-inflammatory (McMillen et al., 1995) and anti¬
inflammatory activities (King et al., 1997). However, whether upregulated ET-1 acts
to reduce or maintain the inflammatory response in the developing scar post-MI in
the rat remains to be clarified.
Neovascularisation was prominent in the infarct at 7 days post-MI and has been
suggested to be an efficient mechanism for restoring coronary flow to the affected
myocardium (Nelissen-Vrancken et al., 1996). Evidence of a role for ET-1 in
angiogenesis is, however, controversial. ET-1 has been reported to induce
angiogenesis via an ETa receptor mediated pathway in endothelial cells in the rat
cornea (Bek & McMillen, 1999). Another in vitro study found a dose-dependent
stimulatory proliferative and migratory effect on endothelial cells isolated from
bovine adrenal capillaries, which was mediated through the ETb receptor only (Ziche
et al., 1995). Also, Goligorsky et al (1999) demonstrated that the mitogenic and
angiogenic effects of ET-1 are mediated via the ETb receptor and that endothelial
nitric oxide synthase (NOS) is requisite for this action. However, Stewart et al.
(1996) showed decreased levels of ET-1 and increased NOS activity during
angiogenesis. In this study, ET-1 immunoreactivity was observed in the endothelia of
newly forming vessels, which appeared at the boundary and within the granulation
tissue of the infarct at 7 days post-CAL. The localisation of ET-1 in these vessels
suggests that it may regulate angiogenesis at this time point. However, whether ET-1
stimulates proliferation, migration and the formation of tubules from these
endothelial cells, or conversely, is involved in reducing further unwarranted vessel
formation in the developing scar is not known.
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In summary, the localisation of ET-1 in fibroblasts producing collagen, endothelial
cells forming microvessels, and inflammatory cells clearing necrotic tissue suggests
ET-1 may have an active role in the developing infarct. However, whether
upregulated ET-1 is beneficial or detrimental to scar formation during this early time
period after MI remains to be established. Furthermore, that both TGF-Pi and ET-1
immunoreactivity is upregulated in these cells at a specific time point during scar
development suggests an interaction between these peptides, though whether ET-1 is
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In the previous chapter, ET-1 immunoreactivity was shown to increase within the
infarct over the first 2 weeks during scar formation with the number of ET-1-stained
cells highest at 7 days. At this time, ET-1 staining could be localised in fibroblasts
synthesising collagen, inflammatory cells involved in clearance of necrotic tissue,
and endothelial cells that were involved in formation of new capillaries. However,
whether increased ET-1 has beneficial or detrimental effects on these active
processes of scar formation is not known.
A number of studies have used ET receptor antagonists to investigate the role of ET-
1 within the heart during the early stage post-myocardial infarction (MI). However, a
large variation in study conditions occurs, including the experimental animal model
used (coronary artery ligation (CAL)/reperfusion in vivo model, Langendorff in vitro
model); the type of ET receptor antagonism (ETA, ETa/b); time of, and duration of
ET receptor antagonist administration; and responses measured (arrhythmias,
haemodynamic changes, area ofmyocardial damage/infarct size).
No study to date has investigated directly the effects of endogenous ET-1 on the
active processes involved in in vivo scar formation post-MI. Many antagonist studies
however have used a CAL/reperfusion model. This model, depending on the timing
of reperfusion after coronary occlusion, produces animal models with varying
degrees of myocardial damage. This is different to the model used in the present
study, in which irreversible occlusion leads to major myocardial damage in the
affected area with blood flow re-entering the infarct, in the initial stages, most
probably via collateral flow (Maxwell et al., 1987). In the CAL/reperfusion model,
beneficial, neutral and detrimental effects of ET receptor antagonism have been
reported in animal models early post-MI, depending on class of antagonist used and
time of administration (Grover et al., 1993; McMurdo et al., 1993; Kojima et al.,
1995; Vitola et al., 1996).
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The published literature, therefore, suggests that ET-1 may have an active role in
events occurring in the heart early post-MI including haemodynamic changes and
determination of infarct size. However, it is not known whether ET-1 has a direct
role on the active processes of scar formation. Therefore, the aim of this chapter was
to investigate the role of increased ET-1 on the processes of scar formation following
CAL in the rat using a non-selective ET receptor antagonist A-182086 (Abbott
Laboratories, Illinois, USA) administered immediately upon recovery from CAL,




All procedures were carried out as described in Chapter 2. Three study time points
after coronary artery ligation (CAL) or sham-operated (sham-op) in the rat were
investigated, namely 2, 7 and 14 days, each with respective antagonist fed and
control diet groups (see Table 2.2). Scar parameters measured included infarct size as
a percentage of the LV free wall, infarct thickness, and myocardium to collagen ratio
within the infarct. The developing scar was also characterised with respect to cellular
content including inflammatory cell infiltration, new vessel formation, collagen
deposition, TGF-Pi and ET-1 immunoreactivity, and TUNEL positive staining.
4.2.1 Coronary artery ligation rat model
MI was induced by ligation of the left anterior descending coronary artery in male
Wistar rats (n=45) as described in section 2.1. After surgery and before recovery
from anaesthesia, a tail-tip blood sample was taken for plasma analysis of LDH
levels as described in section 2.2.1. A value 3 times greater than that found in plasma
from a corresponding sham-op rat indicated a successful ligation. Upon recovery
from anaesthesia, rats were started on the antagonist protocol where individual rats
were randomly fed either food containing the non-selective ET receptor antagonist
A-l82086 (30mg/kg rat/day) or food without the antagonist, as described in section
2.3.3, for the duration of the study.
A-l82086 exhibits good oral bioavailability and substantial plasma half-life (ty2=8.1
hr at a single oral dose of lOmg/kg) in the rat. A-182086 has also been shown to
inhibit S6c-induced depressor responses in anaesthetised rats at >3mg/kg and to dose
dependently inhibit pressor responses to big ET-1 at >10mg/kg (data from Abbott
Laboratories, USA). Previous pilot studies in this thesis (section 2.3.2) showed that
in rats fed A-l82086 (30mg/kg/day) upon recovery from CAL or sham-op surgery
and thereafter daily in their food over 2 days; both ETa and ETe-mediated responses




4.2.2 Haemodynamic measurements, plasma collection and tissue sampling
Either 2, 7 or 14 days after CAL or sham-op, rats were anaesthetised (60mg/kg Na
pentobarbital) and the right carotid artery located, dissected free of extraneous tissue
and cannulated with a polyethylene fluid filled catheter attached to a pressure
transducer, for measurement of MAP and LVEDP as described in section 2.2. Rats
were then exsanguinated via a needle placed in the dorsal aorta from which an ~8ml
blood sample was collected into a 10ml syringe pre-rinsed with heparin. The blood
was aliquoted into pre-chilled test tubes containing 50pl of 10mmol/l EDTA and
immediately centrifuged (2000xg, 4°C, 20mins). Plasma was aliquoted off each
sample and stored at -70°C for future plasma ET-1 and big ET-1 analysis as
described in section 2.2.2.
The heart and lungs were excised, rinsed in ice-cooled physiological saline, then
individually weighed. The heart was then bisected longitudinally from apex to base
so that each half consisted of both right and left ventricles; a section of the lung was
also separated before all samples were placed in 10% neutral buffered formalin
solution for 24hrs fixation prior to further processing and wax embedding. Within the
7 day and 14 day CAL and CAL + A-l 82806 groups, infarct size as a percentage of
the left ventricular free wall was measured from 3pm heart sections stained with van
Gieson's collagen stain and the nucleus stained with Celestine Blue as described in
section 2.3.1.
4.2.3 General Staining and immunohistochemistry
3pm wax embedded heart sections were treated with either van Gieson's collagen
stain, a neutrophil stain naphthol AS-D chloroacetate esterase (Sigma, UK), or a
TUNEL positive cell marker (Dead-End Colometric Apoptosis Detection System,
Promega, UK) as described in section 2.2.3.4. TUNEL-positive cells were counted
using a computerised image analysis system; Zeiss Kontron 300, Image Associates,
UK. Immunohistochemistry was also performed on 3pm heart sections using
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antibodies to ET-1, endothelial cells and inflammatory cells (GSL I antibody), and
TGF-Pi using the alkaline phosphatase method as described in sections 2.4.2. The
apoptosis assay was performed with the assistance ofMr. David O'Regan.
4.2.4 In situ hybridisation
In situ hybridisation was performed (as described in section 2.5) to investigate 1)
whether expression of preproET-1, ETA and ETB receptor mRNA altered within the
heart during scar formation, and 2) if expression was affected by administration of
A-l82086. However, problems arose during the protocol including non-specific
staining and poor quality of highlighted signal. Many attempts were made to
overcome these problems including re-ordering new blocking solution, primary
antibody and hybridisation buffer. Also, concentrations of antibody, blocker and
substrate were changed along with incubation periods for each step. Unfortunately,
these problems could not be overcome in the timeframe set aside for carrying out
these studies, and the experiment was therefore stopped.
4.2.5 Statistical analysis
All data were expressed as mean ± standard error of mean. Multiple group
measurements were compared via one-way ANOVA, while unpaired values within





4.3.1 Effects of coronary artery ligation and antagonist treatment.
For rats undergoing CAL, a plasma LDH value 3x that found in plasma from a sham
rat operated on the same day indicated a successful ligation. During the study period
none of the sham-operated animals died. However, in the CAL group mortality
usually occurred during the 24-hour period after the ligation procedure had been
performed. The average survival 24-hour post-ligation was 69%. Out of the 69% that
survived, 9% of CAL-operated rats had no infarct. Of those rats that died, there was
no significant difference in number of deaths between antagonist treated or untreated
rats (data not shown). Within the antagonist treated groups, 2 CAL rats did not eat
within the first 24 hours after surgery, and were therefore excluded from the study.
4.3.1.1 Organ weights and haemodynamicparameters
At the 2 and 7-day time points, average heart weight (g/kg body weight) in the CAL
group was significantly higher compared to that in the sham-op group, though
administration of A-l82086 in the CAL group did not significantly alter the value at
either time point (see Table 4.1 for all data). At the 14-day time point, average heart
weight in the CAL group was significantly higher compared to that in the sham-op
group. Addition of the non-selective ET receptor antagonist A-l 82086 to the CAL
group significantly reduced heart weight compared to that in the CAL group alone.
However the value in the antagonist treated group was still significantly higher than
that found in the sham-op group (Table 4.1), with or without antagonist.
At 2 days and 14 days post-CAL, mean arterial blood pressure (MAP) was
significantly lower compared to their respective sham-op groups. At 7 days post-
CAL, MAP also tended to be lower compared to the respective sham-op group.
Addition ofA-l 82086 to rats in the 7 and 14-day CAL groups had no effect on MAP.
However, the significance observed in the 2 day CAL group versus the respective
sham-op group was lost in the presence of antagonist (Table 4.1).
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Left ventricular end-diastolic pressure (LVEDP) was significantly increased in the
14-day CAL group compared to the sham-op group. Addition of A-182086 in the
CAL group did not significantly alter LVEDP. There were no significant changes in
LVEDP values in either the 2-day or the 7-day groups (Table 4.1). Measurement of
LVEDP was not accomplished for all rats due to difficulties in directing the cannula
into the left ventricle.
Table 4.1 Effect of CAL and antagonist treatment on organ weights and














2 day CAL 8 4.52±0.20* 6.2810.72 85.0215.40V 8.7310.77 (n=3)
2 day CAL + A-182086 6 4.3110.19* 4.9010.19 93.81110.83 2.46 (n=2)
2 day sham 8 3.6010.08 4.9810.09 109.1116.73 3.97+0.80
2 day sham + A-l 82086 6 3.4610.11 5.1110.14 100.5115.93 5.6510.54
7 day CAL 8 3.8910.07*11 5.63+0.48 90.71+6.1 lcp 7.5611.61 (n=4)
7 day CAL + A-182086 6 3.8810.23 5.5710.65 106.41+5.80 8.5711.93 (n=4)
7 day sham 8 3.3610.04 5.2810.11 104.419.63 6.2410.65 (n=3)
7 day sham + A-l82086 7 3.6210.08* 5.1110.08 112.4917.92 3.62+0.92 (n=3)
14 day CAL 8 4.1510.18*+# 6.8911.02 88.5917.78D<)> 10.1713.04^)
14 day CAL+A-182086 7 3.6010.12* 5.3110.23 85.8013.71V 8.23+2.71
14 day sham 8 3.2310.05 4.7810.07 110.8416.89 2.2810.67 (n=4)
14 day sham+A-182086 7 3.3510.07 4.7010.06 111.7514.22 3.52+1.79 (n=3)
Key: Using one-way ANOVA, heart weights were significantly different between the 2-day
(P<0.01), 7-day (P<0.02), and 14-day (PO.OOl) groups. MAP was significantly different
between the 14-day groups (P<0.01). Within groups, unpaired comparisons were
significantly different as follows: *P<0.005 versus respective sham group; ¥P<0.05 versus
respective sham group; (j)P=0.05 versus respective sham group; +P<0.005 versus respective
sham + A-182086 group; 1|P<0.05 versus respective sham + A-182086 group; (pP=0.05
versus respective sham + A-182086 group; #P<0.05 versus respective CAL + A-182086
group. Group sizes = 6, 7, or 8 unless otherwise stated.
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There were no significant changes in plasma ET-1 or big ET-1 values between CAL
and sham-op groups at any of the 3 time points studied (Table 4.2). Addition ofA-
182086 to CAL and sham-op groups significantly increased plasma ET-1 levels
compared to respective untreated groups at all 3 time points studied, but had no
effect on plasma big ET-1 values. Due to difficulties encountered in measuring
plasma big ET-1, it was not possible to obtain values for all rats in the group.
Table 4.2 Effect of CAL and antagonist treatment on plasma ET-1 and big ET-1
levels for the 12 groups studied.
Group
2 day CAL
2 day CAL + A-182086
2 day sham














7 day CAL+ A-182086
7 day sham
7 day sham + A-182086
14 day CAL
14 day CAL+ A-182086
14 day sham
















Key: Using one-way ANOVA, plasma ET-1 values were significantly different
between the 2-day (P0.001), 7-day (P<0.0001) and 14-day (P<0.001) groups.
Within groups, unpaired values were significantly different as follows: *P<0.05
versus respective untreated group; fP=0.05 versus respective untreated group.
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4.3.1.3 Gross morphology ofheartsfrom CAL and CAL +A-182086 group rats
Hearts from rats in the untreated group generally had a thinned, defined, infarct 14
days post-CAL surgery, similar to that observed in hearts from the 14-day CAL
group in chapter 3. Figure 4.1 (a) shows a cross-section of heart, cut apex to base,
from a rat in the 14-day CAL group, which displays a thinned, mature collagenous
scar in the area of the LV affected by the ligation. Above the scar is the area of non-
infarcted LV, which may undergo hypertrophy and remodelling during the
progression to heart failure. Again, as previously noted in chapter 3, a variation in the
rate of development of a mature scar was observed in some of the hearts at both 7
and 14 days post-CAL, presumably due to the slight variation in position of the
ligation. Therefore, not all 14-day group hearts had developed a thinned mature scar
at this time point.
Gross analysis revealed hearts from rats in the antagonist treated group tended to
have areas of increased myocardial content within the infarct at both time points.
Figure 4.1 (b) depicts a cross-section of heart, cut apex to base, from a rat in the 14-
day CAL + A-l 82086 group displaying a high level of 'salvaged' myocardium in the
infarct. Furthermore, large vessels were present on the outer wall of some infarcts,
indicating a blood supply to the salvaged tissue. Again, not all hearts in either the 7
or 14-day treated groups showed such a high level of salvaged myocardium within
the infarct, with some hearts also displaying areas of thinning and normal scar
formation within the infarct, similar to that observed in the CAL group.
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Figure 4.1 Cross-section ofhearts, cut apex to base, from both the (a) CAL and (b)





Infarct parameters were measured in both 7 and 14-day CAL and CAL + A-182086
groups, but not in the 2-day CAL or CAL + A-182086 groups as a defined infarct
had not formed at this time point.
Within the 7 and 14-day groups, addition of antagonist did not alter infarct size
(expressed as percentage of the LV free wall; Figure 4.2 (a)). However, the
percentage of myocardium within the infarct (Figure 4.2 (b)), and the myocardium to
collagen content of the infarct (Figure 4.2 (c)), expressed as a ratio, were
significantly increased in the presence of A-182086 in both 7 (P<0.01) and 14-day
(P<0.05) CAL-treated groups. Infarct thickness tended to be greater in the antagonist
treated groups. However, significant differences were not observed (Figure 4.2 (d)).
Figure 4.2 Effect of antagonist treatment on (a) infarct size as a % of the LV free
wall; (b) % myocardial content within the infarct; (c) myocardial/collagen content
within the infarct; and (d) infarct thickness as a % ofrespective CAL group, in the 7
and 14-day CAL groups. *P<0.05, **P<0.01 versus respective untreated group.
(a)
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4.3.2 Effect of CAL and A-182086 on the developing scar characterised using
histological and immunohistochemical techniques.
Within the 2, 7 and 14-day CAL groups, van Gieson and neutrophil staining, GSL I,
TGF-(3i and ET-1 immunoreactivity within the infarct were all similar to that
observed in the infarcts of rat hearts from the 2, 7 and 14-day CAL groups in Chapter
3 (sections 3.3.3.1-3).
4.3.2.1 2-day CAL +A-182086
van Gieson's stain highlighted areas of necrosis interspersed with areas of viable
myocardium throughout the infarct (Figures 4.3 (a, b, c)) indicating that antagonist
treatment tended to increase myocardium survival in the developing scar after MI at
this time point. However, an increased accumulation of cells was observed in areas
of necrotic tissue, most likely including proliferating fibroblasts, demonstrating that
ET receptor antagonism did not significantly inhibit this occurrence.
An inflammatory cell response was observed in necrotic tissue within the infarct,
with macrophages (Figure 4.4 (a)) and neutrophils (Figure 4.4 (bj) evident.
However, the size of the area affected by inflammation reflected the size of tissue
areas affected by the ligation. As areas of necrosis within the infarct tended to be less
for the antagonist treated group, so also was the area of the inflammation. TGF-Pi
immunoreactivity in the non-infarcted LV and in salvaged myocardium within the
infarct (Figure 4.4 (cj) was increased compared to that observed in the RV, septum,
or throughout myocardium in the sham or sham + A-182086 groups (not shown),
indicating that ET receptor antagonism had no effect on increased TGF-Pi staining of
cardiomyocytes in these areas. Necrotic myocardium within the infarct showed faint
TGF-Pi staining (Figure 4.4 (c)).
Areas of salvaged myocardial tissue within the infarct displayed ET-1
immunoreactivity similar to that observed in normal viable myocardium (Figure 4.5
(a, c)). Furthermore, ET-1 staining was observed in some macrophages, but few
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Figure 4.3 Images of sections stained with van Gieson's stain from within the infarct,
representative ofhearts from the 2-day CAL + A-182086 group, (a) overview ofarea in
the LV affected by ligation (xlOO magnification); (b, ~k) necrosis and increased cell
content in areas affected by the ligation (x400 magnification); and (c, A) viable
myocardium within the infarct (x400 magnification).
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Figure 4.4 Images from within the infarctfrom sections representative ofhearts from the
2-day CAL + A-182086 group, (a) GSL I immunoreactivity highlighting macrophages
(arrows, x400 magnification); (b) neutrophil staining (x200 magnification); and (c)
TGF-fii immunoreactivity (xlOO magnification).
(c)
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Figure 4.5 Images showing ET-1 immunoreactivity within the infarct of a heart
representative of the 2 day CAL + A-182086 group, (a) overview (parallel to Figure
4.2(a)) of LV affected by ligation (xlOO magnification); (b, -k) loss of staining in
necrotic tissue and increased cell content including macrophages (closed arrowhead)
and a fibroblast (open arrowhead, x400 magnification,); and (c,t) viable myocardium
within the infarct (x200 magnification).
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Figure 4.6 Images from the infarct border representative of hearts from the 2-day
groups, (a) H&E staining (x400 magnification) and (b) parallel section TUNEL-positive
staining (x400 magnification) at the infarct border ofa heart from the 2-day CAL group
compared to (c) TUNEL-positive staining (x400 magnification) at the infarct border ofa
heartfrom the 2-day CAL + A-182086 group.
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fibroblasts, within necrotic areas ofmyocardium (Figure 4.5 (b)). ET-1 staining was
also faint in those cardiomyocytes within necrotic myocardium in the infarct (Figure
4.5 (b)).
Evidence of TUNEL positive labelling was investigated at both the border and
central areas of the infarct and respective sham-op areas in rat hearts from all four 2-
day groups. TUNEL positive cells (staining brown) identified in the infarct as
described in section 2.2.3.4, were evident within central areas of the infarct and at the
border {Figure 4.6 (b)). However, attempts to identify these cells using a parallel
haematoxylin & eosin stained section from an identical area in the same heart
(Figure 4.6 (a)) proved extremely difficult. There was no evidence of TUNEL
positive cells in the noninfarcted LV, RV or septum of CAL rats or in any areas of
sham-op myocardium (not shown). Addition ofA-182086 to the CAL group led to a
significant reduction in TUNEL positive cell number at both the border (Figure 4.6
(c), Figure 4.7 (a)) and central area (Figure 4.7 (b)) of the infarct.
Figure 4.7 Average number of TUNEL-positive nuclei per 0.05mm2 of tissue at (a)
the border and (b) in the centre of the infarct in the 4 treatment groups. *P<0.05
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4.3.2.2 7-day CAL +A-182086
At 7 days, administration of antagonist led to a significant increase in myocardial
content within the infarct of hearts from CAL + A-182086 group rats. The salvaged
myocardium showed a cellular morphology, vascular supply and myoendothelial
distribution similar to that observed in normal or sham-op myocardium (Figure 4.8
(a, c, d)). However, where areas of granulation and necrosis were evident, fibroblasts
were synthesising collagen, indicating that ET-1 is not essential in the regulation of
this process (Figure 4.8 (b)).
As with the finding in the 2-day CAL + A-182086 group, the inflammatory response
at 7 days tended to correlate with the level of necrotic damage present. The size of
the area affected by inflammation in the antagonist treated group, therefore, tended to
be less than in the untreated CAL group. Inflammatory cells evident in granulation
areas included macrophages (Figure 4.9 (a)) and monocytes. New vessel formation
was also present within areas of granulation tissue (Figure 4.9 (b)).
TGF-Pi immunoreactivity was still evident in specific cells within areas of
granulation in the infarct (Figure 4.9 (c)), comparable to that observed throughout
the infarct of hearts in the respective untreated CAL group and also in the 7-day CAL
group in Chapter 3. However, the number of TGF-Pi-stained cells again correlated
with the amount of granulation tissue present. Therefore, in the antagonist treated
CAL group, less TGF-Pi stained cells were evident than in the untreated CAL group.
In salvaged myocardium within the infarct, TGF-Pi staining was greater than that
observed in the RV or septum and similar to that observed in the non-infarcted LV
(not shown).
ET-1 immunoreactivity in the salvaged myocardium was diffuse, with a distribution
similar to that found in normal myocardium (Figure 4.10 (a, c)). Furthermore, in
granulation tissue, ET-1 immunoreactivity was again located in fibroblasts and
inflammatory cells (Figure 4.10 (b)), and in endothelial cells of newly forming
vessels (not shown). Intensity of staining in these cells was similar to that observed
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Figure 4.8 Images from within the infarct, representative of heart sections from the 7
day CAL + A-182086 group, stained with van Gieson's stain, (a) overview of the LV
area affected by ligation (x50 magnification); (b, ~k) collagen synthesis in granulation
tissue (x400 magnification); (c, A) salvaged myocardium within the infarct (x400







Figure 4.9 Images from within granulation tissue of the infarct from heart sections
representative of the 7-day CAL + A-182086 group. GSL I immunoreactivity
highlighting (a) inflammatory cells including macrophages (arrows; xlOOO
magnification), and (b) new vessel formation (x400 magnification); (c) TGF-/3i
immunoreactivity in inflammatory cells (closed arrowhead), fibroblasts (open
arrowhead) and in endothelia ofnew vessels (dotted arrow line; x400 magnification).
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Figure 4.10 Images from within the infarct, representative of heart sections from the 7
day CAL + A-182086 group, showing ET-1 immunoreactivity. (a) overview of the LV
area affected by ligation (x50 magnification); (b, k) ET-1 staining in granulation tissue




in cells within the infarcts of hearts from untreated CAL group rats. ET-1
immunoreactivity was again observed in cells that showed TGF-Pi
immunoreactivity.
4.3.2.3 14-day CAL +A-182086
The significantly increased myocardial cell content within the infarcts of hearts from
the 14-day CAL + A-182086 group rats (Figure 4.11 (a)), compared to the untreated
CAL group alone, again had a cellular morphology, vascular supply and ET-1
immunoreactivity {Figure 4.11 (b)) similar to normal myocardium. The salvaged
myocardium also showed a myoendothelial capillary distribution comparable to that
observed in normal or sham-op myocardium (not shown).
Increased TGF-Pi immunoreactivity was again evident in cardiomyocytes in the non-
infarcted LV and in salvaged myocardium within the infarct (not shown).
Furthermore, mature collagen deposition, TGF-Pi staining, remaining inflammatory
cells and new vessel formation were all observed in areas where granulation tissue
was still present (not shown).
P-MHC immunoreactivity was increased in the non-infarcted LV and in remaining
viable cardiomyocytes within the infarct of hearts from CAL group rats {Figure 4.12.
(b)) compared to sham-op group rats {Figure 4.12 (a)). However, addition of A-
182086 to the CAL group tended to reduce P-MHC immunoreactivity in most
sections in both the non-infarcted LV {Figure 4.12 (cj) and in the salvaged
myocardium within the infarct.
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Figure 4.11 Images from within the infarct ofa heart from the 14-day CAL + A-182086
group. Overview of the infarct stained with (a) van Gieson's stain (x50 magnification)
and (b) showing ET-1 immunoreactivity in a parallel section (x50 magnification).
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Figure 4.12 Images showing (4-MHC immunoreactivity (brown) in the non-infarcted LV
ofhearts representative of the 14-day groups, (a) sham-op; (b) CAL; and (c) CAL + A-
182086 groups (all x400 magnification).
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4.4 Discussion
This study set out to investigate the role of ET-1 within the developing scar of rat
hearts in the early stage post-MI, using a non-selective ET receptor antagonist A-
182086 (Abbott Laboratories, USA). In A-182086-treated and untreated CAL rats,
MI was confirmed by an increased plasma LDH value, measured upon recovery from
surgery, 3x that of a sham rat operated on the same day. Verification that the
antagonist sufficiently blocked ETB receptors was indicated by a significantly
increased plasma ET-1 value in all antagonist-treated groups compared to their
respective untreated groups; the ETB receptor has been shown to be associated with
clearance of ET-1 from plasma (Fukuroda et al., 1994).
Results from this study indicated that oral administration of A-182086 significantly
decreased heart weight at 14 days post-CAL and significantly improved myocardial
cell content within the infarct at both 7 and 14 days post-CAL. The salvaged
myocardium showed a cellular morphology, vascular and myoendothelial supply,
and distribution of ET-1 immunoreactivity similar to that found in normal or sham-
op myocardium.
Although ET-1 immunoreactivity was increased within the infarcts of both the CAL
and CAL + A-182086 treated group at 7 and 14 days, it was not known (at the start
of the present study) if preproET-1, ETA or ETB receptor mRNA levels change in
conjunction with the increase in ET-1 immunoreactivity observed. Also, if changes
were observed, would administration of antagonist have an effect on expression
levels in either the infarct or non-infarcted myocardium of the LV? However,
attempts to investigate mRNA levels using in situ hybridisation in this thesis study
were not successful (see section 4.2.4). Recently, though, Tonnessen et al. (1998)
demonstrated a 3.5 ±1.1-fold and a 6.4 ±0.8-fold upregulation of preproET-1 mRNA
in the noninfarcted and infarcted area of the left ventricle respectively at 7 days post-
MI in the rat, indicating an increase in expression parallel to the increased
immunoreactivity within the infarct. Furthermore, another study reported
significantly increased preproET-1 mRNA expression in the LV of hearts from rats
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15 days post-MI, with administration of bosentan (24 hours after CAL) having no
effect on preproET-1 mRNA levels (0ie et ah, 1998). This finding by 0ie et ah is
consistent with the finding of increased ET-1 immunoreactivity within the infarct
being unaffected by non-selective ET receptor antagonism in the present study,
suggesting ET receptor blockade does not inhibit synthesis of cellular ET-1 in the
developing scar.
Other factors, including Ang II and specific cytokines, have been shown to stimulate
ET-1 synthesis in both endothelial cells (Kanse et ah, 1991) and fibroblasts (Gray et
ah, 1998). ACE inhibitors were shown to suppress both preproET-1 mRNA
overexpression in the kidney of a rat model of immune-complex nephritis (Ruiz-
Ortega et ah, 1997), and reduce endogenous ET-1 secretion, resulting in improved
coronary function and stabilisation of cardiac rhythm after ischaemia in a perfused
rat heart model of ischaemia/reperfusion (Brunner & Opie, 1996). Furthermore,
TGF-Pi was found to stimulate the expression of preproET-1 mRNA by vascular
endothelial cells (Kurihara et ah, 1989). The increased ET-1 immunoreactivity
observed in specific cells at 7 days within the infarct of treated and untreated groups
may, therefore, be a consequence of paracrine stimulation of synthesis from such
factors as Ang II and cytokines. It would be interesting to investigate the action of
the upregulated RAAS on ET-1, ETa and ETb mRNA expression, using an ATi
receptor antagonist administered immediately post-MI in the rat, therefore
determining the influence of increased Ang II on the ET system during early scar
development.
A-182086 significantly improved myocardial content within the infarct at both 7 and
14 days post-CAL. However, where areas of granulation were present within the
developing scar, active processes of scar formation including inflammatory cell
infiltration, collagen synthesis, angiogenesis, and TGF-pi synthesis were still present
and not inhibited by non-selective ET receptor antagonism. Therefore, though A-
182086 did reduce the amount of damaged tissue within the infarct affected by the
ligation, it did not inhibit the processes of scar healing in areas of granulation tissue.
This suggests that though increased ET-1 immunoreactivity was observed within the
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developing scar and may contribute to regulation of the above-mentioned processes,
blockade of its effect was insufficient to halt the scaring process.
Factors other than ET-1, including the RAAS and cytokines, have also been reported
to be increased within the infarct early after MI and can influence scar development.
Levels of renin mRNA were found to be increased 4-, 14-, and 8-fold in the infarcted
LV at 2, 7 and 14 days respectively after MI in rats, suggesting a role for intracardiac
Ang II in the infarct healing process (Passier et al., 1996). Activation of the renin
gene in the border zone of the infarcted area in the early phase after MI was also in
agreement with the activation and localisation of the ACE gene and protein (Passier
et al., 1995). Observations of increased interstitial collagen deposition and the effect
of ACE-inhibitors resulted in the hypothesis that the RAAS might be involved in the
regulation of collagen synthesis in the cardiac interstitium following MI (Michel et
al., 1988). Recent AT receptor antagonist studies have also shown Ang II to be
involved in both interstitial cell proliferation (via the AT2 receptor) and collagen
deposition (via the AT] receptor) in rats (Unger et al., 1998; Kuizinga et al., 1998).
Furthermore, the ACE inhibitor captopril and the ATj receptor antagonist valsartan
were shown to have potent inhibitory effects on pro-inflammatory cytokines
including TNF-a and IL-1 in vitro, suggesting a role for the RAAS in regulation of
pro-inflammatory factors (Peeters et al., 1998). Ang II has also been demonstrated to
stimulate angiogenesis in a murine sponge model of angiogenesis (Machado et al.,
1999).
Cytokine gene expression, including TNF-a, IL-lp, and IL-6, has been reported to
be increased after MI in rat hearts (Ono et al., 1998) and may have predominant roles
in regulating inflammatory responses in the infarcted myocardium (Frangogiannis et
al., 1998). Induction of cytokine expression was also found in leukocytes in acute MI
in an ischaemia/reperfusion rat heart model (Marx et al., 1997). TGF-pi is an
important regulatory peptide in fibrous tissue formation and has numerous actions on
extracellular matrix. It stimulates fibroblast-like cell growth, enhances collagen
synthesis, and suppresses collagen degradation (O'Kane et al., 1997). Furthermore,
TGF-Pi mRNA has been shown to be increased in necrotic tissue within the infarcted
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rat heart after MI, with levels peaking at day 7 (Sun et al., 2000), supporting a role in
the processes of scar formation. The above factors may, therefore, be equally
important regulators of scar formation in the early stage post-MI, and may continue
the reparative processes independent of the presence or influence ofET-1.
As reported in section 3.3.2, increased ET-1 and TGF-(3i immunoreactivity was
observed in similar cells within the infarct at 7 days post-CAL, although it is not
known if ET-1 has a predominant role in regulating TGF-Pi synthesis or vice versa.
However, administration of A-l82086 did not prevent increased TGF-Pi cell specific
immunoreactivity in areas of granulation at this time point, suggesting ET-1 is not
essential in regulation of this peptide. This is in contrast to a recent study showing
significantly reduced TGF-Pi mRNA expression and peptide levels in the LV of a rat
MI model in the presence of bosentan (administered 24 hours post-CAL), further
suggesting that ET-1 may contribute to fibrosis early post-MI via activation of TGF-
pi within the myocardium (Tzanidis & Lim, 1999). However, this previous study did
not discriminate between levels of TGF-Pi in the infarct and non-infarcted LV.
Therefore, this finding may not be dissimilar to the finding in the present study,
where overall distribution of TGF-Pi immunoreactivity tended to be less in the
antagonist treated group, since less granulation tissue was present within the infarct.
The fact that A-l82086 did not inhibit synthesis of TGF-Pi in the developing scar
suggests that other factors present in the infarct may also stimulate TGF-Pi synthesis.
Ang II has been reported to specifically stimulate TGF-Pi expression in the
developing infarct (Sun et al., 1998), and as mentioned earlier, the RAAS itself is
upregulated in the early stage post-MI. Nevertheless, as A-l82086 did not decrease
TGF-Pi staining distribution in granulation tissue or cardiomyocytes, TGF-Pi may
alternatively have a predominant role in stimulation of ET-1 synthesis in the
developing scar. TGF-Pi has been reported to stimulate ET-1 mRNA expression in
vascular endothelial cells in vitro (Kurihara et al., 1989), and upregulate ET-1 and
big ET-1 peptide secretion in a human prostate cancer cell line in vitro (Lechat et al.,
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1999). However, whether TGF-pi has similar effects in vivo, and within the
developing scar, requires further investigation.
Neutrophil infiltration and expression of neutrophil adhesion molecules have been
shown to correlate with myocardial infarct size (Hillis et al., 1999), with rats
deficient in neutrophil adhesion molecules P-selectin, E-selectin, ICAM-1 or
CD11/CD18 all showing reduced myocardial damage in the LV after ischaemia/
reperfusion (Trocha et al., 1999). Though ET-1 has been implicated in stimulating
neutrophil adherence during coronary artery bypass (Bugajski et al., 1999), and
adherence to coronary artery endothelial cells in vitro (Zouki et al., 1999), in the
present study many neutrophils were still observed in the infarct in the presence of
A-l82086 indicating that blockade of ET receptors is insufficient to inhibit
neutrophil infiltration early post-MI. However, many other factors can also stimulate
neutrophil adhesion and infiltration including cytokines (Sawa et al., 1998),
complement, and oxygen free radicals released from hypoxic cardiomyocytes
(reviewed by Jordan et al., 1999). Again, these factors may stimulate neutrophil
infiltration and activation independent of the presence ofET-1.
A modified in situ nick end-labelling (TUNEL) assay (Gavrieli et al., 1992) was used
for assessment of apoptosis in myocardial tissue within the infarct. TUNEL-positive
staining has been shown to increase during the first 6 hours to 2 days after permanent
coronary occlusion (Kajstura et al., 1996), with levels decreasing over 4 weeks
(Cheng et al., 1996). Within the 2-day CAL groups, levels of TUNEL-positive cells
at both the border and within the central area of the infarct were significantly reduced
in the presence ofA-182086. However, interpretation of these results is complicated.
TUNEL-positivity reflects a wide range of cellular conditions including viable cells
undergoing repair, necrosis and apoptosis. Although TUNEL-positivity is not the
best hallmark of apoptosis, there is presently no other way to semi-quantitatively
assess apoptosis in myocardial tissue (Yaoita et al., 2000). To confirm apoptosis,
TUNEL-positive cells would need to be examined via electron microscopy to reveal
condensation and fragmentation of the nucleus, which are hallmarks exclusive to
apoptosis (Yaoita et al., 2000).
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Attempts to identify TUNEL-positive cells using parallel haematoxylin & eosin
stained sections proved extremely difficult. Furthermore, whether antagonist
administration induced a direct inhibition of TUNEL-positive stained cells, or
indirectly reduced the number of infiltrating inflammatory cells and resident cells
affected by ischaemia, therefore leading to a reduction in numbers of cells
undergoing TUNEL-positive staining, could not be determined. However, ET
receptor antagonism did significantly reduce levels of TUNEL-positive staining
within the infarct suggesting ET-1 may have a role in regulating apoptosis post-MI.
No studies to date have investigated the effect of ET-1 on apoptosis post-MI. One
study showed TUNEL-positive staining cells within the infarct after MI included
cardiomyocytes, endothelial cells, macrophages and neutrophils (Takemura et al.,
1998), all of which have been shown to stain positive for ET-1 immunoreactivity in
the present study. However, further studies verifying apoptosis using electron
microscopy, and using double staining techniques along with the TUNEL assay to
identify specific cells (Willingham et al., 1999), are required to clarify whether ET-1
has a role in regulating apoptosis post-MI.
In summary, ET receptor antagonism did not halt the active processes of scar
formation within the infarct including the inflammatory response, angiogenesis,
collagen synthesis, or activation of TGF-Pi. Nevertheless, administration of A-
182086 did significantly improve viable myocardial content of the infarct in both 7
and 14-day CAL-treated groups. The fact that areas of inflammation and increased
cellular content were still evident in the infarct at 2 days post-CAL suggests that the
primary action of antagonist treatment in increasing levels of salvaged myocardium
is manifest at a time earlier than 2 days. Furthermore, 2 CAL + A-182086 group rats
(1 from the 7-day group and 1 from the 14-day group) that did not eat their food over
the first 24 hours, but ate daily thereafter for the duration of the study, developed
thinned defined infarcts with little myocardial cell content. This further implies that
the antagonist effect was occurring within the first 24 hours of treatment. Neither rats
were included in the analysis of these studies.
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The question therefore arises as to how early administration of A-182086 leads to an
improvement in myocardium content within the infarct. The answer may involve
whether myocardial ET-1 tissue levels change acutely after irreversible myocardial
damage. Increased plasma ET-1 concentrations were found in patients with unstable
angina, myocardial infarction (Wieczorek et al., 1994) and immediately following
percutaneous transluminal coronary angioplasty (Malatino et al., 1993). Hypoxia is
also reported to induce ET gene expression and secretion in cultured human
endothelial cells in vitro (Kourembanas et al., 1991); and increase maximal
responses of ET-1 in the rat isolated perfused mesenteric arterial bed in vitro
(Douglas et al., 1991).
Although studies investigating acute changes in tissue levels of ET-1 in the heart
after induced ischaemia in vitro are few in number, studies investigating ET-1 during
ischaemia/reperfusion in vitro have reported an increased release of endogenous ET-
1 in the coronary perfusate (Brunner et al., 1992) and beneficial effects of ET
receptor antagonism on ischaemia/reperfusion-induced myocardial damage (Pernow
& Wang, 1997). Literature investigating acute changes in ET-1 in the heart after
induced ischaemia in vivo found increased ET-1 expression and production of ET-1
in cardiomyocytes (Tonnessen et al., 1995). It is therefore possible that stimulation
of an acute release of ET-1 as a consequence of irreversible hypoxic damage in the
myocardium may potentiate a profound transient vasoconstriction, further reducing
any remaining blood flow around (or into) the affected tissue, thereby augmenting
irreversible ischaemic damage. Evidence of a collateral flow has been reported in the
rat heart during myocardial ischaemia (Maxwell et al., 1987) and in human studies,
where coronary collateral circulation decreased wall motion abnormalities, ST
segment changes and lactate production post-MI (reviewed by Charney & Cohen,
1993). Although transient increases in other vasoconstrictive factors may also occur
during this period, ET-1, being one of the most potent vasoconstrictive peptides
known, may be responsible for most of the damage induced. Therefore, inhibition of
a transient ET-1-mediated vasoconstriction in the acute phase post-MI may explain
how early administration of A-182086 improved myocardial survival within the
infarct while not blocking the later processes of scar formation.
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Recent antagonist studies have allowed further insight into the role of ET-1 in the
heart post-MI. An interesting study by Hu et al. (1998) reported that ETA selective
receptor antagonism administered 3 hours after coronary artery ligation in rats and
continued for 8 weeks aggravated chronic LV remodelling with no improvement in
hemodynamics. Another recent study by Galuppo et al. (1999) also found early ETA
receptor blockade (started 3 hours after CAL) promoted infarct thinning and
expansion in a rat model of MI. The fact that immediate administration of the ETA
receptor antagonist did not improve cardiac parameters in either study (change in
myocardial cell content within the infarcts was not mentioned) suggests that selective
blockade of ETA receptors does not completely inhibit ET-1 mediated effects (such
as vasoconstriction) early post-MI. ETb receptor-mediated pathways are normally
related to induction of vasodilation by enhancement of endothelial nitric oxide
synthesis. However, ETb receptors, present on vascular smooth muscle cells and
cardiomyocytes (Suzuki et al., 1993), can also contribute to the vasoconstrictor effect
of ET-1 (McMurdo et al., 1993; Seo et al., 1994). In a study investigating ischaemia
/reperfusion in the pig, both ET-1 and Ala-ET-1, a selective ETb agonist, caused
coronary vasoconstriction in the post-ischaemic myocardium (Wang et al., 1995).
Furthermore, Zhang et al. (1998) reported coronary vasoconstriction during and after
perfusion with the ETA selective antagonist BQ-123 in isolated Langendorff rat
hearts, but not with the non-selective ET receptor antagonist bosentan, indicating
ETb receptor-mediated vasoconstriction in the presence of ETA receptor antagonism.
Therefore, antagonism of both ET receptors may be required to inhibit any transient
ET-1 induced vasoconstriction during ischaemia.
Timing of antagonist administration also seems to be crucial. ETA receptor
antagonism administered 24 hours post-MI and continued for 4 weeks led to thinning
of the LV scar, LV dilatation and an increase in LVEDP, with an improvement in
RVSP and RAP (Picard et al., 1998). Furthermore, administration of bosentan 24
hours post-MI and continued for 15 days did not reduce hypertrophy in the
noninfarcted LV, though a modest reduction of preload and afterload provided by
bosentan substantially attenuated LV dilatation causing improved pressure volume
relationships (0ie et al., 1998). However, bosentan administered 3 hours post-
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ligation in the rat and continued for 8 weeks had no effect on LVEDP, but reduced
SBP, HR and ventricular ET-1 content (Fraccarollo et al., 1997). None of the studies
alluded to the effect of antagonist treatment on the processes of scar formation or
myocardial content within the scar.
Therefore, the finding that early ETa receptor antagonism in CAL-operated rats (Hu
et al., 1998; Galuppo et al., 1999) did not produce similar findings to the present
study may be due to the potential role of ETb receptors in ET-1 mediated
vasoconstriction during ischaemia. Furthermore, the fact that bosentan administered
24 hours post-MI did not reduce LV hypertrophy (0ie et al., 1998) along with the
finding in the present study that A-182086 administered upon recovery from CAL
surgery reduced heart weight, P-MHC immunoreactivity and improved myocardial
content within the infarct also suggests that timing of antagonist administration, and
therefore early transient changes in myocardial ET-1 levels may be crucial in the
processes of tissue recovery and the extent of ischaemia-induced myocardial damage.
It would, therefore, be interesting, in a future study, to compare the effect on
myocardial content and scar formation after 14 days in (1) rats administered a non¬
selective ET receptor antagonist for the first 24 hours only post-CAL; (2) rats not fed
antagonist in the first 24 hours post-CAL but treated daily thereafter for the duration
of the study; and (3) rats fed antagonist during the first 24 hours post-CAL and
continued daily for the 14 day period. This would confirm if treatment was effective
over the first 24-hour period only, or required throughout the duration of scar
formation.
Although myocardial content within the infarct was improved in the 7- and 14-day
treated groups, there were no significant improvements in MAP or LVEDP at these
time points. Also, it is not clear if the increased myocardial content observed will
have beneficial or detrimental effects on the heart at later points during the
progression towards CHF. Further studies are therefore required using the same
protocol to investigate if chronic A-182086 treatment would improve cardiac
parameters and/or remodelling during development of CHF. One study investigating
chronic non-selective ET receptor antagonism (administered 3 hours after CAL in the
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rat) also found no hemodynamic improvements at 7 days post-CAL. However, after
8 weeks bosentan treatment, left ventricular dilatation was partially prevented and
improved hemodynamics were observed, supporting a role for ET-1 in left
ventricular remodelling after MI (Fraccarollo et al., 1997). Other studies have
reported that long-term treatment with either bosentan (administered 7 days post-MI;
Mulder et al., 1997) or SB209670 (administered 10 days post-MI; Sakai et al., 2000)
markedly increased survival in the rat model of CHF. This increase in survival was
associated with decreases in both preload and afterload and an increase in CO as well
as decreased LV hypertrophy, LV dilatation, and cardiac fibrosis (Mulder et al.,
1997); and also an improvement in alterations of cardiac genes associated with
progression ofCHF (Sakai et al., 2000).
Administration of A-182086 did significantly reduce heart weight in the 14-day CAL
group, which was accompanied by reduced P-MHC immunoreactivity within the
non-infarcted LV and in the salvaged myocardium within the infarct at this time
point. Isoforms of cardiac MHC are altered in the failing myocardium of
experimental CHF animals. Furthermore, the change from a-MHC to P-MHC is
regarded as a molecular marker for hypertrophy in the failing myocardium (Michel et
al., 1988; Parker et al., 1990b). ET-1 has also been shown to stimulate P-MHC
production in ventricular myocardium in vitro (Wang et al., 1992; Ichikawa et al.,
1996). That p-MHC immunoreactivity tended to be reduced in the non-infarcted LV
and salvaged myocardium within the infarct of rat hearts from the A-182086 treated
group suggests that early intervention with the non-selective ET receptor antagonist
may have beneficial effects on wall stress, induction of hypertrophy, and LV
remodelling at later stages post-MI. However, actual tissue levels of P-MHC would
need to be measured in this study to confirm immunohistochemical observations.
Interestingly, 0ie et al. (1998) found no effect of bosentan treatment on LV
hypertrophy 15 days post MI, with treatment started 24 hours post-CAL. This
finding, combined with that from this thesis and that above of Fraccarollo et al.
(1997) and Mulder et al. (1997), suggests that chronic ET antagonism may have both
a direct effect on hypertrophy and remodelling at later stages post-MI, but also an
indirect effect via an overall increase in viable tissue, and therefore a reduced work
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rat) also found no hemodynamic improvements at 7 days post-CAL. However, after
8 weeks bosentan treatment, left ventricular dilatation was partially prevented and
improved hemodynamics were observed, supporting a role for ET-1 in left
ventricular remodelling after MI (Bauersachs et al., 1998). Other studies have
reported that long-term treatment with either bosentan (administered 7 days post-MI;
Mulder et al., 1997) or SB209670 (administered 10 days post-MI; Sakai et al., 2000)
markedly increased survival in the rat model of CHF. This increase in survival was
associated with decreases in both preload and afiterload and an increase in CO as well
as decreased LV hypertrophy, LV dilatation, and cardiac fibrosis (Mulder et al.,
1997); and also an improvement in alterations of cardiac genes associated with
progression ofCHF (Sakai et al., 2000).
Administration of A-182086 did significantly reduce heart weight in the 14-day CAL
group, which was accompanied by reduced (3-MHC immunoreactivity within the
non-infarcted LV and in the salvaged myocardium within the infarct at this time
point. Isoforms of cardiac MHC are altered in the failing myocardium of
experimental CHF animals. Furthermore, the change from a-MHC to [3-MHC is
regarded as a molecular marker for hypertrophy in the failing myocardium (Michel et
al., 1988; Parker et al., 1990b). ET-1 has also been shown to stimulate (3-MHC
production in ventricular myocardium in vitro (Wang et al., 1992; Ichikawa et al.,
1996). That (3-MHC immunoreactivity tended to be reduced in the non-infarcted LV
and salvaged myocardium within the infarct of rat hearts from the A-182086 treated
group suggests that early intervention with the non-selective ET receptor antagonist
may have beneficial effects on wall stress, induction of hypertrophy, and LV
remodelling at later stages post-MI. However, actual tissue levels of (3-MHC would
need to be measured in this study to confirm immunohistochemical observations.
Interestingly, 0ie et al. (1998) found no effect of bosentan treatment on LV
hypertrophy 15 days post MI, with treatment started 24 hours post-CAL. This
finding, combined with that from this thesis and that above of Fraccarollo et al.
(1997) and Mulder et al. (1997), suggests that chronic ET antagonism may have both
a direct effect on hypertrophy and remodelling at later stages post-MI, but also an
indirect effect via an overall increase in viable tissue, and therefore a reduced work
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load on remaining myocardium within the LV, when administered early post-MI.
However, the precise mechanisms of how ET receptor antagonism may reduce




Investigation of the myocardial endothelin





In response to myocardial infarction (MI) compensatory mechanisms are activated in
an attempt to maintain cardiac output and peripheral perfusion. The adaptive
responses are the results of a complex interplay between haemodynamic, myocardial,
and neurohormonal mechanisms (Parmley, 1985). Compensatory responses of the
cardiovascular system may involve factors that act locally at the site of synthesis.
Cardiac myocytes (Suzuki et al., 1993), as well as vascular endothelial cells
(Yanagisawa et al., 1988) produce ET-1. Plasma levels of ET-1 and its precursor big
ET-1 increase post-MI and are important predictors of outcome, with levels
correlating positively with disease severity during development of chronic heart
failure (CHF; Rodeheffer et al., 1992; Omland et al., 1994; Wei et al., 1994).
Endogenous ET-1 contributes to maintenance of vascular tone in healthy men
(Haynes et al., 1994). Kiowski et al. (1995) showed that treatment of CHF patients
with the non-selective ETa/ETb receptor antagonist bosentan markedly improved
haemodynamic parameters and increased cardiac index. Acute administration of ET
receptor antagonists was also found to exert favourable haemodynamic effects in rat
(Teerlink et al., 1994) and dog (Shimoyama et al., 1996) models of heart failure.
A number of studies have investigated the myocardial ET system in human heart
failure. Giaid et al. (1995) reported increased ET-1 immunoreactivity and evidence
of preproET-1 mRNA in cardiomyocytes and endothelial cells in endocardial biopsy
samples from transplanted hearts. Furthermore, ET-1 mRNA expression and
immunoreactive ET-1 have been demonstrated in endothelial cells of human cardiac
tissue from patients with ischaemic heart disease and idiopathic dilated
cardiomyopathy (Plumpton et al., 1996).
In animal studies using rat models of CHF secondary to MI, markedly increased
tissue levels of ET-1 peptide, preproET-1, ETa receptor and ETB receptor mRNA
have been reported in the failing hearts of rats at 3 (Sakai et al., 1996a) and 12 (Sakai
et al., 1996b) weeks post-MI compared to respective sham-op rat hearts.
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Furthermore, addition of the ETa selective receptor antagonist BQ-123 10 days post-
Mi for 12 weeks greatly improved survival, ameliorated LV dysfunction, and
prevented ventricular remodelling, indicating that an upregulated ET system may
contribute to progression ofCHF (Sakai et ah, 1996b).
Following MI, the infarcted region of the myocardium undergoes a process of repair
involving formation of a collagenous scar (as shown in Chapter 3) that is followed by
remodelling of the non-infarcted LV involving hypertrophy and dilatation (Pfeffer &
Braunwald, 1990). In vitro studies have indicated a role for ET-1 in stimulation of
cardiomyocyte hypertrophy (Shubeita et al., 1990; Goto & Warner, 1995) and
upregulation of the ET-1 system in the heart may contribute to excessive hypertrophy
of the myocardium during CHF. Although the above studies suggest an involvement
of the ET-1 system in both myocardial remodelling and hypertrophy post-MI, the
specific cellular localisation of preproET-1 and ET receptor expression in areas
undergoing hypertrophy, or within the developed scar, later post-MI have not been
investigated in vivo.
In Chapters 3 and 4, I investigated the myocardial ET-1 system early post-MI with
particular reference to scar formation. The aims of this chapter were to further
investigate progressive changes in expression of preproET-1, ETA receptor and ETB
receptor mRNA in areas of the myocardium undergoing repair and remodelling later
post-MI. Regions of hypertrophy within the myocardium were identified by
distribution of P-myosin heavy chain (MHC), a molecular marker associated with
hypertrophy (Michel et ah, 1995). Association ofET receptors with the growth factor
cytokine TGF-Pi, and the signalling transcription factor ERK, was also investigated,
the latter being known to be activated by ET-1 and involved in transcriptional
regulation of proto-oncogenes that modulate cell growth and proliferation (Quian et
ah, 1991; Davis, 1995). In addition, changes in the ET system were investigated




All procedures were carried out as described in Chapter 2. Rats were investigated
twice post-MI, at 5 and 12 weeks, each with respective sham-operated groups. The
developed scar was characterised histologically with respect to collagen deposition
using van Gieson's stain. Immunohistochemistry was performed using antibodies to
GSL I, TGF-Pi, ET-1, ETB receptor, P-MHC and the extracellular regulated kinase
ERK. Expression of preproET-1, ETa receptor and ETB receptor mRNA was
investigated by in situ hybridisation.
5.2.1 Coronary artery ligation rat model
MI was induced by ligation of the left anterior descending coronary artery in male
Wistar rats (n=20) as described in Section 2.1. Upon recovery from surgery, rats
were housed in groups of 2 and allowed access to normal rat chow and water ad
libitum for the duration of the study. All surgical procedures were carried out by Dr.
Gillian Gray.
5.2.2 Plasma collection and tissue sampling
Either 5 or 12 weeks after CAL or sham operation, rats were anaesthetised (60mg/kg
Na pentobarbital i.p.) and then exsanguinated via the carotid artery where an ~5ml
blood sample was collected into a 10ml syringe pre-rinsed with heparin. The blood
was aliquoted into pre-chilled test tubes containing 50pl of 10mmol/l final
concentration EDTA and immediately centrifuged (2000xg, 4°C, 20mins). Plasma
was aliquoted off each sample and stored at -70°C for future plasma ET-1 and big
ET-1 analysis as described in section 2.2.2.
The heart and lungs were excised, rinsed in ice-cooled physiological saline, then
individually weighed. The heart was then bisected longitudinally from apex to base
so that each half consisted of both right and left ventricles; a section of the lung was
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also separated before all samples were placed in 10% neutral buffered formalin
solution for 24hrs fixation prior to further processing and wax embedding. Within the
5 and 12 week post-CAL groups, infarct size as a percentage of the left ventricular
wall was measured from 3pM heart sections stained with van Gieson's collagen stain
and the nucleus stained with Celestine Blue as described in section 2.3.1.
5.2.3 General staining and immunohistochemistry
3pm wax embedded heart sections were treated with van Gieson's collagen stain
highlighting collagen as described in section 2.3.3. Immunohistochemistry was also
performed on 3pm heart sections using antibodies to GSL, ET-1 and TGF-Pi using
the alkaline phosphatase detection method, and antibodies to ETb receptors, P-MHC
and ERK using the peroxidase detection method as described in sections 2.4.2 and
2.4.3.
5.2.4 In situ hybridisation
In situ hybridisation was performed on 3pm wax embedded heart sections using
probes to preproET-1, ETa and ETb receptor mRNA as described in sections 2.5.3-
2.5.5. PreproET-1, ETA receptor and ETB receptor mRNA were semi-quantified in
heart sections using a computerised image analysis system (Zeiss Kontron 300,
Image Associates, UK) as described in section 2.6.1. In situ procedures were
developed and carried out by Dr. Pauline McEwan.
5.2.5 Statistical analysis
All data was displayed as mean±SEM. In situ hybridisation data were analysed
between groups by one-way ANOVA and significance was established within groups
using a Student's t-test. Unpaired observations between organ weights and plasma
levels from 5 and 12-week MI and respective sham groups were assessed by




5.3.1 Effects of coronary artery ligation
Survival rate during the study period was 70%. Death was limited to the first 24-hour
period after surgery. Table 5.1 below summarises organ weights, LV infarct sizes,
and plasma ET-1 and big ET-1 values from the relevant groups.









Heart Weight 2.95±0.11 *3.48±0.16 3.12±0.14 3.17±0.70
(g/kg Body Weight) (n=7) (n=7) (n=7) (n=5)
Lung Weight 3.62±0.15 5.13±0.91 3.6±0.17 4.40±0.09
(g/kg Body Weight) (n=7) (n=7) (n=7) (n-5)
Infarct Size No Infarct 43.6±8.4 No Infarct 49.0±11.2
(as % ofLV free wall) (n=6) (n=4)
Plasma ET-1 3.1±0.8 3.2±1.2 5.0±0.8 5.9±2.1
(pg/ml) (n=3) (n~3) (n=5) (n=3)
Plasma big ET-1 24.8±3.0 23.7±2.8 26.4±5.2 38.1±14.3
(pg/ml) (n=3) (n=3) (n=5) (n=3)
Key: *P<0.05 versus respective sham-op group.
Organ weights were not measured for 2 of the 12-week post-MI rats. Furthermore,
due to difficulties encountered in measuring plasma ET-1 and big ET-1, it was not
possible to obtain values for all of the rats. Heart weights were significantly
increased at 5 weeks, but not 12 weeks, post-MI compared to the sham-op group.
Lung weights tended to be increased at both time points in the post-MI groups,
though no significant difference was observed. From the plasma values gained, levels
of big ET-1 tended to be higher in the post-MI group at 12 weeks compared to the




5.3.2 Distribution of preproET-1, ETa and ETb receptor mRNA.
Within the sham-op hearts, preproET-1 mRNA was expressed abundantly throughout
all chambers, being located in cardiomyocytes in both atria and ventricles (Figure
5.1 (a)). Within the 5-week and 12-week post-MI hearts, preproET-1 mRNA was
again expressed abundantly throughout atria, RV, septum and non-infarcted LV
(Figure 5.1 (b, c)). Distribution of preproET-1 mRNA expression was similar to that
of ET-1 immunoreactivity (Figure 5.8 (a, b, cj). At 5 and 12 weeks post-MI within
the infarct, preproET-1 mRNA was present only in remaining cardiomyocytes, with
areas of collagen deposition showing little expression (Figure 5.1 (d)). Levels within
the infarct were therefore significantly decreased (P<0.001, Figure 5.2 (a, b))
compared to respective LV areas in myocardium from sham-op rat hearts. However,
expression in the RV and non-infarcted LV away from the scar remained unchanged
(Figure 5.2 (a, b)). For preproET-1 and subsequent expression studies using ETA and
ETb receptor antisense, treatment of consecutive sections with appropriate sense
control probes showed little evidence of non-specific binding or background activity
(Figure 5.1 (e), Figure 5.3 (c)).
In sham-op myocardium, ETA receptor mRNA was localised throughout the heart in
atria, RV and LV (Figure 5.3 (a)) and within the vascular media of intramyocardial
blood vessels (not shown). A similar distribution of ETA receptor mRNA was found
in myocardium from 5 (Figure 5.3 (b)) and 12-week post-MI rat hearts except within
the infarct where ETA mRNA levels were significantly lower (P<0.01 at 5 weeks
post-MI and P<0.001 at 12 weeks post-MI, Figure 5.4 (a, b)), being restricted to the
few remaining cardiomyocytes with no evidence of ETA mRNA in deposited
collagen within the scar (not shown). There was no difference in ETA expression
within the RV, septum or non-infarcted LV of hearts from the 5 or 12-week post-MI
groups compared to sham-op controls (Figure 5.4).
ETb receptors were expressed at low levels throughout the hearts of sham-op rats and
could be observed as small clusters in cardiomyocytes in both RV and LV (Figure
5.5 (a)). ETb receptor mRNA was similarly distributed within cardiomyocytes in the
166
Figure 5.1 PreproET-1 mRNA in situ hybridisation images from sections representative
ofhearts from the 5 and 12-week groups. PreproET-1 mRNA expression in (a) the LVof
a sham-op heart; and (b) in the non-infarcted LV ofa 5-week post-Mi, and (c) 12-week
post-MI heart (arrows highlighting signal in cardiomyocytes); (d) the infarct border ofa
5-weekpostMI heart showing lack ofmRNA expression in collagen fibrils (arrows); and
(e) a sense slide showing an area within the RV of a 5-week sham-op heart (arrows






Figure 5.2. PreproET-1 mRNA expression in the right ventricle (RV), area of
infarction or sham-operation (OP/INF), and left ventricle (LV) ofrat hearts at (a) 5






















































Figure 5.3 In situ hybridisation images of ETa receptor mRNA from heart sections
representative ofthe 5-week groups. ETa receptor mRNA expression in (a) the LVofa 5-
week sham heart (x400 magnification); (b) the non-infarcted LV of a 5-week post-MI
heart (x400 magnification), and (c) a sense section showing no ETa receptor mRNA
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Figure 5.4. ETA receptor mRNA expression in the right ventricle (RV), area of
infarction or sham-operation (OP/INF), and left ventricle (LV) of rat hearts at (a) 5












Figure 5.5 In situ hybridisation images of ETb receptor mRNA from heart sections
representative of5 and 12-week groups. ETb receptor mRNA expression in (a) the LVof
a 5-week sham heart; (b) the non-infarcted LV of a 5-week post-Mi heart and (c) 12-







RV, LV and septum, whereas ETb receptor protein was confined to myoendothelial
and vascular endothelial cells in sham-op hearts (Figure 5.9 (a)). ETb receptor
mRNA levels were significantly lower within the infarct at 5 (P<0.01, Figure 5.6 (a))
and 12 (P<0.05, Figure 5.6 (b)) weeks post-MI, being restricted to remaining
cardiomyocytes (not shown). At 5 weeks post-MI, there were no changes in ETB
mRNA expression in the non-infarcted LV, RV or septum {Figure 5.6 (a)) compared
to sham controls. However, at 12 weeks post-MI in the non-infarcted LV, ETb
mRNA expression increased by approximately 20-fold compared with sham-op
controls (PO.OOl, Figure 5.5 (b), Figure 5.6 (b)). The increase in ETB receptor
mRNA in the non-infarcted LV at the later time point coincided with the specific
increase in ETb receptor protein also observed only at this time point. Low levels of
ETb receptor mRNA expression were found in the RV and septum, similar to those
observed in the myocardium of hearts from sham-op group rats {Figure 5.6 (b)).
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Figure 5.6. ETb receptor mRNA expression in the right ventricle (RV), area of
infarction or sham-operation (OP/INF), and left ventricle (LV) of rat hearts at (a) 5
and (b) 12 weeks post-MI or sham-operation (n-7). *P<0.05, **P<0.01
















































5.3.3 Histological and immunohistochemical characterisation.
A thinned, defined, scar was present in 6 of the 5-week post-MI and 4 of the 12-week
post-MI rat hearts. For those hearts not showing a thinned scar, an area ofmyocardial
damage was evident below the ligation. Scars consisted predominantly of mature
cross-linked collagen fibrils with a few remaining cardiomyocytes {Figure 5.7 (a,
b)). There was evidence of a few microvessels present within the scar with larger,
more established, vessels also observed throughout the scar region {Figure 5.7 (c)).
ET-1 immunoreactivity at both 5 and 12 weeks was diffuse throughout the non-
infarcted LV {Figure 5.7 (d), Figure 5.8 (a)), with distribution and intensity of
staining similar to that observed in the RV and septum of post-MI rats and
throughout the myocardium of sham-op rat hearts (not shown). Within the infarct,
ET-1 staining was sparse at both time points {Figure 5.7 (d), Figure 5.8 (a)), being
confined to remaining cardiomyocytes {Figure 5.7 (e), Figure 5.8 (c) and a few
inflammatory cells and fibroblasts (not shown).
To verify distribution of immunoreactive staining using the ET-1 antibody from
Biodesign, UK, another ET-1 antibody was used (a gift from Dr. A. Davenport), this
antibody being produced in-house and directed towards mature ET-1 peptide. The
antibody from Dr. Davenport's laboratory demonstrated ET-1 immunoreactivity
again located in cardiomyocytes throughout the non-infarcted LV, RV and septum,
with sparse staining in the infarct region of heart sections from the 12-week post-MI
group {Figure 5.8 (b)). Distribution of immunoreactivity was identical to that found
with the antibody used from Biodesign, UK {Figure 5.8 (a)).
ETb receptor protein immunoreactivity was confined to myoendothelial and vascular
endothelial cells in sham-op hearts {Figure 5.9 (a)). At 5 and 12 weeks post-MI, ETb
receptor immunoreactivity was scarce within the infarct (not shown). In the non-
infarcted LV at 12 weeks but not 5 weeks post-MI, ETb receptor immunoreactivity
was increased specifically in the area adjacent to the infarct, and could also be
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Figure 5.7 Images from sections representative of5-weekpost-MI group hearts, (a) van
Gieson's staining of the non-infarcted L V and infarct (x50 magnification), and (b, ~k) a
magnified image from within the infarct ofmature collagenfibrils (x200 magnification);
(c, \) remaining microvessels within the infarct highlighted with GSL I (arrows, x200
magnification); (d) a parallel section to (a) showing ET-1 staining in the non-infarcted
LV with sparse staining in the infarct (x50 magnification) and (e) a magnified area of
the infarct showing ET-1 immunoreactivity in remaining cardiomyocytes (xlOO
magnification).
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Figure 5.8 Images from sections representative of the 12-week post-MI group hearts.
ET-1 immunoreactivity in (a) the non-infarcted LV border with sparse staining in the
infarct, using an ET-1 specific antibody from Biodesign, UK, and (b) a parallel section
showing identical ET-1 staining using an antibody directed toward mature ET-1 peptide
(a giftfrom A. Davenport, both images x50 magnification); (c, A) a magnified area from
within the infarct of (a), ET-1 is restricted to remaining cardiomyocytes (x200
magnification); and (d) TGF-fi staining in the non-infarcted LV and remaining
cardiomyocytes (arrows) in the infarct (x200 magnification).
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located in cardiomyocytes (Figure 5.9 (b)). ETB receptor protein staining in the RV
and septum was similar to that observed throughout hearts in the 5-week post-MI and
sham-op groups.
TGF-pi immunoreactivity was sparse within the infarct at 5 and 12 {Figure 5.8 (d))
weeks post-MI, being located in only a few vascular endothelial cells and fibroblasts
(not shown). However, increased staining was present in cardiomyocytes close to,
and adjacent to, the infarct border {Figure 5.8 (d)). Distribution and intensity of
staining in the RV and septum at both times post-MI was similar to that found in the
myocardium from respective sham-op group rats (not shown).
P-MHC immunoreactivity was sparse in the RV and LV of hearts from both 5 and
12-week {Figure 5.10 (a)) sham-op groups. At 5 & 12 weeks post-MI however, areas
of intense staining within cardiomyocytes were evident in the non-infarcted LV
{Figure 5.10 (b, c)). Remaining cardiomyocytes within the area of infarction were
also intensely stained, but immunoreactivity was greatest in the non-infarcted LV.
ERK was detected in myoendothelial cells, cardiomyocytes {Figure 5.11 (a)) and
vascular smooth muscle cells of intramyocardial blood vessels in sham-op rat hearts.
Although ERK was present in both RV and LV, the LV of hearts from sham-op and
post-MI rats showed higher levels of expression than the RV (not shown). At 5
weeks post-MI, ERK was present in intact cardiomyocytes and in the vascular
smooth muscle layer of blood vessels within the scar region of the infarct (not
shown). ERK was also present in the non-infarcted LV {Figure 5.11 (b)), though
showed a similar level of immunoreactivity to that observed in the 5-week sham
controls. At 12 weeks post-MI however, the highest intensity of ERK staining was
detected in the non-infarcted LV {Figure 5.11 (c)), with staining greater than that
observed at 5 weeks.
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Figure 5.9 Images of ETb immunoreactivity (brown) in sections representative of 12-
week group hearts. Nuclei are stainedpurple with haematoxylin. ETb staining within (a)
the LV of a 12-week sham heart, and (b) the non-infarcted LV of a 12-week post-Mi
heart (both images x200 magnification).
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F Figure 5.10 Images showing /3-MHC immunoreactivity (brown) in sections from 5 and
a) 12-week group hearts. Nuclei are stained purple with haematoxylin. J3-MHC staining
w within (a) the LV ofa 12-week sham heart; (b) the non-infarcted LV ofa 5-week heart,
L and (c) 12-weekpost-Mi heart (all images x400 magnification),
m
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Figure 5.11 Images ofERK immunoreactivity (brown) from sections representative of 5
and 12-week group hearts. Nuclei are stained purple with haematoxylin. ERK staining
within (a) the LV ofa heart from the 5-week sham-op group; and (b) the non-infarcted





Coronary artery ligation resulted in a myocardial infarction (MI) with infarct sizes
40-50% of the LV free wall and a mortality of 30% that was limited to the 24-hour
period after surgery. This rat model, therefore, resembled others demonstrating
moderate infarction (Fraccarollo et al., 1997; Mulder et al., 1997; Mulder et al.,
1998) rather than those with large infarctions and higher mortality (Sakai et al.,
1996a; 1996b; 1998; Kobayashi et al., 1999). Heart weight was significantly
increased at 5 weeks, but not 12 weeks, post-MI compared to sham-op controls. The
lack of a significant increase observed at 12 weeks may have been due to a lower
number of heart weight values in the post-MI group, as heart weight was not
recorded for 2 of the animals at the time of experiment.
Plasma ET-1 levels were similar in both post-MI groups compared to their respective
sham-op groups. Big ET-1 levels were also similar in the post-MI and sham-op
groups at 5 weeks, however there was a tendency for big ET-1 levels to increase at
the later time post-MI compared to the respective sham-op group. Due to the small
group numbers for plasma values, it is difficult to interpret these data accurately.
However, the observed tendency for elevated plasma big ET-1 at 12 weeks post-MI
may be associated with a progression of heart failure and an increased synthesis of
ET-1. Big ET-1, having a more stable half-life and slower clearance rate from the
plasma than ET-1 is thought to correlate more reliably with progression of heart
failure than plasma ET-1 itself (Burkhardt et al., 2000). Plasma ET-1 was found to
increase only in patients with moderate (NYHA class III) or severe (NYHA class IV)
heart failure compared with healthy subjects and individuals with asymptomatic
(NYHA class I) or mild (NYHA class II) heart failure (Wei et al., 1994), and in
animals with severe CHF (Sakai et al., 1996a).
In sham-op hearts, preproET-1 mRNA and ET-1 peptide immunoreactivity was
widespread throughout all 4 chambers of the heart and was associated with
cardiomyocytes and the endothelium of coronary blood vessels (McEwan et al.,
1998b). ETa receptor mRNA was also found abundantly throughout the
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myocardium, consistent with its role as the major receptor mediating the effects of
ET-1 in cardiomyocytes (Miyauchi & Goto, 1999). ETb receptor mRNA was
detected in lesser quantities and was also located in cardiomyocytes throughout the
myocardium. The observation of preproET-1 mRNA expression in cardiomyocytes
throughout the myocardium correlating with the distribution of ET-1 peptide
immunoreactivity, and the presence of ETa and ETB receptor mRNA in similar cells,
suggests the presence of a local cardiac ET system in the heart with the ability to
synthesise, and be stimulated by, ET-1. These findings complement previous studies
demonstrating a local ET production in the heart, with ET-1 secreted from the
endocardium, myocardium, and the coronary endothelium, thereby acting in a
paracrine and autocrine fashion on myocytes (Suzuki et al., 1993; Evans et ah,
1994). It further adds to these studies by localising the distribution of preproET-1,
ETa and ETb receptor mRNA to cardiomyocytes throughout the myocardium. The
present study is also in agreement with human studies showing expression of
endothelin peptides and mRNA in the heart (Plumpton et al., 1996) and
autoradiographic studies showing the existence of ET receptors in human ventricular
myocardium (Bax et al., 1993; Molenaar et al., 1993).
At 5 and 12 weeks post-MI, levels of preproET-1 and ETa receptor mRNA in the
RV, septum or non-infarcted LV areas of the heart were similar to that observed in
respective areas in sham-op controls. A similar distribution of ET-1 peptide
immunoreactivity to that of preproET-1 mRNA was detected in the non-infarcted
LV, RV and septum of post-MI rat hearts and to that throughout the myocardium of
sham-op rat hearts. At 5 and 12 weeks post-MI, the infarcted region consisted of a
thinned, mature collagen-filled scar containing few cardiomyocytes and some
remaining inflammatory cells and microvessels. Levels of preproET-1, ETa receptor
and ETb receptor mRNA within the infarct were significantly reduced at both times
compared to a similar area in respective sham-op hearts. mRNA for preproET-1 and
ETb receptors could be detected only in remaining cardiomyocytes, and for ETa
receptors in cardiomyocytes and vascular medial smooth muscle cells. Distribution
of ET-1 and TGF-(3i peptide staining was also reduced compared to that observed
previously in the developing scar during the 2 weeks post-MI, with immunoreactivity
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being restricted to cardiomyocytes in the peri-infarct area and a few remaining
inflammatory cells near to the infarct border. The observation of reduced ET-1
staining in the infarct supports previous findings of reduced ET-1 immunoreactivity
within the scar observed at 3 (Kobayashi et al., 1999) and 6 (0ie et al., 1997) weeks
post-MI in the rat. Overall, these studies, along with the findings in Chapter 3 and 4,
suggest a transient upregulation of ET-1 within the scar with increased levels of
immunoreactivity associating with development of a mature scar over the first 2
weeks only.
Previous animal studies investigating the ET-1 system in hearts post-MI have
reported varying levels of expression and immunoreactivity, depending on severity
of infarct and duration of study post-MI. Kobayashi et al. (1999) reported
upregulation of preproET-1, ETa receptor and ETB receptor mRNA throughout
hearts from rats 3 weeks after chronic MI (infarct -70% of the LV). Other studies by
the same group also showed increased preproET-1 mRNA expression and ET-1
peptide immunoreactivity in the LV at 3 (Sakai et al., 1996a) and 12 (Sakai et al.,
1996b) weeks after chronic MI in the rat. In a less severe rat model of MI, where
infarcts were -40-50% of the LV, levels of preproET-1 mRNA were found to
increase substantially in the infarcted and non-infarcted LV 1 week post-MI, before
returning towards baseline at 6 weeks post-MI (Oie et al., 1997, T0nnessen et al.,
1998). The similar level of expression of preproET-1 in the non-infarcted LV at both
time points post-MI in the present study agrees with findings by Oie and T0nnessen,
using rats with similar infarct sizes. This contrasts with the results from Sakai's
group who showed upregulation of the ET system in rats with severe infarcts. Taken
together, these studies suggest a relationship between the severity of infarction and
activation of the myocardial ET system post-MI.
At 12 weeks, but not 5 weeks, post-MI a profound increase in ETb receptor mRNA
expression was observed in the non-infarcted LV only, with levels significantly
greater than those observed in the RV or septum of the same hearts, and also than
those found throughout 12-week sham-op hearts. The increase in ETb receptor
mRNA expression was associated with an increase in ETb receptor protein
184
Chapter 5
immunoreactivity, indicating an increase in expression of functional receptors. Gray
et al. (2000) also recently reported specific upregulation of ETB receptor
immunoreactivity, at 12 weeks but not 5 weeks, within the media of small mesenteric
arteries from the same rats studied here. This previous study further indicated that a
loss of vascular responsiveness following MI was not associated with increased ET-1
synthesis but is temporally linked to upregulation of ETB receptors in the smooth
muscle layer, which in turn is connected to inhibition of contraction via the ETA
receptor. Taken together with the results from the present study, these findings
indicate that increased ETB receptor mRNA expression is not just a phenomenon
restricted to the heart, but is also observed in the vasculature.
Other investigators have reported an increase in cardiac ETB. receptor expression in
conjunction with an increase in preproET-1 and ETA receptor mRNA post-MI
(Kobayashi et al., 1999), although the cellular site of upregulation was not
investigated. In a recent study, however, Smith et al. (in press) demonstrated
selective upregulation ofmyocardial ETB receptor mRNA in the non-infarcted LV of
female ovariectomised rats 10-11 weeks post-MI. Interestingly, increased ETB
receptor mRNA was also localised to cardiomyocytes within the non-infarcted LV of
these rats, which had an average infarct size of ~40% of the LV, similar to that found
here. In the present study, increased ETB receptor mRNA and immunoreactivity at 12
weeks post-MI was detected in the peri-infarct area of the non-infarcted LV, with
little expression detected in remaining cardiomyocytes within the infarct and no
expression detected at sites of deposited collagen at either time point, suggesting that
ETb receptors do not have a role in the scar at these time points. Furthermore, the
lack of change in ETb receptor expression in the RV, and the observation that lung
weight was not significantly increased, suggests that increased ETB receptor
expression was not associated with RV hypertrophy at the time points studied, nor
was increased ETB expression a general phenomenon in the post-MI heart.
Two main questions therefore arise from this finding; 1) what causes the specific
increase in ETB receptors?, and 2) what role do the receptors have in the non-
infarcted LV at this time? In response to the first question, a number of physiological
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and/or hormonal factors may be involved in upregulation of ETb receptors within the
non-infarcted LV. A progressive increase in wall stress is associated with LV
dysfunction during heart failure. Furthermore, a recent study by Morawietz et al.
(2000) demonstrated upregulation of ETb receptor mRNA by long-term arterial
laminar stress in human umbilical vein endothelial cells in vitro. Although it is not
known whether a similar effect is observed in cardiomyocytes in vivo, increased
mechanical wall stress may be involved in regulation of ETB receptor expression in
these cells. In cultured cardiac myocytes, mechanical stretch can induce ET-1
expression (Yamazaki et al., 1995), providing further evidence that increased
mechanical stresses are a possible mechanism for the induction of the ET system in
myocardium. Elowever, that upregulated ETb receptor mRNA expression alone was
observed only at 12 weeks post-MI in the present study could be a characteristic of
the MI model used, and may be a consequence of the progression from compensatory
hypertrophy during LV dysfunction to decompensated heart failure. Furthermore,
though this chapter only investigated the ET system up to a time of 12 weeks,
upregulation of preproET-1 and ETA mRNA may occur at a time after 12 weeks in
this model.
Other mediators that may be involved in upregulation of ETb receptors include the
RAAS and norepinephrine, which are also increased during heart failure and can
stimulate hypertrophy (Schunkert et al., 1990; Kanno et al., 1993; Colucci, 1997;
Barth et al., 2000). The relationship between ET-1 and the RAAS is noteworthy.
Myocardial expression of angiotensin converting enzyme (ACE) is increased in rats
with pressure overload ventricular hypertrophy and in the viable myocardium
following experimental MI (Schunkert et al., 1990; Callah et al., 1995). Furthermore,
Schunkert and colleagues demonstrated that the upregulation of ACE in the
hypertrophied LV is associated with an increased intracardiac conversion of Ang I to
Ang II (Schunkert et al., 1993). Interestingly, in cultured cardiomyocytes, Ang II has
been shown to induce the expression of mRNA for the ETB receptor (Kanno et al.,
1993), thereby indicating a possible mechanism of increased ETb receptor mRNA
expression by upregulated Ang II in the non-infarcted LV. However, further tests are
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needed to determine whether Ang II generation is increased in the same area as is
ETb receptor mRNA; specifically, the non-infarcted LV.
There may be several possible roles for upregulated ETB receptors in the non-
infarcted LV. In the present study, co-localisation of increased ETb receptor
expression with increased (3-MHC immunoreactivity occurred in a specific area of
the heart that may be subjected to increased progressive wall stress. As mentioned in
Chapter 4, isoforms of cardiac MHC are altered in the failing myocardium of
experimental CHF animals. Furthermore, the change from a-MHC to P-MHC is
regarded as a molecular marker for hypertrophy in the failing myocardium (Michel et
al., 1988; Parker et al., 1990b). ET-1 has also been shown to stimulate p-MHC
production in ventricular myocardium in vitro (Wang et al., 1992; Ichikawa et al.,
1996). Therefore, the fact that a significant upregulation of ETB receptors was
observed exclusively in an area of the heart where hypertrophy was specifically
located suggests a potential role for ETb receptors in regulation of processes such as
hypertrophy and remodelling of the non-infarcted LV myocardium. Furthermore,
ET-1 has been reported to exert hypertrophic effects in adult rabbit ventricular
cardiomyocytes via stimulation of ETB receptors (Mullan et al., 1997).
During the past decade, significant progress has been made in identifying key
intracellular signalling mechanisms that contribute to hypertrophic growth. These
include protein kinase C, and the mitogen-activated protein kinase pathways, of
which 3 major types exist: the extracellular signal-regulated protein kinase (ERK), c-
jun N-terminal kinase (JNK), and p38 mitogen-activated protein kinase pathways
(reviewed by Ruwhof & van der Laarse, 2000). In cardiac myocytes, the ERK
pathway can be stimulated upon G-protein receptor occupation by binding of such
peptides as ET-1 (Bogoyevitch et al., 1994). Transcriptional activation of ERK was
also shown to be modified by ETB receptors (Aquilla et al., 1996). Interestingly,
upregulated ETB receptor mRNA and increased ERK immunoreactivity were both
found specifically in the non-infarcted LV at 12 weeks, but not 5 weeks, post-MI,
suggesting further evidence of a role for ETB receptors in regulating hypertrophy,
possibly via an ERK-mediated intracellular pathway.
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However, increased p-MHC staining was detected in the non-infarcted LV at 5
weeks post-MI in the present study, which does not match the time course for the
observed upregulation in ETb receptor expression, indicating that ETB receptors may
not have a role in initiation of the hypertrophic response. Nevertheless, it is possible
that ETb receptors may be involved in secondary processes that modulate
hypertrophy that has been initiated earlier by other mediators such as TGF-ps or the
RAAS, or, transiently, by ET-1 itself. Both TGF-Ps (Li et al., 1997) and the RAAS
(reviewed by Wiollert et al., 1999) have been shown to stimulate cardiac
hypertrophy in vitro. Furthermore, TGF-Pi immunoreactivity was found to be
increased specifically in border myocytes in the non-infarcted LV at 5 and 12 weeks
post-MI, with no changes in staining in the RV or septum. However, it is not known
whether myocardial tissue levels of TGF-Pi were sufficiently upregulated to induce
hypertrophy in the rat model used in the present study.
A number of antagonist studies have investigated the role of ET receptors on
hypertrophy post-MI. ETa receptor antagonists have been shown to reduce LV
hypertrophy and P-MHC expression, improve cardiac function, and increase survival
following a large MI (Sakai et al., 1996a, 1996b, 1998), despite the fact that ETB
receptors are also upregulated in the same model (Kobayashi et al., 1999). However,
in a less severe model, with smaller infarcts, treatment with the ETa receptor
antagonist had no effect on LV hypertrophy (Mulder et al., 1998), while the non¬
selective ET receptor antagonist bosentan reduced LV hypertrophy (Mulder et al.,
1997) or LV dilatation (Fraccarollo et al., 1997). The results of the present study
showing an increase in ETB receptor mRNA expression with no change in ETa
receptor or preproET-1 mRNA expression after moderate MI may therefore help
explain the above observations, outlining the importance of mixed ET receptor
antagonism after moderate MI. This may not only be the case when LV dysfunction
is caused by MI. A recent study reported that ETa receptor antagonism improved LV
dysfunction in severe but not mild heart failure induced by rapid ventricular pacing
(Schirger et al., 1999).
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Only one antagonist study has specifically investigated the role of ETb receptors
post-MI in vivo. Mulder et al. (2000) recently showed that chronic, simultaneous
blockade of both ETa and ETb receptors improved systemic and cardiac
haemodynamics, as well as LV function and remodelling, to the same extent as ETA
receptor blockade alone in a rat CHF model after moderate MI. However, these
effects were associated with a significant reduction of heart rate only with
simultaneous ETA-ETB receptor blockade. Furthermore, chronic, selective ETb
receptor blockade per se, while having no adverse haemodynamic effects or showing
functional improvement, reduced cardiac collagen accumulation.
The fact that no increased plasma ET-1 levels or adverse haemodynamic effects were
observed with chronic selective ETb receptor or simultaneous ETA and ETb receptor
antagonism in the above study is very interesting. The effects of chronic ETB
receptor antagonism were previously unknown, though in theory, the blockade of
ETb receptors may have deleterious effects, either by reducing ETB-mediated
endothelium-dependent vasodilation or by decreasing ET-1 clearance (Fukuroda et
al., 1994) and thus increasing plasma ET-1 levels. In Chapter 3, administration of a
non-selective ET receptor antagonist to post-MI rats for 2 weeks led to a specific
increase in plasma ET-1 levels. However, that chronic treatment (over 4 weeks) led
to no increased elevated plasma ET-1 levels or adverse haemodynamic effects
(Mulder et al., 2000) suggests that plasma ET-1 may be cleared by an alternative
mechanism during long-term ETB receptor blockade and that chronic ETb receptor
antagonism may be tolerated as a potential therapy against heart failure.
Upregulated ETB receptors may alternatively have other roles in the non-infarcted
LV such as mediating contractility or rhythmicity of the myocardium (Molenaar et
al., 1993; Miyauchi & Masaki, 1999). Mulder et al. (2000) showed that long-term
combined ETa/ETb receptor blockade in a rat chronic heart failure model led to a
significant decrease in heart rate compared to long-term via specific ETA receptor
inhibition, indicating a potential role for the ETb receptor in this process.
Conversely, ETB can transmit growth inhibitory effects associated with apoptosis
(Okazawa et al., 1998). Cardiomyocyte-specific apoptosis was shown to contribute
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to the transition from LV hypertrophy to LV dysfunction (Condorelli et al., 1999).
However ERK has been shown to protect cardiomyocytes from apoptosis (Aikawa et
al., 1997). The balance between these influences and interactions with other systems
such as the RAAS and progressive physiological wall stress may therefore determine
the course ofmyocardial remodelling during heart failure.
In conclusion, the association of increased ETb receptor mRNA with growth
regulatory genes suggests a role for ETb receptors in modulation of the LV response
to MI, although further studies using ET receptor antagonists are required to confirm
their specific role. Furthermore, the above antagonist studies along with the present







Heart failure is a major and increasing cause of cardiovascular morbidity and
mortality, due at least in part to the fact that its various haemodynamic,
neuroendocrine and other pathological mechanisms remain incompletely understood.
The introduction of the angiotensin-converting enzyme (ACE) inhibitors has clearly
improved symptoms and decreased mortality, but established heart failure still
impairs quality of life more than any other chronic illness (Dargie & McMurray,
1994). ET-1 has been implicated in the pathophysiology of CHF with increasing
plasma concentrations correlating with the degree of haemodynamic and functional
impairment. Furthermore, there are many similarities between ET-1 and the RAAS
such as their vasoconstrictor, mitogenic and anti-natriuretic properties, all of which
aggravate progression of CHF. At the onset of this thesis, the distribution of the local
myocardial ET system within the normal heart, and if, when, or where components
of the ET system may change during the development of heart failure following MI
had not been investigated.
In this thesis, I set out to initially characterise the ET-1 system in healthy hearts of
rats with reference to ET-1 peptide distribution and cellular localisation in the
myocardium and coronary vasculature. Another aim was to investigate any
involvement of the myocardial ET-1 system during scar formation following MI
induced by coronary artery ligation (CAL) in the rat. Finally the myocardial ET-1
system was studied with reference to myocardial hypertrophy and fibrosis later post-
Mi. In summary, I set out to further investigate the myocardial ET-1 system as a
viable target for future drug therapy for heart failure. By investigating changes in
regulation of the ET-1 system both early and later post-MI, I hoped to identify the
possible type of antagonism and the times at which potential therapy may be most
beneficial.
The primary finding of this thesis was the evidence of ET-1 peptide present in the
normal rat heart. ET-1 immunoreactivity could be located to cardiomyocytes,
myoendothelial cells and some coronary vascular endothelial cells within
myocardium from normal and sham-op rats indicating the presence of mature ET-1
peptide in these cells under normal physiological conditions. This finding agrees
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with recent research showing ET-1 immunoreactivity throughout the myocardium of
control group rat hearts from MI studies (Sakai et al., 1996b; 0ie et al., 1997;
Tonnessen et al., 1998).
That ET-1 immunoreactivity was observed within the myocardium does not confirm
on its own the presence of a local myocardial ET-1 system. ET-1 immunoreactivity
may be highlighting bound ET-1 peptide, which may have been produced away from
the heart and taken up by myocardial tissue from circulating plasma. However, in
situ hybridisation studies using sham-op rat hearts further showed that preproET-1
mRNA was widespread throughout all 4 chambers of the heart and associated with
cardiomyocytes and the endothelium of coronary blood vessels. ETA receptor mRNA
and, to a much lesser extent, ETb receptor mRNA was also detected throughout the
myocardium. These results complement the finding of ET-1 peptide
immunoreactivity throughout the myocardium and confirm previous suggestions of a
local cardiac ET system in the heart with the ability to synthesise, and be activated
by, ET-1 (Suzuki et al., 1993; Molenaar et al., 1993; Evans et al., 1994; Plumpton et
al., 1996). Furthermore, it extends these studies by localising the distribution of
preproET-1, ETA receptor and ETB receptor mRNA to cardiomyocytes throughout
the myocardium.
Endogenous generation of ET-1 was shown to contribute to basal vascular tone in
healthy humans (Haynes & Webb, 1994), and also to regulation of basal coronary
tone in the rat isolated heart (Goodwin et al., 1998). Recent studies have also
indicated a role for the local cardiac ET system in contributing to contractility in the
normal healthy heart. Kelso et al. (2000) reported that the ETA receptor subtype, and
not the ETb receptor subtype, mediates the positive inotropic effect of ET-1 in LV
cardiomyocytes isolated from the rabbit heart. Furthermore, MacCarthy et al. (2000)
reported that endogenous ET-1 has a tonic positive inotropic effect on cardiac
contraction in normal subjects, independent of the effects of the peripheral
vasculature, and is inhibited by blockade of the ETA receptors. In summary, these
studies along with the present data indicate the presence of a local myocardial ET
system, which has a role in regulation ofphysiological effects within the heart.
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The next finding in this thesis indicated transient regulation of myocardial ET-1
within the infarct during scar formation post-MI. After CAL surgery in the rat, ET-1
immunoreactivity was shown to increase within the developing scar over the first 14
days post-MI, with the number of ET-1 staining cells within the infarct peaking at 7
days. ET-1 immunoreactivity could be localised in remaining cardiomyocytes and
areas of granulation, with staining present in the cytoplasm of inflammatory cells
involved in clearance of necrotic tissue, fibroblasts synthesising collagen and
endothelial cells involved in new vessel formation. Furthermore, fibroblasts,
endothelial cells, and inflammatory cells within granulation tissue showing ET-1
immunoreactivity at 7 days post-MI, also showed TGF-(3i immunoreactivity. Other
recent studies have also shown increased ET-1 staining in the scar early post-MI with
staining localised to similar cells as mentioned above (0ie et al., 1997; Tonnessen et
al., 1998). Since there were no changes in plasma ET-1 concentrations at either the 2,
7 or 14-day times studied, these results suggested that locally synthesised ET-1 was
upregulated within the infarct early post-MI and was present in cells involved in
active processes of scar formation. However, preproET-1 mRNA expression was not
measured in this part of the study and the possibility that there is increased uptake of
plasma ET-1 from the circulation into the infarcted region cannot be excluded.
This question of whether upregulated ET-1 within the infarct was beneficial or
detrimental in scar formation was addressed in Chapter 4, which investigated the role
of upregulated ET-1 within the developing scar using a non-selective ET receptor
antagonist A-182086 (30mg/kg/day) administered to rats upon recovery from CAL
surgery, and continued daily for the duration of the study. Results from this study
indicated a reduced TUNEL-positive cell count within the infarct of the 2-day
CAL+A-182086 group, a decreased heart weight within the 14-day CAL+A-18086
group and a significant increase in myocardial content within the infarct of hearts
from rats in the 7 and 14-day CAL+A-18086 groups. However, where areas of
granulation were observed in the infarct area, active processes of scar formation
including inflammation, collagen synthesis, TGF-Pi activation and new vessel
formation were still evident between 2 and 14 days post-CAL, indicating that
blockade of ET receptors was not sufficient to halt these processes. Furthermore, 2
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CAL + A-182086 group rats (1 from the 7-day group and 1 from the 14-day group)
that did not eat their food over the first 24 hours, but ate daily thereafter for the
duration of the study, developed thinned defined infarcts with little myocardial
content. This implies that antagonist-mediated improved myocardial cell content
within the infarct was a phenomenon related to the first 24 hours of treatment.
As mentioned in the discussion of Chapter 4, synthesis and release of myocardial
ET-1 is increased during hypoxia in vitro and plasma levels are transiently elevated
post-MI. The action of non-selective ET receptor antagonism administered
immediately upon recovery from CAL may, therefore, be inhibiting an acute,
transient, ET-1-mediated vasoconstriction, which further reduces any remaining
blood flow or collateral circulation into or around the affected area. The fact that
heart weight was lower at 14 days in the CAL + A-18086 group, along with reduced
P-MHC immunoreactivity in the non-infarcted left ventricle (LV) and salvaged
myocardium of the infarct, may be due to the increased myocardial content within
the infarct lowering wall stress in the LV. This would therefore reduce the workload
in remaining cardiomyocytes and any compensatory hypertrophic response in the
LV. Overall, these findings indicate that early administration of a non-selective ET
receptor antagonist increases myocardial content within the infarct, which may in
turn reduce ventricular remodelling by lowering workload in the remaining LV
myocardium. Furthermore, upregulated ET-1 within the developing scar at 7 and 14
days post-MI does not appear to be critical in regulating the active processes of scar
formation.
Having considered the results, there are now several additional studies I would like
to perform to strengthen the thesis and enhance the understanding of the role of the
myocardial ET-1 system post-MI. Further experiments are required to investigate
whether an acute, transient, increase in myocardial ET-1 levels is observed over the
first 48 hours after surgery. Plasma ET-1 levels could be measured along with
investigation of ET-1 immunoreactivity within the infarct (ET-1 staining within the
infarct was sparse at 2 days post-MI) and in situ hybridisation studies highlighting
preproET-1 mRNA levels. These data would help to clarify whether myocardial
195
Chapter 6
necrosis within the infarct is further augmented by acute, transient, increases in
myocardial ET-1 levels, and that the benefits of early non-selective antagonism are
mediated by blocking this effect.
The salvaged myocardium within infarcts of hearts from the CAL + A-182086 group
rats showed a cellular morphology, vascular supply and ET-1 immunoreactivity
similar to normal myocardium. However, actual tissue protein levels of ET-1 peptide
or expression levels of preproET-1, ETa and ETB receptor mRNA from specific
areas of the heart could not be measured. Acquiring these data via reverse
transcription polymerase chain reaction (rtPCR) and in situ hybridisation studies
would confirm my results indicating viable salvaged myocardium with the ability to
express and synthesis ET-1. It is also not known whether the salvaged myocardium
retains its functional capacity. A recent review stated that the scar formed after
infarction has the ability to contract through the presence of myofibroblasts (Sun &
Weber, 2000). Hence, future functional studies could be performed, for example
using echocardiography, to identify whether contractility of the LV wall improves
after ET antagonist treatment. Furthermore, whether early antagonist treatment
improves myocardial remodelling within the LV in the long-term requires further
investigation via additional chronic antagonist studies.
Endothelin converting enzyme (ECE)-l is an important component of the ET-1
synthesis pathway (see section 1.2.2). Studies investigating ECE post-MI have found
no change in ECE-1 mRNA or ECE-1 immunoreactivity (Kobayashi et al., 1999) in
the rat model of MI. However, increased ECE-1 mRNA has been measured in
arterial tissue in human cardiovascular disease (Bohnemeier et al., 1998).
Furthermore, it is not known whether expression of ECE-1 changes, or has an
important regulatory role, within the infarct during scar formation early post-MI. It
would, therefore, be interesting to characterise ECE (immunohistochemically and via
in situ hybridisation) to determine whether upregulation occurs along with increased
ET-1 during scar formation. Also, with the advent of new potent non-peptide
inhibitors of ECE-1 (De Lombaert et al., 2000), it would be interesting to compare
196
Chapter 6
the effects of an ECE inhibitor to those found using a non-selective ET receptor
antagonist in the present study.
The involvement of locally produced angiotensin (Ang) II in tissue repair post-MI
(reviewed by Sun & Weber, 2000) and in the pathophysiology of cardiac
hypertrophy (Wollert et al., 1999) suggests an important role for this peptide in heart
failure. Ang II has been shown to stimulate cardiomyocyte hypertrophy via paracrine
release of ET-1 and TGF-Pi from fibroblasts in vitro (Gray et al., 1998). The fact
that many active processes of scar formation including collagen synthesis,
inflammation, angiogenesis and TGF-Pi activation are observed in granulation tissue
suggests that Ang II may have an important role in these processes outwith the
presence or influence of ET-1. It would be interesting, therefore, to investigate the
ET-1 system in hearts from rats treated with an ACE inhibitor or an AT i receptor
antagonist post-CAL, to identify whether increased ET-1 immunoreactivity is a
consequence of increased stimulation of ET-1 synthesis by Ang II. It would also be
interesting to investigate Ang II immunoreactivity in hearts from the A-182086-
treated and untreated CAL groups to identify whether non-selective ET receptor
antagonism affects regulation of the local myocardial RAAS early post-MI.
Chapter 5 investigated the myocardial ET-1 system at later times post-MI in the rat
with specific reference to preproET-1, ETa and ETb receptor mRNA expression.
Unfortunately, due to problems in measuring some plasma ET-1 and big ET-1 values
and heart weights, and without LVEDP measurements, interpretation of these data in
confirming CHF per se was not possible in the 5- and 12-week post-MI groups, and
is an obvious weakness in this study. Nevertheless, CAL surgery did produce rats
with moderate sized infarcts (-40-50% of the LV free wall), indicating, at least, a rat
model with LV dysfunction.
At 5 and 12 weeks post-MI, expression of preproET-1, ETa receptor and ETB
receptor mRNA was significantly reduced within the infarct. Furthermore, there were
no changes in either preproET-1 or ETa receptor mRNA at both times, in the non-
infarcted LV, RV or septum. These results are in agreement with other studies using
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rats with similar sized infarcts at 6 weeks post-MI (0ie et ah, 1997, T0nnessen et al.,
1997) and contrast with studies using rats with much larger infarcts where
upregulated expression of the ET-1 system was observed in the LV at 3 (Sakai et al,
1996a; Kobayashi et al., 1999) and 12 (Sakai et al., 1996b) weeks post-MI. Overall,
this suggests a relationship between the severity of infarction and activation of the
myocardial ET system post-MI.
At 12 weeks, but not 5 weeks, a profound increase in ETb receptor expression was
observed in the non-infarcted LV only, associating with an increase in ERK
immunoreactivity and a progressive increase in P-MHC staining. The fact that the
significant upregulation of ETb receptors was observed exclusively in an area of the
heart where hypertrophy and increased ERK were located suggest a specific role for
ETb receptors in regulation of processes such as hypertrophy and remodelling of the
non-infarcted LV myocardium. Therefore, in this moderate MI model, ETb receptors
may be involved in maintaining a hypertrophic response in the heart during changes
from compensatory to decompensated heart failure. Further studies are required,
however, to clarify whether a direct association exists between increased ETB
receptor expression and increased ERK activation and P-MHC immunoreactivity
within the non-infarcted LV. A number of situations are possible whereby a
stimulating factor may increase ETB receptor mRNA expression and activate ERK
independently of each other. Also, whether P-MHC is further increased as a
consequence of increased ETb receptor expression or whether increased P-MHC
immunoreactivity is independent of increased ETb receptor expression is unclear.
The above experiments may be investigated using ET receptor antagonists. Since
changes in ETb receptor expression were observed at 12 weeks and not 5 weeks post-
MI, it would be interesting, therefore, to investigate changes in hypertrophy and
remodelling within the LV of rat hearts administered either a non-selective ET, or a
selective ETA, receptor antagonist at 5 weeks post-MI. A recent paper reported that
late treatment with either an AT] receptor blocker or an ACE inhibitor in
spontaneously hypertensive rats, between 18 and 22 months of age, reversed
myocyte hypertrophy indicating that it is possible to significantly reverse
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remodelling pharmacologically even if therapy is initiated near the onset of failure
(Tamura et al., 2000). Comparing the findings from separate non-selective ET, and
ETa selective, antagonist studies would clarify whether specific ETB receptor
upregulation was beneficial or detrimental to changes within the LY during
progression of heart failure. It would also identify whether ET-1 is involved in
increased activation ofERK via an upregulated ETB receptor-mediated pathway.
Clinical implications
In the present study, a potential therapeutic role for non-selective ET receptor
antagonism has been identified in the acute phase after MI. Administration of A-
182086 led to an increased myocardial content within the infarct, lower heart weights
and reduced (3-MHC staining, which may have beneficial effects on hypertrophy and
ventricular remodelling that contribute to the development of CHF. These effects
may be mediated through an indirect effect of ET receptor antagonism on an acute
ET-1 mediated vasoconstriction within the LV induced via hypoxia and/or
irreversible cell damage. Furthermore, a similar study using a selective ETa receptor
antagonist reported aggravated chronic LV remodelling with no improvement in
haemodynamics (Hu et ah, 1998), indicating the therapeutic potential of a non¬
selective antagonist over selective ETa receptor antagonism during post-MI scar
formation.
Interestingly, selective ETB receptor mRNA expression is upregulated specifically in
the non-infarcted LV at 12 weeks post-MI in the rat model subjected to moderate MI.
Whether upregulated ETB receptors are directly involved in regulation of
hypertrophy at a later time point in heart failure is of great interest, and may indicate
a beneficial choice of using a non-selective ET receptor antagonist over that of a
selective ETA receptor antagonist as a potential therapy during this time. Recent
clinical research in heart failure has identified a therapeutic role for ET receptor
antagonism during the later stages ofCHF. The REACH-1 trial (reviewed by Mylona
& Cleland, 1999) reported improvements in symptoms using the non-selective ET
receptor antagonist bosentan (500mg BID), though an increase in hepatic
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transaminases led to a premature halt in the study. However, a follow-up study found
that a lower concentration of bosentan (125mg BID, Krum et al., 1999) was well
tolerated and maintained the clinical improvement observed in REACH-1. The use of
selective ETb receptor antagonism in the clinical setting remains uncertain at present.
Only one study to date has investigated chronic selective ETb receptor antagonism in
the rat CHF model, which indicated no adverse effects and reduced cardiac collagen
accumulation (Mulder et al., 2000). Suprisingly, an increase in plasma ET-1 levels
was not observed. However, in the same study, simultaneous administration of a
selective ETa and ETB receptor antagonist improved systemic and cardiac
haemodynamics, as well as LV function and remodelling, to the same extent as ETA
receptor blockade alone. In addition, a significant reduction of heart rate was
associated only with simultaneous ETa-ETb receptor blockade. These findings
suggest potential therapeutic benefits of using a non-selective ET receptor antagonist
compared to selective ETA or ETb receptor antagonists alone in a rat model of CHF
after moderate MI.
Another major finding of this thesis was the relationship between infarct size and
activation of the ET-1 system post-MI. Therefore, further studies need to be
performed to identify whether selective ET receptor antagonism is required for the
varied pathological states of CHF.
Conclusion
In conclusion, this thesis has indicated transient upregulation of the ET-1 system
during scar development early post-MI and specific regulation of ET receptors
related to severity later post-MI. Although further research is required in both the
laboratory and at the clinical level to complement findings in the present study, the
present study indicates that acute and/or chronic targeting of the ET-1 system may
prove beneficial in the fight towards improving symptoms, reducing hospital





All salts were purchased from BDH, UK.
Buffers
Phosphate Buffered Solution (PBS) pH 7.6
1. Dissolve 12.7g di-sodium hydrogen orthophosphate in 80 ml deionised H2O.
Microwave for 30 seconds.
2. In a separate container, dissolve 1.7g of sodium di-hydrogen orthophosphate in
80 ml deionised H2O.
3. Add both solutions to 800 ml deionised H2O and pH to 7.6 with concentrated
HC1.
4. Make up final volume to 1L with deionised H2O.
Tris-Buffered Solution (TBS) pH 7.8
1. Dissolve 6.04g of tris in 80 ml deionised H2O. Add 2.77 ml of concentrated HC1.
2. In a separate container, dissolve 8.1 g of sodium chloride in 900 ml deionised
H20.
3. Mix the 2 solutions, adjust to pH 7.8 using concentrated HC1 and make up to 1L.
IOxPBSfor in situ
1. Dissolve 80g of sodium chloride, 2g of potassium chloride, 29g of sodium di-
hydrogen orthophosphate, and 2g of potassium di-hydrogen orthophosphate in
900ml deionised H2O.
2. Adjust volume to 1L and autoclave.
Tris-EDTA (TE) Buffer for in situ.




The following substances were added to 2.94 ml of deionised H2O:
1. 1.2 ml of 5M sodium chloride
2. lOOpl of 1M tris (pH 7.5)
3. 40pl of 250mM EDTA
4. 500pl of lOmg/ml salmon sperm DNA (Sigma, UK)
5. 20pl of 50mg/ml yeast tRNA (Sigma, UK), make up to 500ml with deionised
H20
6. 200pl of denhardt's (Sigma, UK)
Radioimmunoassay buffer
To 1L of deionised H20 the following compounds were added:
1. 3.853g of sodium dihydrogen phosphate
2. 18.07g of disodiumhydrogen phosphate
3. 2.927g of sodium chloride
4. lg bovine serum albumen (Sigma, UK)
5. 1 OOmg sodium azide (BDH, UK)
6. 1 ml Triton X-100 (BDH, UK)
4% Paraformaldehyde
1. Dissolve 2.4g of sodium di-hydrogen orthophoshate and 11.36g of di-sodium
hydrogen orthophosphate in 1L ofDEP H20.
2. Heat to approximately 80°C, then add 40g paraformaldehyde (BDH, UK).
3. Stir for 1 hour at approximately 80°C, then store at 4°C.





To 50ml of distilled H2O, add:
1. 50ml of saturated aqueous picric acid solution (BDH, UK)
2. 9ml of 1% aqueous acid fuschin solution (BDH, UK)
Aminopropylethoxysaline (TESPA) Slide Coating
Bathe slides for 10 seconds in each of the following:
1. 10% HC1 in 70% ethanol
2. DEPH2O
3. 100% acetone
Air dry the slides, then 10 seconds in each of the following:
4. 2% TESPA in acetone
5. 100% acetone
6. 100% acetone




Agocha A., Lee H.W. & Eghbali-Webb M. (1997) Hypoxia regulates basal and
induced DNA synthesis and collagen type I production in human cardiac fibroblasts:
Effects of transforming growth factor beta (1), thyroid hormone, angiotensin II and
basic fibroblast growth factor. J. Mol. Cell. Cardiol. 29, 2233-2244.
Aikawa R., Komuro I., Yamazaki T. et al. (1997) Oxidative stress activates
extracellular signal-regulated kinases through Src and Ras in cultured cardiac
myocytes of neonatal rats. J. Clin. Invest. 100, 1813-1821.
Allcock G.H., Warner T.D. & Vane J.R. (1993) The endothelin receptor antagonists
BQ-123 and PD-145065 reverse established vasoconstrictor responses to endothelin-
1 in vitro. Br. J. Pharmacol. 110, 150.
Andersson B. & Waagstein F. (1993) The spectrum and outcome of congestive-
heart-failure in a hospitalised population. Circulation 88, 358-358.
Anversa P., Cheng W., Liu Y., Leri A., Redaelli G. & Kajstura J. (1998) Apoptosis
and myocardial infarction. Basic Res. Cardiol. 93, 8-12.
Apps D.K., Cohen B.B. & Steel C.M. (1992) Clinical Enzymology. In: Biochemistry:
A Concise Textfor Medical Students, (eds Apps D.K., Cohen B.B. & Steel C.M.), 5th
edn, pp. 52-54. Bailliere Tindal.
Aquilla E., Whelchel A., Knot H.J., Nelson M. & Posada J. (1996) Activation of
multiple mitogen-activated protein kinase signal transduction pathways by the
endothelin B receptor requires the cytoplasmic tail. J. Biol. Chem. 271, 31572-31579.
Arai H., Hori S., Aramori I., Ohkubo H. & Nakanishi S. (1990) Cloning and
expression of a cDNA-encoding an endothelin receptor. Nature 348, 730-732.
Asano K., Dutcher D.L., Port J.D. et al. (1997) Selective downregulation of the
angiotensin II AT (l)-receptor subtype in failing human ventricular myocardium.
Circulation 95, 1193-1200.
Bakris G., Bursztyn M., Gavras I., Bresnahan M. & Gavras H. (1997) Role of
vasopressin in essential hypertension: Racial differences. J. Hypertens. 15, 545-550.
Barnes K., Shimada K., Takahashi M., Tanzawa K. & Turner A.J. (1996)
Metallopeptidase inhibitors induce an upregulation of endothelin converting enzyme
levels and its redistribution from the plasma membrane to an intracellular
compartment. J. Cell Sci. 109, 919-928.
Barth W., Deten A., Bauer M. et al. (2000) Differential remodelling of the left and
right heart after norepinephrine treatment in rats: studies on cytokines and collagen.
J. Mol. Cell. Cardiol. 32, 273-284.
204
References
Batra V.K., Mcneilj J.R., Xu Y.J., Wilson TW. & Gopala-Krishnan V. (1993) ETB
receptors on aortic smooth muscle cells of spontaneously hypertensive rats. Am. J.
Physiol. 264, C479-C484.
Battistini B., Chailler P., Dorleansjuste P., Briere N. & Sirois P. (1993) Growth
regulatory properties of endothelins. Peptides 14, 385-399.
Bauersachs D., Fraccarollo D., Hu K. et al. (1998) Chronic ischaemic heart failure in
the rat increases vascular superoxide production by an NADH-dependent oxidase:
contribution to endothelial dysfunction. Circulation 98, 3851.
Bax W.A., Bruinvels A.T., van Sylen R.J., Saxena P.R. & Hoyer D. (1993)
Endothelin receptors in the human coronary artery, ventricle and atrium: a
quantitative autoradiographic analysis. Arch. Pharmacol. 348, 403-410.
Bek E.L. & McMillen M.A. (1999) Endothelin receptor A mediates endothelin-
induced angiogenesis. FASEB J. 13, A362.
Belloni A.S., Andreis P.G., Neri G. & Nussdorfer G.G. (1995) Endothelin-1 (ET-1)
and cyclosporine-A (CsA) stimulate steroid secretion from rat adrenal cortex -
evidence that both ET-1 and CsA secretagogue effects are mediated by the B-subtype
of ET-1 receptors. Biomed. Res.-Tokyo 16, 287-294.
Benigni A. (2000) Endothelin antagonists in renal disease. Kid. Int. 57, 1778-1794.
Berridge M.J. (1993) Inositol trisphosphate and calcium signalling. Nature 361, 315-
325.
Bishop J.E., Greenbaum R., Gibson D.G., Yacoub M. & Laurent G.J. (1990)
Enhanced deposition of predominantly type-I collagen in myocardial disease. J. Mol.
Cell. Cardiol. 22, 1157-1165.
Bishorpic N.H., Simpson P.C. & Ordahl C.P. (1987) Induction of the skeletal alpha-
actin gene in alpha-1 adrenoreceptor-mediated hypertrophy of rat cardiomyocytes. J.
Clin. Invest. 80, 1194.
Bogoyevitch M.A., Glennon P.E., Andersson M.B. et al. (1994) Endothelin-1 and
fibroblast growth factors stimulate the mitogen-activated protein kinase signalling
cascade in cardiac myocytes - the potential role of the cascade in the integration of 2
signalling pathways leading to myocyte hypertrophy. J. Biol. Chem. 269, 1110-1119.
Bohnemeier H., Pinto Y., Horkay F. et al. (2000) Endothelin converting enzyme-1
mRNA expression in human cardiovascular disease. Clin. Exp. Hypertens. 20, 417-
437.
Bokil H.S., Porter J.P. & Joshua I.G. (1999) Decreased endothelin receptor (ETB)
mRNA expression in aortic tissue ofDOCA-salt hypertension. FASEB J. 13, Al 12.
205
References
Bonin P.D., Leadley R.J. & Erickson L.A. (1993) Growth factor induced modulation
of endothelin-1 binding to human smooth muscle cells. J. Cardiovasc. Pharmacol.
22, S125-S127.
Bonvallet S.T., Oka M., Yano M. et al. (1993) BQ-123, an ET (A) Receptor
antagonist, attenuates endothelin-1-induced vasoconstriction in rat pulmonary
circulation. J. Cardiovasc. Pharmacol. 22, 39-43.
Bremnes T., Paasche J.D., Mehlum A. et al. (2000) Regulation and intracellular
trafficking pathways of endothelin receptors. J. Biol. Chem. 275,17596-17604.
Brown L.A., Nunez D.J., Brookes C.I.O. & Wilkins M.R. (1995) Selective increase
in endothelin-1 and endothelin-A receptor subtype in the hypertrophied myocardium
of the aorto-venacaval fistula rat. Cardiovasc. Res. 29, 768-774.
Brunner F., Dutoit E.F., & Opie L.H. (1992) Endothelin release during ischemia and
reperfusion of isolated perfused rat hearts. J. Mol. Cell. Cardiol. 24, 1291-1305.
Brunner F. & Opie L.H. (1996) Endothelin subtype A receptors mediate endothelin-1
effects on ischaemic contracture and reperfusion function in the rat. Circulation 94,
3550.
Bugajski P., Kalawski R., Balinski M. et al. (1999) Plasma-mediated stimulation of
neutrophil superoxide anion production during coronary artery bypass grafting: Role
of endothelin-1. Thorac. Cardiovasc. Surg. 47, 144-147
Bugge E. & Ytrehus K. (1996) Endothelin-1 can reduce infarct size through protein
kinase C and K- ATP channels in the isolated rat heart. Cardiovasc. Res. 32, 920-
929.
Buja L.M. & Entman M.L. (1998) Modes of myocardial cell injury and cell death in
ischaemic heart disease. Circulation 98, 1355-1357.
Burke S.E. & Nelson R.A. (1997) Endothelin-receptor antagonist FR 139317 reduces
infarct size in a rabbit model when given before, but not after, coronary artery
occlusion. J. Cardiovasc. Pharmacol. 29, 87-92.
Burkhardt M., Barton M. & Shaw S.G. (2000) Receptor- and non-receptor-mediated
clearance of big-endothelin and endothelin-1: different effects of acute and chronic
ETa receptor blockade. J. Hypert. 18, 273-279.
Burrell K.M., Molenaar P., Dawson P.J. & Kaumann A.J. (2000) Contractile and
arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade
with SB 209670. J. Pharmacol. Exp. Therapeut. 292, 449-459.
Burrell L.M., Risvanis J., Johnston C.I., Naitoh M. & Balding L.C. (2000)
Vasopressin receptor antagonism -a therapeutic option in heart failure and
hypertension. Exp. Physiol. 85, S259-S265.
206
References
Callah M., Nicoletti A., Arnal J.F. et al. (1995) Cardiac angiotensin converting
enzyme overproduction indicates interstitial activation in renovascular hypertension.
Cardiovasc. Res. 30, 231-239.
Cannan C.R., Burnett J.J.C. & Lerman A. (1996) Enhanced coronary
vasoconstriction to endothelin-B receptor activation in experimental congestive heart
failure. Circulation 93, 646-651.
Cao L. & Gardner D.G. (1995) Natriuretic peptides inhibit DNA-synthesis in cardiac
fibroblasts. Hypertension 25, 227-234.
Carey R.M., Jin X.H., Wang Z.Q. & Siragy H.M. (2000) Nitric oxide: a
physiological mediator of the type 2 (AT(2)) angiotensin receptor. Acta Physiol.
Scand. 168, 65-71.
Cargnelli G., Rossi G.P., Pessina A.C. et al. (1998) Changes of blood pressure and
aortic strip contractile responses to ET-1 of heterozygous female transgenic rats,
TGR(mRen2)27. Pharmacol. Res. 37, 207-211.
Casscells W., Bazoberry F., Speir E. et al. (1990) Transforming growth factor-beta-1
in normal heart and in myocardial-infarction. Ann. New York Acad. Sci. 593, 148-
160.
Cavero P.G., Miller W.L., Heublein D.M., Aarhus L.L. & Burnett J.C.J. (1990)
Endothelin in experimental congestive heart failure in the anaesthetised dog.
Am. J.Physiol. (Renal Fluid Electrolyte Physiol.) 259, F312-F317.
Chanez P., Vignola A.M., Albat B. et al. (1996) Involvement of endothelin in
mononuclear phagocyte inflammation in asthma. J. All. Clin. Immunol. 98, 412-420.
Charney R. & Cohen M. (1993) The role of the coronary collateral circulation in
limiting myocardial ischaemia and infarct size. Am. Heart. J. 126, 937-945.
Cheng W., Kajstura J., Nitahara J.A. et al. (1996) Programmed cell death affects the
viable myocardium after myocardial infarction in rats. Exp. Cell Res. 226, 316-327.
Clerk A. & Sugden P.H. (1997) Regulation of phospholipases C and D in rat
ventricular myocytes: Stimulation by endothelin-1, bradykinin and phenylephrine. J.
Mol. Cell. Cardiol. 29, 1593-1604.
Cleutjens J.P.M., Verluyten M.J.A., Smits J.F.M. & Daemen M.J.A.P. (1995)
Collagen remodelling after myocardial-infarction in the rat-heart. Am. J. Pathol.
147, 325-338.
Cleutjens J.P.M., Blankesteijn W.M., Daemen M.J.A.P. et al. (1999) The infarcted




Clozel M., Gray G.A., Breu V., Loffler B.M. & Osterwalder R. (1992) The
endothelin et(B) Receptor mediates both vasodilation and vasoconstriction in vivo.
Biochem. Biophys. Res. Commun. 186, 867-873.
Coghlan J.P., Aldred P., Haralambidis J. et al. (1985) Hybridisation histochemsitry.
Anal. Biochem. 149, 1-28.
Colucci W.S. (1997) Molecular and cellular mechanisms of myocardial failure. Am.
J. Cardiol. 80 [11A], 15L-25L.
Condorelli G., Morisco C., Stassi G. et al. (1999) Increased cardiomyocyte apoptosis
and changes in pro-apoptotic and anti-apoptotic genes bax and bcl-2 during left
ventricular adaptations to chronic pressure overload in the rat. Circulation 99, 3071-
3078.
Corder R. & Barker S. (1999) The expression of endothelin-1 and endothelin-
converting enzyme-1 (ECE-1) are independently regulated in bovine aortic
endothelial cells. J. Cardiovasc. Pharmacol. 33, 671-677.
Crawford D.C., Chobanian A.V. & Brecher P. (1994) Angiotensin-II induces
fibronectin expression associated with cardiac fibrosis in the rat. Circ. Res. 74, 727-
739.
Cristol J.P., Warner T.D., Thiemermann C. & Vane J.R. (1993) Mediation via
different receptors of the vasoconstrictor effects of endothelins and sarafotoxins in
the systemic circulation and renal vasculature of the anaesthetised rat. Br. J.
Pharmacol. 108, 776-779.
Croft J.B., Giles W.H., Pollard R.A. et al. (1999) Heart failure survival among older
adults in the United States - A poor prognosis for an emerging epidemic in the
Medicare population. Arch. Intern. Med. 159, 505-510.
Cromack D.T., Sporn M.B., Roberts A.B. et al. (1987) Transforming growth-factor
beta levels in rat wound chambers. J. Surg. Res. 42, 622-628.
Cunningham M.E., Bergreen E.W., & McMillen M.A. (1996) Endothelin-stimulated
monocytes and macrophages (M phi) produce neutrophil activating peptide-1 (NAP-
1) and macrophage activating peptide-1 (MCP-1) in vitro. FASEB J. 10, 1483.
Cunningham M.E., Huribal M., Bala R.J. et al. (1997) Endothelin-1 and endothelin-4
stimulate monocyte production of cytokines. Crit. Care Med. 25, 958-964.
Danser A.H.J., Saris J.J., Schuijt M.P. & van Kats J.P. (1999) Is there a local renin-
angiotensin system in the heart? Cardiovasc. Res. 44, 252-265.
Darby I., Skalli O., & Gabbiani G. (1990) Alpha-smooth muscle actin is transiently




Dargie H.J. & McMurray J.J. (1994) Diagnosis and management of heart failure. Br.
Med. J. 308, 321-328.
Darzynkiewicz Z., Bruno S., Delbino G. et al. (1992) Features of apoptotic cells
measured by flow cytometry. Cytometry 13, 795-808.
Davenport A.P., O'Reilly G., Molenaar P., Maguire J., Kuc R.E., Sharkey A., Bacon
C. & Ferro A. (1993) Human endothelin receptors characterised using reverse
transcriptase-polymerase chain reaction, insitu hybridisation, and subtype-selective
ligands BQ-123 and BQ-3020: evidence or expression of ETb receptors in human
vascular smooth muscle. J.Cardiovasc.Pharmacol. 22, S22-S25.
Davenport A.P., Kuc R.E., Plumpton C., Mockridge J.W., Barker P.J. & Huskisson
N.S. (1998) Endothelin-converting enzyme in human tissues. Histochem. J. 30, 359-
374.
Davis R.J. (1995) Transcriptional activation by MAP kinases. Mol. Reprod. & Dev.
42, 459-467.
Dawes K.E., Cambrey A.D., Campa J.S. et al. (1996) Changes in collagen
metabolism in response to endothelin-1: Evidence for fibroblast heterogeneity. Int. J.
Biochem. Cell. Biol. 28, 229-238.
De Lombaert S., Blanchard L., Stamford L.B. et al. (2000) Potent and selective non-
peptide inhibitors of endothelin-converting enzyme-1 with sustained duration of
action. J. Med. Chem. 43, 488-504.
De Mey J.G. & Vanhoutte P.M. (1983) Anoxia and endothelium-dependent
reactivity of the canine femoral artery. J. Physiol. 335, 67-74.
De Mey J.G. & Moeremans M. (1986) Raising and testing polyclonal antibodies for
immunohistochemistry. In: Immunocytochemistry, Modern Methods and
Applications, (eds Polack J.M. & Van Noorden S.), pp. 3-12. Wright, Bristol.
Desmouliere A., Geinoz A., Gabbiani F. & Gabbiani G. (1993) Transforming growth
factor beta-1 induces alpha-smooth muscle actin expression in granulation-tissue
myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122,
103-111.
Detar R. & Bohr D.F. (1972) Contractile responses of isolated vascular smooth
muscle during prolonged exposure to anoxia. Am.J.Physiol. (Heart Circ.Physiol)
222, 1269-1277.
Devesly P., Phillips P.E., Johns A., Rubanyi G. & Parker-Botelho L.H. (1990)
Receptor kinetics differ for endothelin-1 and endothelin-2 binding to swiss 3T3
fibroblasts. Biochem. Biophys. Res. Commun. 172, 126-134.
Dickstein K., Chang P., Willenheimer R. et al. (1995) Comparison of the effects of
losartan and enalapril on clinical status and exercise performance in patients with
moderate or severe chronic heart-failure. J. Am. Coll. Cardiol. 26, 438-445.
209
References
Doggrell S.A. & Brown L. (1998) Rat models of hypertension, cardiac hypertrophy
and failure. Cardiovasc. Res. 39, 89-105.
Douglas S.A., James S. & Hiley C.R. (1991) Endothelial modulation and changes in
endothelin pressor activity during hypoxia in the rat isolated perfused superior
mesenteric arterial bed. Br. J. Pharmacol. 103, 1441-1448.
Douglas S.A., Meek T.D. & Ohlstein E.H. (1994) Novel receptor antagonists
welcome a new era in endothelin biology. TIPS 15, 313-316.
Dupuis J., Goresky C.A. & Fournier A. (1996) Pulmonary clearance of circulating
endothelin-1 in dogs in vivo: Exclusive role of ET(B) receptors. J. App. Physiol. 81,
1510-1515.
Ehrenreich H., Anderson R.W., Fox C.H. et al. (1990) Endothelins, peptides with
potent vasoactive properties, are produced by human macrophages. J. Exper. Med.
172,1741-1748.
Elshourbagy N.A., Lee J.A., Korman D.R. et al. (1992) Molecular-cloning and
characterisation of the major endothelin receptor subtype in porcine cerebellum. Mol.
Pharmacol. 41, 465-473.
Elshourbagy N.A., Korman D.R., Wu H.L. et al. (1993) Molecular characterisation
and regulation of the human endothelin receptors. J. Biol. Chem. 268, 3873-3879.
Emori T., Flirata Y., Ohta K. et al. (1989) Concomitant secretion of big endothelin
and its c-terminal fragment from human and bovine endothelial cells. Biochem.
Biophys. Res. Commun. 162,217-223.
Emori T., Hirata Y. & Marumo F. (1990) Specific receptors for endothelin-3 in
cultured bovine endothelial cells and its cellular mechanism of action. Febs Lett. 263,
261-264.
Emori T., Hirata Y., Ohta K. et al. (1991) Cellular mechanism of endothelin-1
release by angiotensin and vasopressin. Hypertension 18, 165-170.
Emoto N. & Yanagisawa M. (1995) Endothelin-converting enzyme-2 is a membrane-
bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol.
Chem. 270, 15262-15268.
Entman M.L., Youker K., Shappell S.B., Siegel C., Rothlein R., Dreyer W.J.,
Schmalstieg F.C. & Smith C.W. (1990) Neutrophil adherence to isolated adult canine
myocytes - evidence for a cd 18-dependent mechanism. J. Clin. Invest. 85, 1497-
1506.
Ercan Z.S., Ilhan M., Kilinc M. & Turker R.K. (1996) Arrhythmogenic action of




Evans H.G., Lewis M.J. & Shah A.M. (1994) Modulation of myocardial relaxation
by basal release of endothelin from endocardial endothelium. Cardiovasc. Res. 28,
1694-1699.
Fajardo L.F., Prionas S.D., Kwan H.H. et al. (1996) Transforming growth factor beta
1 induces angiogenesis in vivo with a threshold pattern. Lab. Invest. 74, 600-608.
Falk E. & Shah P.K. (1996) Pathology of acute ischaemic syndromes. In: Acute
myocardial infarction and other acute ischaemic syndromes. Ch.3, Edition 8, ed
CaliffRM, Mosby.
Fareh J., Touyz R.M., Schiffrin E.L. & Thibault G. (1996) Endothelin-1 and
angiotensin II receptors in cells from rat hypertrophied heart - Receptor regulation
and intracellular Ca2+ modulation. Circ. Res. 78, 302-311.
Ferrari R. & Agnoletti G. (1989) Atrial natriuretic peptide - its mechanism of release
from the atrium. Int. J. cardiol. 24, 137-149.
Ferrari R., Ceconi C., Curello S. & Visioli O. (1998) The neuroendocrine and
sympathetic nervous system in congestive heart failure. Eur. Heart J. 19, F45-F51.
Filep J.G., Fournier A., & Foldesfilep E. (1995) Acute pro-inflammatory actions of
endothelin-1 in the guinea-pig lung - involvement of ET(A) And ET(B) receptors.
Br. J. Pharmacol. 115, 227-236.
Fishbein M.C., Maclean D. & Maroko P.R. (1978) The histopathological evolution
ofmyocardial infarction. Chest 73, 843-849.
Force T. (1998) Mechanisms of endothelin-induced mitogenesis in vascular smooth
muscle cells. In: Endothelin: Molecular Biology, Physiology, and Pathology., pp.
121-166. Human Press.
Force T. & Bonventre J.V. (1998) Growth factors and mitogen activated protein
kinases. Hypertension 31, 152-161.
Forssmann W.G., Richter R. & Meyer M. (1998) The endocrine heart and natriuretic
peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin
system. Histochem. & Cell Biol. 110, 335-357.
Fraccarollo D., Hu K., Galuppo P. et al. (1997) Chronic endothelin receptor blockade
attenuates progressive ventricular dilatation and improves cardiac function in rats
with myocardial infarction. Circulation 96, 3963-3973.
Frangogiannis N.G., Youker K.A., Rossen R.D. et al. (1998) Cytokines and the
microcirculation in ischemia and reperfusion. J. Mol. Cell. Cardiol. 30, 2567-2576.
Fukuroda T., Noguchi K., Tsuchida S. et al. (1990) Inhibition of biological actions of




Fukuroda T., Fujikawa T., Ozaki S. et al. (1994) Clearance of circulating endothelin-
1 by ET(B) receptors in rats. Biochem. Biophys. Res. Commun. 199, 1461-1465.
Gabriel A., Kuddus R.H., Rao A.S. et al. (1999) Down-regulation of endothelin
receptors by transforming growth factor beta 1 in hepatic stellate cells. Journal of
Hepatology 30, 440-450.
Gall J.G. & Pardue M. (1969) Formation and detection of RNA-DNA hybrid
molecules in cytological preparations. Proc. Natl. Acad. Sci. 63, 378-383.
Galuppo P., Fraccarollo D., Gaudron P. et al. (1999) Endothelin A receptor blockade
after myocardial infarction promotes early infarct expansion. Circulation 100, 2963.
Ganten D., Lindpaintner K., Ganten U. et al. (1991) Transgenic rats -new animal
models in hypertension research. Hypertension 17, 843-855.
Garjani A., Wainwright C.L., Zeitlin I.J., Wilson C. & Slee S.J. (1995) Effects of
endothelin-1 and the ET(A)-Receptor antagonist, BQ-123, on ischaemic arrhythmias
in anaesthetised rats. J. Cardiovasc. Pharmacol. 25, 634-642.
Gavrieli Y., Sherman Y. & Ben-Sasson S.A. (1992) Identification of programmed
cell death in situ via specific labelling of nuclear DNA fragmentation. J. Cell. Biol.
119,493-501.
Geshi E., Nomizo A., Arata Y., et al. (1999) Effect of non-selective endothelin
blockade, TAK-044, on the ischaemic cellular injury of rat heart. Basic Res. Cardiol.
94, 94-101.
Giaid A., Kimura S., Chen M.F. et al. (1991) Immunocytochemical localisation of
endothelin-like immunoreactivity in the heart ofman and rat. Hypertension 17, 444-
445.
Giaid A., Saleh D., Yanagisawa M. & Forbes R.D.C. (1995) Endothelin-1
immunoreactivity and messenger-RNA in the transplanted human heart.
Transplantation 59, 1308-1313.
Gillespie M., Owasayo J., McMurty I. & O'Brien R. (1986) Sustained coronary
vasoconctriction provoked by a peptidergic substance released from endothelial cells
in culture. Jn. Pharmacol. Exp. Ther. 236, 339-343.
Golden C.L., Nick H.S. & Visner G.A. (1998) Thrombin regulation of endothelin-1
gene in isolated human pulmonary endothelial cells. Am. J. Physiol.-Lung Cell.r &
Mol. Physiol. 18, L854-L863.
Goligorsky M.S., Budzikowski A.S., Tsukahara H. et al. (1999) Co-operation
between endothelin and nitric oxide in promoting endothelial cell migration and
angiogenesis. Clin. Exp. Pharmacol. Physiol. 26, 269-271.
212
References
Gonon A.T., Wang Q.D., Shimizu M. et al. (1998) The novel non-peptide selective
endothelin A receptor antagonist LU 135252 protects against myocardial ischaemic
and reperfusion injury in the pig. Acta Physiol. Scand. 16, 131-137.
Gonzalez F., Seth A., Raden D., Bowman D., Fay F. & Davis R. (1993) Serum-
induced translocation of mitogen-activated protein kinase to the cell surface ruffling
membrane and the nucleus. J. Cell Biol. 122, 1089-1101.
Goodwin A.T., Amrani M., Gray G.C., Jayakumar J. & Yacoub M. (1998) Role of
endogenous endothelin in the regulation of basal coronary tone in the rat. J. Physiol.
511,549-557.
Goto K. & Warner T.D. (1995) Molecular pharmacology -endothelin versatility.
Nature 375, 539-540.
Gray G.A., Breu V. & Clozel M. (1995) Endothelin receptors that modulate
contraction of the rat fundus. J. Cardiovasc. Pharmacol. 26, S126-S129.
Gray G.A. & Webb D.J. (1996) The endothelin system and its potential as a
therapeutic target in cardiovascular disease. Pharmacol.Ther. 72, 109-148.
Gray G.A., Mickley E.J., Webb D.J. & McEwan P.E. (2000) Localisation and
function of ET-1 and ET receptors in small arteries post-myocardial infarction:
Upregulation of smooth muscle ETb receptors that modulate contraction. Br. J.
Pharmacol. 130, 1735-1744.
Gray M.O., Long C.S., Kalinyak J.E. et al. (1998) Angiotensin II stimulates cardiac
myocyte hypertrophy via paracrine release of TGF-beta(l) and endothelin-1 from
fibroblasts. Cardiovasc. Res. 40, 352-363.
Gronostajski R.M. (1987) Site-specific DNA-binding of nuclear factor-i - effect of
the spacer region. Nucleic Acids Res. 15, 5545-5559.
Grover G.J., Dzwonczyk S. & Parham C.S. (1993) The endothelin-1 receptor
antagonist BQ-123 reduces infarct size in a canine model of coronary-occlusion and
reperfusion. Cardiovasc. Res. 27, 1613-1618.
Guarda E., Katwa L.C. & Weber K.T. (1993) Effects of endothelin on collagen
turnover in cardiac fibroblasts. Cardiovasc. Res. 27, 2130-2134.
Gui G., Xu D., Emoto N. & Yanagasawia M. (1993) Intracellular localisation of
membrane-bound endothelin-converting enzyme from rat lung. J. Cardiovasc.
Pharmacol. 22, S35-S56.
Hafizi S., Goodwin A.T., Chester A.H. & Yacoub M.H. (1996) Endothelin-1 is a
potent co-mitogen for cultured human coronary artery smooth muscle cells: Synergy
with growth factors. Circulation 94, 1391-1391.
213
References
Hafizi S., Wharton J., Chester A.H. et al. (1998) Endothelin-1 stimulates collagen
synthesis in cultured human cardiac fibroblasts via the ETa receptor. Circulation 98,
922.
Hafizi S., Allen S.P., Goodwin A.T., Chester A.H. & Yacoub M.H. (1999)
Endothelin-1 stimulates proliferation of human coronary smooth muscle cells via the
ETa receptor and is co-mitogenic with growth factors. Atherosclerosis 146, 351-359.
Hagar J.M. (1994) Endogenous endothelin-1 impairs Endothelium-dependent
relaxation after myocardial-ischemia and reperfusion. Am. J. Physiol. (Heart Circ.
Physiol.) 36, HI 833-H1841.
Hand M.F., Haynes W.G. & Webb D.J. (1999) Reduced endogenous endothelin-1 -
mediated vascular tone in chronic renal failure. Kid. Int. 55, 613-620.
Hanehira T., Kohno M. & Yoshikawa J. (1997) Endothelin production in cultured
vascular smooth muscle cells - Modulation by the atrial, brain, and C-type natriuretic
peptide system. Metab.-Clin. & Exp. 46, 487-493.
Hansen C.A., Schroering A.G. & Robishaw J.D. (1995) Subunit expression of signal-
transducing G-proteins in cardiac tissue -implications for phospholipase C-beta
regulation. J. Mol. Cell. Cardiol. 27,471-484.
Harrison V.J., Barnes K., Turner A.J. et al. (1995) Identification of endothelin-1 and
big endothelin-1 in secretory vesicles isolated from bovine aortic endothelial cells.
Proc. Natl. Acad. Sci. 92, 6344-6348.
Haynes W.G. & Webb D.J. (1994) Contribution of endogenous generation of
endothelin-1 to basal vascular tone. Lancet 344, 852-854.
Haynes W.G., Strachan F.E., Gray G.A. & Webb D.J. (1995a) Forearm
vasoconstriction to endothelin-1 is mediated by ET(A) and ET(B) receptors in vivo in
humans. J! Cardiovasc. Pharmacol. 26, S40-S43.
Haynes W.G., Strachan F.E. & Webb D.J. (1995b) Endothelin ET(A) and ET(B)
receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.
Circulation 92, 357-363.
Haynes W.G., Ferro C.J., Okane K.P.J, et al. (1996) Systemic endothelin receptor
blockade decreases peripheral vascular resistance and blood pressure in humans.
Circulation 93, 1860-1870.
Haywood G.A., Gullestad L., Katsuya T. et al. (1997) AT(1) and AT(2) angiotensin
receptor gene expression in human heart failure. Circulation 95, 1201-1206.
Herizi A., Jover B., Bouriquet N. & Mimran A. (1998) Prevention of the




Hide E.J., Piper J. & Thiemermann C. (1995) Endothelin-1-induced reduction of
myocardial infarct size by activation of ATP-sensitive potassium channels in a rabbit
model ofmyocardial-ischaemia and reperfusion. Br. J. Pharmacol. 116, 2597-2602.
Hilaldandan R., Urasawa K. & Brunton L.L. (1992) Endothelin inhibits adenylate-
cyclase and stimulates phosphoinositide hydrolysis in adult cardiac myocytes. J.
Biol. Chem. 267, 10620-10624.
Hillis G.S., Mangione A., Dalsey W. et al. (1999) Neutrophil CD18 adhesion
molecule expression predicts infarct size in a rabbit model of myocardial infarction.
Circulation 100,4284.
Hinson J.P., Kapas S., Teja R. & Vinson G.P. (1991) Effect of the endothelins on
aldosterone secretion by rat zona glomerulosa cells in vitro. J. Ster. Biochem. Mol.
Biol. 40, 437-439.
Hirata Y., Yoshimi H., Takaichi S., Yanagisawa M. & Masaki T. (1988) Binding and
receptor downregulation of a novel vasoconstrictor endothelin in cultured rat
vascular smooth muscle cells. Febs Lett. 239, 13-17.
Hirata Y., Fukuda Y., Yoshimi H. et al. (1989) Specific receptor for endothelin in
cultured rat cardiocytes. Biochem. Biophys. Res. Commun. 160, 1438-1444.
Hirata Y., Kanno K., Watanabe T.X. et al. (1990) Receptor binding and
vasoconstrictor activity of big endothelin. Eur. J. Pharmacol. 176, 225-228.
Hirsch A.T., Talsness C.E., Schunkert H., Paul M. & Dzau V.J. (1991) Tissue-
specific activation of cardiac angiotensin converting enzyme in experimental heart
failure. Circ. Res. 69, 475-482.
Hokimoto S., Yasue H., Fujimoto K. et al. (1996) Expression of angiotensin-
converting enzyme in remaining viable myocytes of human ventricles after
myocardial infarction. Circulation 94, 1513-1518.
Hood W.B., McCarthy B. & Lown B. (1967) Myocardial infarction following
coronary ligation in dogs: haemodynamic effects of isoprotorenol and
acetylstrophantidin. Circ. Res. 21, 199.
Hori S., Komatsu Y., Shigemoto R., Mizuno N. & Nakanishi S. (1992) Distinct
tissue distribution and cellular-localisation of 2 messenger ribonucleic-acids
encoding different subtypes of rat endothelin receptors. Endocrinology 130, 1885-
1895.
Hosoda K., Nakao K., Tamura N. et al. (1992) Organisation, structure, chromosomal
assignment, and expression of the gene encoding the human endothelin-a receptor. J.
Biol. Chem. 267, 18797-18804.
Hosoda K., Hammer R.E., Richardson J.A. et al. (1994) Targeted and natural
(Piebald-lethal) Mutations of endothelin-b receptor gene produce megacolon
associated with spotted coat colour in mice. Cell 79, 1267-1276.
215
References
Hsu S.M., Raine L. & Fanger H. (1981) Use of avidin-biotin-peroxidase complex
(ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled
antibody (PAP) procedures. J. Histochem. Cytochem. 29, 577-580.
Hu J., Discher D.J., Bishopric N.H. & Webster K.A. (1998) Hypoxia regulates
expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1
binding site on the antisense strand. Biochem. Biophys. Res. Commun. 245, 894-899.
Hu K., Gaudron P., Schmidt T.J., et al. (1998) Aggravation of left ventricular
remodelling by a novel specific endothelin ETA antagonist EMD94246 in rats with
experimental myocardial infarction. J. Cardiovasc. Pharmacol. 32, 505-508.
Hupf H., Grimm D., Riegger G.A.J. & Schunkert H. (1999) Evidence for a
vasopressin system in the rat heart. Circ. Res. 84, 365-370.
Hutchinson I.V. (1998) An endothelin-transforming growth factor beta pathway in
the nephrotoxicity of immunosuppressive drugs. Curr. Opin. Nephrol. Hypert. 7,
665-671.
Ichikawa K., Hidai C., Okuda C. & Kimata S. (1996) Endogenous endothelin-1
modulates cardiac hypertrophy and switching ofmyosin heavy chain gene expression
in rat ventricular myocardium. J! Am. Coll. Cardiol. 27, 1286-1291.
Ignarro L.J. (1989) Endothelium-derived nitric oxide -actions and properties. FASEB
J. 3,31-36.
Ikura T., Sawamura T., Shiraki T. et al. (1994) cDNA cloning and expression of
bovine endothelin-converting enzyme. Biochem. Biophys. Res. Commun. 203, 1417-
1422.
Imai T., Hirata Y., Eguchi S. et al. (1992) Concomitant expression of receptor
subtype and isopeptide of endothelin by human adrenal-gland. Biochem. Biophys.
Res. Commun. 182, 1115-1121.
Inoue A., Yanagisawa M., Kimura S. et al. (1989) The human endothelin family - 3
structurally and pharmacologically distinct isopeptides predicted by 3 separate genes.
Proc. Natl. Acad. Sci. 86, 2863-2867.
Ishikawa T., Yanagisawa M., Kimura S., Goto K. & Masaki T. (1988) Positive
inotropic action of novel vasoconstrictor peptide endothelin on guinea-pig atria. Am.
J. Physiol. 255, H970-H973. " '
Ito H., Hirata Y. & Hiroe M. (1991) Endothelin-1 induces hypertrophy with
enhanced expression of muscle-specific genes in cultured neonatal rat
cardiomyocytes. Circ. Res. 69, 209-215.
Itoh H., Pratt R.E. & Dzau V.J. (1990) Atrial natriuretic polypeptide inhibits
hypertrophy of vascular smooth muscle cells. J. Clin. Invest. 86, 1690-1697.
216
References
Iverson O.H. (1989) The cell kinetics of the inflammatory reaction. Introduction and
overview. Curr. Top. Path. 79, 1-5.
James A.F., Xie L.H., Fujitani Y., Hayashi S. & Horie M. (1994) Inhibition of the
cardiac protein-kinase A-dependent chloride conductance by endothelin-1. Nature
370, 297-300.
John H.A. & Birnstiel M.L. (1969) RNA-DNA hybrids at the cytological level.
Nature 223, 582-587.
Jordan J.E., Zhao Z.Q. & Vinten-Johansen J. (1999) The role of neutrophils in
myocardial ischemia-reperfusion injury. Cardiovasc. Res. 43, 860-878.
Kaddoura S. & PooleWilson P.A. (1996) Endothelin-1 in heart failure: A new
therapeutic target? Lancet 348,418-419.
Kajstura J., Cheng W., Reiss K. et al. (1996) Apoptotic and necrotic myocyte cell
deaths are independent contributing variables of infarct size in rats. Laboratory
Investigation 74, 86-107.
Kanno K., Hirata Y., Tsujino M. et al. (1993) Up-regulation of ETb receptor subtype
mRNA by angiotensin II in rat cardiomyocytes. Biochem. Biophys. Res. Commun.
194, 1282-1286.
Kanse S.M., Takahashi K., Lam H.C. et al. (1991) Cytokine stimulated endothelin
release from endothelial cells. Life Sci. 48, 1379-1384.
Karaki H., Sudjarwo A., Elori M. et al. (1993) Induction of Endothelium-dependent
relaxation in the rat aorta by IRL-1620, a novel and selective agonist at the
endothelin ET(B)- Receptor. Br. J. Pharmacol. 109, 486-490.
Karne S., Jayawickreme C.K. & Lerner M.R. (1993) Cloning and characterisation of
an endothelin-3 specific receptor ET(C) Receptor From xenopus-laevis dermal
melanophores. J. Biol. Chem. 268, 19126-19133.
Katwa L.C., Guarda E. & Weber K.T. (1993) Endothelin receptors in cultured adult-
rat cardiac fibroblasts. Cardiovasc. Res. 27, 2125-2129.
Katwa L.C., Campbell S.E., Tanner M.A. & Myers P.R. (1999) The upregulation of
endothelin and its receptors in porcine coronary arteries in a double balloon injury
model of restenosis. Basic Res. Cardiol. 94, 445-453.
Kelso E.J., McDermott B.J., Silke B. & Spiers J.P. (1996) Contractile effects of
endothelin-1 and endothelin-3, mediated by ET(A) and ET(B) receptor subtypes, in
ventricular cardiomyocytes isolated from rabbit myocardium. Br. J. Pharmacol. 118,
131.
Kelso E.J., McDermott B.J., Silke B. & Spiers J.P. (2000) Endothelin A receptor
subtype mediates endothelin-induced contractility in left ventricular cardiomyocytes
isolated from rabbit myocardium. J. Pharmacol. Exp. Ther. 294, 1047-1052.
217
References
Khan M.A., Dashwood M.R., Mumtaz F.H. et al. (1999) Upregulation of endothelin
a receptor sites in the rabbit diabetic kidney: Potential relevance to the early
pathogenesis of diabetic nephropathy. Nephron 83, 261-267.
Kim S. & Iwao H. (2000) Molecular and cellular mechanisms of angiotensin II-
mediated cardiovascular and renal diseases. Pharmacol. Rev. 52, 11-34.
King J.M., Srivastava K.D., Stefano G.B. et al. (1997) Human monocyte adhesion is
modulated by endothelin B receptor-coupled nitric oxide release. J. Immunol. 158,
880-886.
King K.L., Winer J. & Mather J.P. (1996) Endogenous cardiac vasoactive factors
modulate endothelin production by cardiac fibroblasts in culture. Endocrine 5, 95-
102.
Kiowski W., Sutsch G., Hunziker P. et al. (1995) Evidence for endothelin-1-
mediated vasoconstriction in severe chronic heart failure. Lancet 346, 732-736.
Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L. et al. (1993) Adult human aortic
smooth muscle cells in culture produce active TGF- beta. Am. J. Physiol. 265, C571-
C576.
Kloog Y., Ambar I., Sokolovsky M. et al. (1988) Sarafotoxin, a novel
vasoconstrictor peptide -phosphoinositide hydrolysis in rat-heart and brain. Science
242, 268-270.
Kobayashi T., Miyauchi T., Sakai S. et al. (1999) Expression of endothelin-1, ETa
and ETb receptors, and ECE and distribution of endothelin-1 in failing rat heart. Am.
J. Physiol. (Heart Circ. Physiol.) 45, H1197-H1206.
Kohan D.E. (1997) Endothelins in the normal and diseased kidney. American
Journal ofKidney Diseases 29, 2-26.
Kojda G., Kottenberg K., Nix P. et al. (1996) Low increase in cGMP induced by
organic nitrates and nitro-vasodilators improves contractile response of rat
ventricular myocytes. Circ. Res. 78, 91-101.
Kojima M., Kusumoto K., Fujiwara S. et al. (1995) Role of endogenous endothelin
in the extension of myocardial infarct size studied with the endothelin receptor
antagonist, TAK-044. J. Cardiovasc. Pharmacol. 26, S365-S368.
Kourembanas S., Marsden P.A., Mcquillan L.P. et al. (1991) Hypoxia induces
endothelin gene-expression and secretion in cultured human endothelium. J. Clin.
Invest. 88, 1054-1057.
Kourembanas S., Morita T., Liu Y.X. & Christou H. (1997) Mechanisms by which




Kulkarni A.B., Huh C.G., Becker D. et al. (1993) Transforming growth factor-beta-1
null mutation in mice causes excessive inflammatory response and early death. Proc.
Natl. Acad. Sci. 90, 770-774.
Kumar C., Mwangi V., Nuthulaganti P. et al. (1994) Cloning and characterisation of
a novel endothelin receptor from xenopus heart. J. Biol. Chem. 269, 13414-13420.
Kurihara H., Yoshizumi M., Sugiyama T. et al. (1989) Transforming growth factor-
beta stimulates the expression of endothelin messenger-RNA by vascular endothelial
cells. Biochem. Biophys. Res. Commun. 159, 1435-1440.
Kurihara Y., Kurihara H., Suzuki H. et al. (1994) Elevated blood pressure and
craniofacial abnormalities in mice deficient in endothelin-1. Nature 368, 703-710.
Kusumoto K., Fujiwara A., Ikeda S., Watanabe T. & Fujino M. (1996)
Pharmacological characterisation of cardiovascular responses induced by endothelin-
1 in the perfused rat heart. Eur. J. Pharmacol. 296, 65-74.
Kuwaki T., Cao W.H. & Kumada M. (1994) Endothelin in the brain and its effect on
central control of the circulation and other functions. Jap. J. Physiol. 44, 1-18.
Kuwaki T., Kurihara Y., Kurihara H., Yazaki Y. & Kumada M. (1995) Role of
endothelin in central cardiorespiratory control - modern and classical approaches.
News in Physiol. Sci. 10, 228-233.
Krause S.M., Lynch J.J., Stabilito 1.1., & Woltmann R.F. (1994) Intravenous
administration of the endothelin-1 antagonist BQ-123 does not ameliorate
myocardial ischaemic injury following acute coronary artery occlusion in the dog.
Cardiovasc. Res. 28, 1672-1678.
Krum H., Charlon V., Wildmann T., & Packer M. (1999) Long-term open-label
experience with an endothelin receptor antagonist, bosentan, in patients with severe
chronic heart failure. Circulation 100, A3408.
Kuizinga M.C., Smits J.F.M., Arends J.W. et al. (1998) AT(2) receptor blockade
reduces cardiac interstitial cell DNA synthesis and cardiac function after rat
myocardial infarction. J. Mol. Cell. Cardiol. 30, 425-434.
Kurihara H., Yoshizumi M., Sugiyama T. et al. (1989) Transforming growth factor-
beta stimulates the expression of endothelin messenger-RNA by vascular endothelial
cells. Biochem. Biophys. Res. Commun. 159, 1435-1440.
Lai H., Williams K.I. & Woodward B. (1998) Comparative study of effects of ET-1,
big ET-1 and SX6C in rat isolated pulmonary arteries and veins. Br. J. Pharmacol.
123,291.
Lang R.M., Elkayam U., Yellen L.G. et al. (1997) Comparative effects of losartan
and enalapril on exercise capacity and clinical status in patients with heart failure. J.
Am. Coll. Cardiol. 30, 983-991.
219
References
La Villa G., Lazzeri C., Fronzaroli C., Franchi F. & Gentilini P. (1995) Brain
natriuretic peptide. Ann. Ital. Med. Int. 10, 233-241.
Lechat P., Packer M., Chalon S. et al. (1998) Clinical effects of beta-adrenergic
blockade in chronic heart failure - A meta-analysis of double-blind, placebo-
controlled, randomised trials. Circulation 98, 1184-1191.
Lechat P., Brunhuber K.W., Hofmann R., et al. (1999) The Cardiac Insufficiency
Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13.
Lechleitner P. (1993) Endothelin-1 in patients with complicated and uncomplicated
myocardial infarction. Clin. Invest. 70, 1070-1072.
Lee A.A., Dillmann W.H., Mcculloch A.D. et al. (1995) Angiotensin-II stimulates
the autocrine production of transforming growth factor-beta-1 in adult rat cardiac
fibroblasts. J. Mol. Cell. Cardiol. 27, 2347-2357.
Lee J.Y., Warner R.B., Adler A.L. et al. (1994) The ETa receptor antagonist
FR139317 reduces myocardial infarction induced by coronary artery occlusion and
reperfusion in the rat. FASEB J. 8, A854.
Lenormand P., Sardet C. et al. (1993) Growth factors induce nuclear translocation of
MAP kinases (P42(Mapk) And p44(Mapk)) but not of their activator MAP kinase
kinase (P45(Mapkk)) in fibroblasts. J. Cell Biol. 122, 1079-1088.
Li H.B., Chen S.J., Chen Y.F. et al. (1994) Enhanced endothelin-1 and endothelin
receptor gene expression in chronic hypoxia. J. App. Physiol. 77, 1451-1459.
Li J.M. & Brooks G. (2000) Differential protein expression and subcellular
distribution of TGF beta-1, beta-2 and beta-3 in cardiomyocytes during pressure
overload-induced hypertrophy. J. Mol. Cell. Cardiol. 29, 2213-2224.
Lijnen P. & Petrov V. (1999) Renin-angiotensin system, hypertrophy and gene
expression in cardiac myocytes. J. Mol. Cell. Cardiol. 31, 949-970.
Lin H.Y., Kaji E.H., Winkel G.K., Ives H.E. & Lodish H.F. (1991) Cloning and
functional expression of a vascular smooth muscle endothelin-1 receptor. Proc. Natl.
Acad. Sci. 88, 3185-3189.
Lindpaintner K., Lu W.Y., Niedermajer N. et al. (1993) Selective activation of
cardiac angiotensinogen gene expression in post-infarction ventricular remodelling in
the rat. J. Mol. Cell. Cardiol. 25, 133-143.
Ling B.N. (1994) Luminal endothelin-1 inhibits apical Na and CI channels in
cultured rabbit CCT principal cells. J. Am. Soc. Neph. 5, 292.
Liu Y.H., Yang X.P., Sharov V.G. et al. (1997) Effects of angiotensin-converting
enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart




Loffler B.M., Kalina B. & Kunze H. (1991) Partial characterisation and subcellular-
distribution patterns of endothelin-1, endothelin-2 and endothelin-3 binding sites in
human liver. Biochem. Biophys. Res. Commun. 181, 840-845.
Lonn E. & McKelvie R. (2000) Regular review - Drug treatment in heart failure. Br.
Med. J. 320, 1188-1192.
Love M.P., Haynes W.G., Webb D.J. & McMurray J.J.V. (1994) Anti-endothelin
therapy is of potential benefit in heart failure. Circulation 90, 547.
MacCarthy P.A., Grocott-Mason R., Prendergast B.D. & Shah A.M. (2000)
Contrasting inotropic effects of endogenous endothelin in the normal and failing
human heart - Studies with an intra-coronary ETa receptor antagonist. Circulation
101, 142-147.
Macchi C., Malendowicz L.K., Meneghelli V. & Nussdorfer G.G. (1999)
Endothelin-1 stimulates arginine-vasopressin and atrial natriuretic peptide release by
rat adrenal medulla: receptor subtypes involved and possible functional relevance.
Med. Sci. Res. 27, 163-165.
Machado R.D.P., Santos R.A.S., & Andrade S.P. (1999) Opposing actions of
angiotensins on angiogenesis. Life Sci. 66, 67-76.
MacKenna B.R. & Calander R. (1997) Transport Sysytems: The heart, blood vessels
and body fluids. In: Illustrated Physiology, 6th edn, pp. 102-108. Churchill
Livingstone.
MacLellan W.R. & Schneider M.D. (1997) Death by design - Programmed cell death
in cardiovascular biology and disease. Circ. Res. 81, 137-144.
MacMahon S., Sharpe N., Doughty R., et al. (1997) Randomised, placebo-controlled
trial of carvedilol in patients with congestive heart failure due to ischaemic heart
disease. Lancet 349, 375-380.
Maguire J.J., Kuc R.E., Oreilly G. & Davenport A.P. (1994) Vasoconstrictor
endothelin receptors characterised in human renal artery and vein in vitro. Br. J.
Pharmacol. 113,49-54.
Malatino L.S., Grassi R., Stancanelli B. et al. (1993) Release of immunoreactive
endothelin from the heart during percutaneous transluminal coronary angioplasty.
Am. Heart. J. 126, 700-702.
Malek A.M., Zhang J., Jiang J.W., Alper S.L. & Izumo S. (1999) Endothelin-1 gene
suppression by shear stress: Pharmacological evaluation of the role of tyrosine
kinase, intracellular calcium, cytoskeleton, and mechanosensitive channels. J. Mol.
Cell. Cardiol. 31, 387-399.
Margulies K.B., Hildebrand F.L., Lerman A., Perrella M.A. & Burnett J.C. (1990)
Increased endothelin in experimental heart failure. Circulation 82, 2226-2230.
221
References
Maroko P.R., Kjekshus J.K. & Sobel B.E. (1971) Factors influencing infarct size
following experimental coronary artery occlusions. Circulation 67, 1016-1023.
Marx N., Neumann F.J., Ott I. et al. (1997) Induction of cytokine expression in
leukocytes in acute myocardial infarction. J. Am. Coll. Cardiol. 30, 165-170.
Massart P.E., Hodeige D.G., Van Mechelen EI. et al. (1998) Angiotensin II and
endothelin-1 receptor antagonists have cumulative hypotensive effects in canine Page
hypertension. J. Hypertens. 16, 835-841.
Mathison Y. & Israel A. (1998) Endothelin ETb receptor subtype mediates nitric
oxide cGMP formation in rat adrenal medulla. Brain Res. Bull. 45, 15-19.
Matsumoto T., Wada A., Tsutamoto T. et al. (1999) Vasorelaxing effects of atrial
and brain natriuretic peptides on coronary circulation in heart failure. Am. J. Physiol.
(Heart Circ. Physiol.) 45, H1935-H1942.
Matsumura Y., Hisaki K., Takaoka M. & Morimoto S. (1990) Phosphoramidon, a
metalloprotease inhibitor, suppresses the hypertensive effect of big endothelin-1.
Eur. J. Pharmacol 185, 103-106.
Maxwell M.J., Goldie R.G. & Henry P.J. (1998) Ca2+ signalling by endothelin
receptors in rat and human cultured airway smooth muscle cells. Br. J. Pharmacol.
125, 1768-1778.
Maxwell M.P., Hearse D.J. & Yellon D.M. (1987) Species variation in the coronary
circulation during regional myocardial ischaemia: a critical determinant of the rate of
evolution and extent ofmyocardial infarction. Cardiovasc. Res. 21, 737-746.
McDonald D., Bailie J., Archer D. & Chakravarthy U. (1995) Molecular
characterisation of endothelin receptors and the effect of insulin on their expression
in retinal microvascular pericytes. J. Cardiovasc. Pharmacol. 26, S287-S289.
McEwan P.E., Valdenaire O., Sutherland L., Webb D.J. & Gray G.A. (1998a) A non¬
radioactive method for localisation of endothelin receptor mRNA in situ. J.
Cardiovasc. Pharmacol. 31, S443-S446.
McEwan P.E., Sherry L., Webb D.J. & Gray G.A. (1998b) Localisation of
myocardial prepro endothelin-1 mRNA and endothelin-1 in a rat model of chronic
heart failure. J. Mol. Cell. Cardiol. 30, A101.
McEwan P.E., Sherry L., Kenyon C.J., Webb D.J. & Gray G.A. (2000) Regulation of
the myocardial endothelin system by angiotensin II and losartan. J. Cardiovasc.
Pharmacol, in press.
McKay R.G., Pfeffer M.A., Pasternak R.C. et al. (1986) Left-ventricular remodelling




McMillen M.A., Huribal M., Cunningham M.E. et al. (1995) Endothelin-1 increases
intracellular calcium in human monocytes and causes production of interleukin-6.
Crit. Care Med. 23, 34-40.
McMurdo L., Corder R., Thiemermann C. & Vane J.R. (1993) Incomplete inhibition
of the pressor effects of endothelin-1 and related peptides in the anaesthetised rat
with BQ-123 provides evidence for more than one vasoconstrictor receptor. Br. J.
Pharmacol. 108,557-561.
McMurray J.J., Ray S.G., Abdullah I., Dargie H.J. & Morton J.J. (1992) Plasma
endothelin in chronic heart failure. Circulation 85, 1374-1379.
Meyer M., Lehnart S., Pieske B. et al. (1996) Influence of endothelin 1 on human
atrial myocardium - Myocardial function and subcellular pathways. Basic Res.
Cardiol. 91, 86-93.
Michel J.B., Lattion A.L., Salzmann J.L. et al. (1988) Hormonal and cardiac effects
of converting enzyme inhibition in rat myocardial infarction. Circ. Res. 62, 641-650.
Michel J.B., Nicolletti A. & Arnal J.F. (1995) Left ventricular remodelling following
experimental myocardial infarction. Eur. Heart J. 16, 49-57.
Mickley E.J., Gray G.A. & Webb D.J. (1997) Activation of endothelin ET(A)
receptors masks the constrictor role of endothelin ET(B) receptors in rat isolated
small mesenteric arteries. Br. J. Pharmacol. 120, 1376-1382.
Minshall R.D., Nakamura F., Becker R.P. & Rabito S.F. (1995) Characterisation of
bradykinin B2 receptors in adult myocardium and neonatal rat cardiomyocytes. Circ.
Res. 76, 773-780.
Miyauchi T., Yanagisawa M., Tomizawa T. et al. (1989) Increased plasma-
concentrations of endothelin-1 and big endothelin-1 in acute myocardial-infarction.
Lancet 2, 53-54.
Miyauchi T. & Goto K. (1999) Heart failure and endothelin receptor antagonists.
TIPS, 20, 210-217.
Miyauchi T. & Masaki T. (1999) Pathophysiology of endothelin in the
cardiovascular system. Ann. Rev. Physiol. 61, 391-415.
Molenaar P., Oreilly G., Sharkey A. et al. (1993) Characterisation and localisation of
endothelin receptor subtypes in the human atrio-ventricular conducting system and
myocardium. Circ. Res. 72, 526-538.
Molet S., Furukawa K., Maghazechi A., Hamid Q. & Giaid A. (2000) Chemokine-
and cytokine-induced expression of endothelin-1 and endothelin converting enzyme -
1 in endothelial cells. J. All. Clin. Immunol. 105, 333-338.
Moncada S. & Higgs E.A. (1991) Endogenous nitric oxide - physiology, pathology
and clinical relevance. Eur. J. Clin. Invest. 21, 361-374.
223
References
Moody C.J., Dashwood M.R., Sykes R.M. et al. (1990) Functional and
autoradiographic evidence for endothelin-1 receptors on human and rat cardiac
myocytes - comparison with single smooth muscle cells. Circ. Res. 67, 764-769.
Morawietz H., Talanow R., Szibor M. et al. (2000) Regulation of the endothelin
system by shear stress in human endothelial cells. J. Physiol. 525, 761-770.
Mortensen L.H. (1999) Endothelin and the central and peripheral nervous systems: A
decade of endothelin research. Clin. Exp. Pharmacol. Physiol. 26, 980-984.
Mulder P., Richard V., Derumeaux G. et al. (1997) Role of endogenous endothelin in
chronic heart failure. Circulation 96, 1976-1982.
Mulder P., Richard V., Bouchart F. et al. (1998) Selective ETA receptor blockade
prevents left ventricular remodelling and deterioration of cardiac function in
experimental heart failure. Cardiovasc. Res. 39, 600-608.
Mulder P., Boujedaini H., Richard V. et al. (2000) Selective endothelin-A versus
combined endothelin-A/endothelin-B receptor blockade in rat chronic heart failure.
Circulation 102, 491-493.
Mullan D.M., Bell D., Kelso E.J. & McDermott B.J. (1997) Involvement of
endothelin (ET)A and ETB receptors in the hypertrophic effects of ET-1 in rabbit
ventricular cardiomyocytes. J. Cardiovasc. Pharmacol. 29, 350-359.
Mylona P. & Cleland J.G.F. (1999) Update of REACH-1 and MERIT-HF clinical
trials in heart failure. Eur. J. Heart Failure 1, 197-200.
Naitoh M., Power J., Phillips P.A. et al. (1998) Effects of chronic AVP V2 receptor
blockade in congestive heart failure in sheep - Comparison with chronic ACE
inhibition. Adv. Exp. Med. Biol. 449, 445-446.
Nakahara S., Emoto N. & Matsuo M. Isolation of an alternative spliced variant of
bovine ECE-2. (1999) ET-6 Conference Proceeding
Nakamura M., Arakawa N., Yoshida H. et al. (1993) Increased plasma endothelin
concentrations in patients with acute heart failure after myocardial infarction. Jap.
Circ. J. -Eng ed. 57, 371-378.
Nambi P., Pullen M., Wu H.L. et al. (1992) Dexamethasone down-regulates the
expression of endothelin receptors in vascular smooth muscle cells. J. Biol. Chem.
267, 19555-19559.
Naruse M., Kawana M., Hifumi S. et al. (1991) Plasma-immunoreactive endothelin,
but not thrombomodulin, is increased in patients with essential hypertension and
ischaemic heart disease. J. Cardiovasc. Pharmacol. 17, S471-S474.
Nelissen-Vrancken H.J., Debets J.J.M., Snoeckx L.H.E.H. et al. (1996) Time-related
normalisation of maximal coronary flow in isolated perfused hearts of rats with
myocardial infarction. Circulation 93, 349-355.
224
References
Nicoletti A. & Michel J.B. (1999) Cardiac fibrosis and inflammation: interaction
with hemodynamic and hormonal factors. Cardiovasc. Res. 41, 532-543.
Nio Y., Matsubara H., Murasawa S., Kanasaki M. & Inada M. (1995) Regulation of
gene-transcription of angiotensin-II receptor subtypes in myocardial infarction. J.
Clin. Invest. 95, 46-54.
Nitta K., Uchida K., Kimata N. et al. (1995) Endothelin-1 mediates erythropoietin-
stimulated glomerular endothelial cell-dependent proliferation of mesangial cells.
Eur. J. Pharmacol.-Environ. Toxicol. Pharmacol. Section 293, 491-494.
Nolly H.L., Damiani M.T., Miatello R.M. & Abate C.D. (1997) Kallikrein,
kininogen and kinins released from isolated perfused rat hearts. Hypertension 29,
255.
Nunez D.J.R., Brown M.J., Davenport A.P. et al. (1990) Endothelin-1 messenger-
RNA is widely expressed in porcine and human tissues. J. Clin. Invest. 85, 1537-
1541.
Ohnishi H., Oka T., Kusachi S. et al. (1998) Increased expression of connective
tissue growth factor in the infarct zone of experimentally induced myocardial
infarction in rats. J. Mol. Cell. Cardiol. 30, 2411-2422.
0ie E., Vinge L.E., Tonnessen T. et al. (1997) Transient, isopeptide-specific
induction ofmyocardial endothelin-1 mRNA during congestive heart failure in rats.
Am. J. Physiol. (Heart Circ. Physiol.) 273, H1727-H1736.
0ie E., Bjonerheim R., Grogaard H.K. et al. (1998) ET-receptor antagonism,
myocardial gene expression, and ventricular remodelling during CHF in rats. Am. J.
Physiol. (Heart Circ. Physiol. ) 275, H868-H877.
O'Kane S. & Ferguson M.W. (1997) Transforming growth factor betas and wound
healing. Int. J. Biochem. Cell. Biol. 29, A78.
Okazawa M., Shiraki T., Ninomiya El., Kobayashi S. & Masaki T. (1998)
Endothelin-induced apoptosis of A375 human melanoma cells. J. Biol. Chem. 273,
12584-12592.
Olivetti G., Abbi R., Quaini F. et al. (1997) Apoptosis in the failing human heart.
New Eng. J. Med. 336, 1131-1141.
Omland T., Lie R.T., Aakvaag A., Aarsland T. & Dickstein K. (1994) Plasma
endothelin determination as a prognostic indicator of one-year mortality after acute
myocardial infarction. Circulation 89, 1573-1579.
Ono K., Eto K., Sakamoto A. et al. (1995) Negative chronotropic effect of




Ono K., Matsumori A., Shioi T., Furukawa Y. & Sasayama S. (1998) Cytokine gene
expression after myocardial infarction in rat hearts. Circulation 98, 149-156.
Opgaard O.S., Cantera L., Adner M. & Edvinsson L. (1996) Endothelin-A and -B
receptors in human coronary arteries and veins. Reg. Peptides 63, 149-156.
Orzechowski H.D., Richter C.M., Funke-Kaiser H. et al. (1997) Evidence of
alternative promoters directing isoform-specific expression of human endothelin
converting enzyme-1 mRNA in cultured endothelial cells. J. Mol. Med. 75, 512-521.
Ozaka T., Doi Y., Kayashima K. & Fujimoto S. (1997) Weibel-Palade bodies as a
storage site of calcitonin gene-related peptide and endothelin-1 in blood vessels of
the rat carotid body. Anatom. Rec. 247, 388-394.
Pacher R., Berglerklein J., Globits S. et al. (1993) Plasma big endothelin-1
concentrations in congestive heart failure patients with or without systemic
hypertension. Am. J. Cardiol. 71, 1293-1299.
Pacher R., Stanek B., Hulsmann M. et al. (1996) Prognostic impact of big
endothelin-1 plasma concentrations compared with invasive hemodynamic
evaluation in severe heart failure. J. Am. Coll. Cardiol. 27, 633-641.
Packer M., Bristow M.R., Cohn J.N. et al. (1996) The effect of carvedilol on
morbidity and mortality in patients with chronic heart failure. New Eng. J. Med. 334,
1349-1355.
Packer M., Caspi A., Charlon V. et al. (1998) Multicenter, double-blind, placebo-
controlled study of long-term endothelin blockade with bosentan in chronic heart
failure - Results of the REACH-1 trial. Circulation 98, 12.
Parameshwar J., Shackell M.M., Richardson A., Poole-Wilson P.A. & Sutton G.C.
(1992) prevalence of heart failure in 3 general practices in northwest London. Br. J.
Gen. Pract. 42, 287-289.
Parker T.G., Packer S.E. & Schneider M.D. (1990a) Peptide growth factors can
provoke fetal contractile protein gene expression in rat cardiac myocytes. J. Clin.
Invest. 85, 507-514.
Parker T.G., Chow K.L., Schwartz R.J. & Schneider M.D. (1990b) Modulation of
cardiac and skeletal alpha-actin promoters in cardiac myocytes exhibits discordant
control by TGF beta-1 and fibroblast growth factors. Clin. Res. 38, A239.
Parmley W.W. (1985) Pathophysiology of congestive heart failure. Am. J. Cardiol.
55, A9-A14.
Passier R.C.J.J., Smits J.F.M., Verluyten M.J.A. et al. (1995) Activation of
angiotensin-converting enzyme expression in infarct zone following myocardial
infarction. Am. J. Physiol. (Heart Circ. Physiol.) 38, H1268-H1276.
226
References
Passier R.C.J.J., Smits J.F.M., Verluyten M.J.A. et al. (1996) Expression and
localization of renin and angiotensinogen in rat heart after myocardial infarction. Am.
J. Physiol. (Heart Circ. Physiol.) 40, H1040-H1048.
Paul M., Bachmann J. & Ganten D. (1992) The tissue renin-angiotensin systems in
cardiovascular disease. Trends in Cardiovasc. Med. 2, 94-99.
Paul M., Stoll M., Kreutz R. & Fernandez-Alfonso M.S. (1996) The cellular basis of
angiotensin converting enzyme mRNA expression in rat heart. Basic Res. Cardiol.
91, 57-63.
Peeters A.C.T.M., Netea M.G., Kullberg B.J. et al. (1998) The effect of renin-
angiotensin system inhibitors on pro- and anti- inflammatory cytokine production.
Immunology 94, 376-379.
Peiper G.M., Todd G.L., Wu S.T. et al. (1980) Attenuation of myocardial acidosis by
propranolol during ischaemic arrest and reperfusion. Cardiovasc. Res. 14, 646-653.
Peiro C., Redondo J., Rodriguez-Martinez M.A. et al. (1995) Influence of
Endothelium on cultured vascular smooth muscle cell proliferation. Hypertension 25,
748-751.
Pernow J. & Wang Q.D. (1997) Endothelin in myocardial ischaemia and reperfusion.
Cardiovasc. Res. 33, 518-526.
Perry G., Brown E., Thornton R. et al. (1997) The effect of digoxin on mortality and
morbidity in patients with heart failure. New Eng. J. Med. 336, 525-533.
Pfeffer M.A., Pfeffer J.M., Fishbein M.C. et al.. (1979) Myocardial infarct size and
ventricular function in rats. Circ. Res. 44, 503-512.
Pfeffer M.A., Lamas G.A., Vaughan D.E., Parisi A.F. & Braunwald E. (1988) Effect
of captopril on progressive ventricular dilatation after anterior myocardial infarction.
New Eng. J. Med. 319, 80-86.
Pfeffer M.A. & Braunwald E. (1990) Ventricular remodelling after myocardial
infarction -experimental observations and clinical implications. Circulation 81,
1161-1172.
Pfeffer M.A. (1995) Left ventricular remodelling after acute myocardial infarction.
Annu.Rev.Med. 46, 455-466.
Piacentini L., Gray M., Honbo N.Y. et al. (2000) Endothelin-1 stimulates cardiac
fibroblast proliferation through activation of protein kinase C. J. Mol. Cell. Cardiol.
32, 565-576.
Piano M.R., Bondmass M. & Schwertz D.W. (1998) The molecular and cellular
pathophysiology of heart failure. Heart & Lung 27, 3-19.
227
References
Picard P., Smith P.J.W., Monge J.C. et al. (1998) Co-ordinated upregulation of the
cardiac endothelin system in a rat model of heart failure. J. Cardiovasc. Pharmacol.
31, S294-S297.
Plumpton C., Champeney R., Ashby M.J., Kuc R.E. & Davenport A.P. (1993)
Characterisation of endothelin isoforms in human heart: endothelin-2 demonstrated.
J. Cardiovasc. Pharmacol. 22, S26-S28.
Plumpton C., Ashby M.J., Kuc R.E., Oreilly G. & Davenport A.P. (1996) Expression
of endothelin peptides and mRNA in the human heart. Clin. Sci. 90, 37-46.
Poole-Wilson P.A. (1989) Chronic heart failure. Causes, pathophysiology, prognosis,
clinical manifestations, investigations.
Prins B.A., Hu R.M., Nazario B. et al. (1994) Prostaglandin E(2) and prostacyclin
inhibit the production and secretion of endothelin from cultured endothelial cells. J.
Biol. Chem. 269, 11938-11944.
Quian S.W., Kondaiah P., Casscells W., Roberts A.B. & Spiorn M.B. (1991) A
second messenger RNA species of transforming growth factor beta 1 in infarcted rat
heart. Cell Reg. 2, 241-249.
Rebsamen M.C., Church D.J., Morabito D., Vallotton M.B. & Lang U. (1997) Role
of cAMP and calcium influx in endothelin-1-induced ANP release in rat
cardiomyocytes. Am.J.Physiol. (Endocrine Physiol.) 273, 922-931.
Resink T.J., Scott-Burden T., Boulanger C., Weber E. & Buhler F.R. (1990a)
Internalisation of endothelin by cultured human vascular smooth muscle cells -
characterisation and physiological significance. Mol. Pharmacol. 38, 244-252.
Resink T.J., Hahn A.W.A., Scott-Burden T. et al. (1990b) Inducible endothelin
messenger RNA expression and peptide secretion in cultured human vascular smooth
muscle cells. Biochem. Biophys. Res. Commun. 168, 1303-1310.
Rich M.W. (1997) Epidemiology, pathophysiology, and etiology of congestive heart
failure in older adults. J. Am. Geriatric. Soc. 45, 968-974.
Riches D.W.H. (1996) Macrophage involvement in wound repair, remodelling, and
fibrosis. In: The Molecular and Cellular Biology of Wound Repair., 2nd edn, pp. 95-
141. Plenum Press, New York.
Rodeheffer R.J.A., Lerman D., Heublein M. & Burnett J.C.J. (1992) Increased
plasma concentration of endothelin in congestive heart failure in humans. Mayo.
Clin. Proc. 67, 719-724.
Rosen B., Barg J. & Zimlichman R. (1999) The effects of angiotensin II, endothelin-
1, and protein kinase C inhibitor on DNA synthesis and intracellular calcium
mobilisation in vascular smooth muscle cells from young normotensive and
spontaneously hypertensive rats. Am. J. Hypertens. 12, 1243-1251.
228
References
Rossi G.P., Sacchetto A., Cesari M. & Pessina A.C. (1999) Interactions between
endothelin-1 and the renin- angiotensin- aldosterone system. Cardiovasc. Res. 43,
300-307.
Rubanyi G.M. & Polokoff M.A. (1994) Endothelins -molecular biology,
biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol. Rev. 46,
325-415.
Rubanyi G.M. & Vanhoutte P.M. (2000) Hypoxia releases a vasoconstrictor
substance from canine vascular endothelium. J. Physiol. 364, 45-56.
Ruetten H., Thiemermann C. & Vane J.R. (1996) Endothelin-1 enhances the
synthesis of tumour necrosis factor-alpha in cultured macrophages and in the
anaesthetised rat. Br. J. Pharmacol. 117, 31.
Ruiz-Ortega M., Gomez-Garre D., Liu X.H. et al. (1997) Quinapril decreases renal
endothelin-1 expression and synthesis in a normotensive model of immune-complex
nephritis. J. Am. Soc. Neph. 8, 756-768.
Rumberger J.A. (1994) Ventricular dilatation and remodelling after myocardial-
infarction. Mayo Clin. Proceedings 69, 664-674.
Russell F.D., Skepper J.N. & Davenport A.P. (1998) Human endothelial cell storage
granules - A novel intracellular site for isoforms of the endothelin-converting
enzyme. Circ. Res. 83, 314-321.
Ruwhof C. & van der Laarse A. (2000) Mechanical stress-induced cardiac
hypertrophy: mechanisms and signal transduction pathways. Cardiovasc. Res. 47,
23-37.
Sadoshima J. & Izumo S. (1993) Molecular characterisation of angiotensin-II-
induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts -
critical role of the AT(1) receptor subtype. Circ. Res. 73, 413-423.
Sakai S., Miyauchi T., Sakurai Y. et al. (1996a) Endogenous endothelin-1
participates in the maintenance of cardiac function in rats with congestive heart
failure: marked increase in endothelin-1 production in the failing heart. Circulation
93,1214-1222.
Sakai S., Miyauchi T., Kobayashi M. et al. (1996b) Inhibition of myocardial
endothelin pathway improves long-term survival in heart failure. Nature 384, 353-
355.
Sakai S., Miyauchi T., Kobayashi T. et al. (1998) Altered expression of isoforms of
myosin heavy chain mRNA in the failing rat heart is ameliorated by chronic




Sakai S., Miyauchi T. & Yamaguchi I. (2000) Long-term endothelin receptor
antagonist administration improves alterations in expression of various cardiac genes
in failing myocardium of rats with heart failure. Circulation 101, 2849-2853.
Sakamoto A., Yanagisawa M., Sakurai T. et al. (1991) Cloning and functional
expression of human cDNA for the ETb endothelin receptor. Biochem. Biophys. Res.
Commun. 178, 656-663.
Sakurai T., Yanagisawa M., Takuwa Y. et al. (1990) Cloning of a cDNA-encoding a
non-isopeptide-selective subtype of the endothelin receptor. Nature 348, 732-735.
Sakurai T., Yanagisawa M., Inoue A. et al. (1991) cDNA cloning, sequence-analysis
and tissue distribution of rat preproendothelin-1 messenger RNA. Biochem. Biophys.
Res. Commun. 175,44-47.
Sargent C.A., Liu E.C.K., Chao C.C., Webb M.L. & Grover G.J. (1994) Role of
endothelin receptor subtype B (ETb) in myocardial ischaemia. Life Sci. 55, 1833-
1844.
Sawa Y., Ichikawa H., Kagisaki K. et al. (1998) Interleukin-6 derived from hypoxic
myocytes promotes neutrophil-mediated reperfusion injury in myocardium. J.
Thorac. Cardiovasc. Surg. 116, 511-517.
Schaper W. & Pasyk S. (1976) Influence of collateral flow on the ischaemic
tolerance of the heart following acute and subacute coronary occlusion. Circulation
53, 157-162.
Schirger J.A., Hornig El., Ondrej L. & Burnett J.C. (1999) Early initiation of ETA
receptor antagonism improves cardiovascular hemodynamics in severe but not mild
experimental CE1F. Circulation 98, A14.
Schmidt M., Kroger B., Jacob E. et al. (1994) Molecular characterisation of human
and bovine endothelin converting enzyme (ECE-1). Febs Lett. 356, 238-243.
Schrier R.W., Abdallah J.G., Weinberger H.H.D. & Abraham W.T. (2000) Therapy
of heart failure. Kid. Int. 57, 1418-1425.
Schunkert H., Dzau V.J., Tang S.S. et al. (1990) Increased rat cardiac angiotensin
converting enzyme activity and messenger RNA expression in pressure overload left
ventricular hypertrophy -effects on coronary resistance, contractility, and relaxation.
J. Clin. Invest. 86, 1913-1920.
Schunkert H., Jahn L., Izumo S., Apstein C.S. & Lovell B.H. (1991) Localisation and
regulation of c-fos and c-jun protooncogene induction by systolic wall stress in
normal and hypertrophied rat hearts. P.C.N.A. 88, 11480-11484.
Schunkert H., Jackson B., Tang S.S. et al. (1993) Distribution and functional




Schweizer A., Valdenaire O., Nelbock P. et al. (1997) Human endothelin-converting
enzyme (ECE-1): three isoforms with distinct subcellular localisations. Biochem. J.
328, 871-877.
Selye H., Bajusz E., Grasso S. & Mendell P. (1960) Simple technique for the surgical
occlusion of coronary vessels in rats. Angiology 11, 398-407.
Seo B., Oemar B.S., Siebenmann R. et al. (1994) Both ET(A) And ET(B) Receptors
mediate contraction to endothelin-1 in human blood-vessels. Circulation 89, 1203-
1208.
Setsuta K. (1995) Origin and pathophysiological role of increased plasma endothelin-
1 in patients with acute myocardial infarction. Angiology 46, 557-565.
Sharif I., Kane K.A. & Wainwright C.L. (1998) Endothelin and ischaemic
arrhythmias -antiarrhythmic or arrhythmogenic? Cardiovasc. Res. 39, 625-632.
Shetty S.S., Okada T., Webb R.L., Delgrande D. & Lappe R.W. (1993) Functionally
distinct endothelin-B receptors in vascular endothelium and smooth muscle.
Biochem. Biophys. Res. Commun. 191, 459-464.
Shibata S., Himeno A., Shigematsu K. et al. (1997) Endothelin receptors in rat
pituitary gland. Cell. Mol. Neurobiol. 17, 89-100.
Shimada K., Takahashi M. & Tanzawa K. (1994) Cloning and functional expression
of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 269,
18275-18278.
Shimoyama H., Sabbah H.N., Borzak S. et al. 1996) Short-term hemodynamic
effects of endothelin receptor blockade in dogs with chronic heart failure.
Circulation 94, 779-784.
Shubeita H.E., Mcdonough P.M. et al. (1990) Endothelin induction of inositol
phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in
ventricular myocytes -a paracrine mechanism for myocardial cell hypertrophy. J.
Biol. Chem. 265, 20555-20562.
Singer R.H., Lawerence J.B. & Villnave C. (1986) Optimisation of in situ
hybridisation using isotopic and non-isotopic detection methods. Biotechniques 4,
230.
Smith P.J.W., Ornatsky O., Stewart D.J. et al. (2000) The effects of estrogen-
replacement on infarct size, cardiac remodelling, and the endothelin system
following myocardial infarction in ovariectomised rats. Circulation In Press.




Smits van Krimpen C., Schoemaker R.G. et al. (1992) Angiotensin II
receptor blockade after myocardial infarction in rats: effects on hemodynamics,
myocardial DNA synthesis, and interstitial collagen content. J. Cardiovasc.
Pharmacol. 20, 772-778.
Sokolovsky M. (1994) Endothelins and sarafotoxins -receptor heterogeneity. Int. J.
Biochem. 26, 335-340.
Spratt J.C.S., Goddard J., Labinjoh C. et al. (1999) The haemodynamic effects of
systemic endothelin A receptor antagonism in healthy humans in vivo. Br. J. Clin.
Pharmacol. 47, 576.
Stein B., Frank P., Schmitz W., Scholz H. & Thoenes M. (1996) Endotoxin and
cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via
induction of nitric oxide synthase. J. Mol. Cell. Cardiol. 28, 1631-1639.
Stewart D.J., Kubac G., Costello K.B. & Cernacek P. (1991) Increased plasma
endothelin-1 in the early hours of acute myocardial infarction. J. Am. Coll. Cardiol.
18,38-43.
Stewart D.J., Teichert-Kuliszewska K., Bendeck M.P. et al. (1996) Expression of
nitric oxide synthase III and endothelin-1 in an in vitro model of angiogenesis.
Circulation 94, 895.
Strachan F.E., Spratt J.C., Wilkinson I.B. et al. (1999) Systemic blockade of the
endothelin-B receptor increases peripheral vascular resistance in healthy men.
Hypertension 33, 581-585.
Sudjarwo S.A., Hori M., Tanaka T. et al. (1994) Subtypes of endothelin ET(A) and
ET(B) receptors mediating venous smooth muscle contraction. Biochem. Biophys.
Res. Commun. 200, 627-633.
Sugden P.H. & Bogoyevitch M.A. (1996) Endothelin-1-dependent signalling
pathways in the myocardium. Trends in Cardiovasc. Med. 6, 87-94.
Sumner M.J., Cannon T.R., Mundin J.W., White D.G. & Watts I.S. (1992)
Endothelin ETa and endothelin ETb receptors mediate vascular smooth muscle
contraction. Br. J. Pharmacol. 107, 858-860.
Sun Y.O. & Ramires F.J.A. (1996) Transforming growth factor-beta 1 (TGF-beta 1)
receptor binding in the infarcted rat heart. Circulation 94, 747.
Sun Y.O., Zhang J.Q., Zhang J.K. et al. (1998) Angiotensin II, transforming growth
factor-beta(l) and repair in the infarcted heart. J. Mol. Cell. Cardiol. 30, 1559-1569.
Sun Y.O. & Weber K.T. (2000) Infarct scar: a dynamic tissue. Cardiovasc. Res. 46,
250-256.
Sun Y.O., Zhang J.Q., Zhang J. et al. (2000) Cardiac remodelling by fibrous tissue
after infarction in rats. J. Lab. Clin. Med. 135, 316-323.
232
References
Sunako M., Kawahara Y. & Kariya K. (1989) Endothelin-induced biphasic formation
of 1,2-diacylglycerol in cultured rabbit vascular smooth muscle cells - mass analysis
with a radio-enzymatic assay. Biochem. Biophys. Res. Commun. 160, 744-750.
Suzuki T., Kumazaki T., & Mitsui Y. (1993) Endothelin-1 is produced and secreted
by neonatal rat cardiac myocytes in vitro. Biochem. Biophys. Res. Commun. 191,
823-830.
Swan EI.J.C. (1993) Left ventricular systolic and diastolic dysfunction in the acute
phases of myocardial ischaemia and infarction, and in the later phases of recovery.
Eur. Heart J. 14, SA48-SA56.
Swedberg K. (1987) Effects of enalapril on mortality in severe congestive-heart-
failure -results of the co-operative north Scandinavian enalapril survival study
(CONSENSUS). New Eng. J. Med. 316, 1429-1435.
Swynghedauw B. (1999) Molecular mechanisms ofmyocardial remodelling. Physiol.
Rev.s 79, 215-262.
Takahashi M., Matsushita Y., Iijima Y. & Tanzawa K. (1993) Purification and
characterisation of endothelin-converting enzyme from rat lung. J. Biol. Chem. 268,
21394-21398.
Takahashi N., Calderone A., Izzo J.N.J, et al. (1994) Hypertrophic stimuli induce
transforming growth factor beta-1 expression in rat ventricular myocytes.
J.Clin.Invest. 94, 1470-1476.
Takanashi M. & Endoh M. (1991) Characterization of positive inotropic effect of
endothelin on mammalian ventricular myocardium. Am. J. Physiol. 261, H611-H619.
Takemura G., Ohno M., Hayakawa Y. et al. (1998) Role of apoptosis in the
disappearance of infiltrated and proliferated interstitial cells after myocardial
infarction. Circ. Res. 82, 1130-1138.
Takuwa N., Takuwa Y., Yanagisawa M., Yamashita K. & Masaki T. (1989) A novel
vasoactive peptide endothelin stimulates mitogenesis through inositol lipid turnover
in swiss 3T3 fibroblasts. J. Biol. Chem. 264, 7856-7861.
Tamura T., Said S., Harris J., Lu W. & Gerdes A.M. (2000) Reverse remodelling of
cardiac myocyte hypertrophy in hypertension and failure by targeting of the renin-
angiotensin system. Circulation 102, 253-259.
Teerlink J.R., Loffler B.M., Hess P., Maire J.P., Clozel M. & Clozel J.P. (1994) Role
of endothelin in the maintenance of blood pressure in conscious rats with chronic
heart failure -acute effects of the endothelin receptor antagonist Ro-47-0203
(bosentan). Circulation 90, 2510-2518.
Tharaux P.L., Chatziantoniou C., Casellas D. et al. (1999) Vascular endothelin-1
gene expression and synthesis and effect on renal type I collagen synthesis and




Thompson N.L., Bazoberry F., Speir E. et al. (1988) Transforming growth factor
beta-1 in acute myocardial infarction in fats. Growth Fac. 1, 91-99.
Timms A.D. & Davies S.W. (2000) In: Heart Failure, Grower Medical Publishing.
Tomita H., Egashira K., Ohara Y. et al. (1998) Early induction of transforming
growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis
induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32,
273-279.
Tomita K., Nonoguchi H. & Marumo F. (1990) Effects of endothelin on peptide-
dependent cyclic adenosine monophosphate accumulation along the nephron
segments of the rat. J. Clin. Invest. 85, 2014-2018.
Tomita K., Nonoguchi H., Terada Y. & Marumo F. (1993) Effects of ET-1 on water
and chloride transport in cortical collecting ducts of the rat. Am. J. Physiol. 264,
F690-F696.
Tonnessen T., Giaid A., Yanagasawia M. et al. (1993) Release of endothelin from
the porcine heart after short-term coronary artery occlusion. Cardiovasc. Res. 27,
1482-1485.
Tonnessen T., Giaid A., Yanagasawia M. & Christensen G. (1995) Increased in vivo
expression and production of endothelin-1 by porcine cardiomyocytes subjected to
ischaemia. Circ. Res. 76,161-112.
Tonnessen T., Christensen G., Oie E..et al.. (1997) Increased cardiac expression of
endothelin-1 mRNA in ischaemic heart failure in rats. Cardiovasc. Res. 33, 601-610.
Tonnessen T., Lunde P.K., Giaid A. et al. (1998) Pulmonary and cardiac expression
of preproendothelin-1 mRNA are increased in heart failure after myocardial
infarction in rats. Localisation of preproendothelin-1 mRNA and endothelin peptide.
Cardiovasc. Res. 39, 633-643.
Trocha S.D., Jones S.P., Kevil C.G. et al. (1999) Adhesion molecule deficient mice
and myocardial ischaemia-reperfusion injury. Circulation 100, A2869.
Turner A.J. & Murphy L.J. (1995) Molecular pharmacology of endothelin converting
enzymes. Biochem. Pharmacol. 51, 91-102.
Tzanidis A. & Lim S. (1999) Does endothelin mediate cardiac fibrosis following
myocardial infarction via activation of transforming growth factor beta 1?
Circulation 100, A279.
Uddman E., Moller S., Adner M. & Edvinsson L. (1999) Cytokines induce increased
endothelin ETb receptor-mediated contraction. Eur. J. Pharmacol. 376, 223-232.
Unger T., Culman J. & Gohlke P. (1998) Angiotensin II receptor blockade and end-
organ protection: pharmacological rationale and evidence. J. Hypert. 16, S3-S9.
234
References
Urata H., Kinoshita A., Perez D.M. et al. (1991) Cloning of the gene and cDNA for
human heart chymase. J. Biol. Chem. 266, 17173-17179.
Valdenaire O., Rohrbacher E. & Mattei M.G. (1995) Organisation of the gene
encoding the human endothelin-converting enzyme (ECE-1). J. Biol. Chem. 270,
29794-29798.
Valdenaire O., Lepailleur-Enouf D., Egidy G. et al. (1999) A fourth isoform of
endothelin-converting enzyme (ECE-1) is generated from an additional promoter -
Molecular cloning and characterisation. Eur. J. Biochem. 264, 341-349.
Velasco C.E., Yanagisawa M., Williamson J.L. & Triana J.F. (1993)
Cardioprotective action of endothelin-1 during ischemia. Circulation 88, 544.
Vigne P., Marsault R., Breittmayer J.P. & Frelin C. (1990) Endothelin stimulates
phosphatidylinositol hydrolysis and DNA -synthesis in brain capillary endothelial
cells. Biochem. J. 266, 415-420.
Vila-PetroffM.G., Younes A., Egan J., Lakatta E.G. & Sollott S.J. (1999) Activation
of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in
cardiac myocytes. Circ. Res. 84, 1020-1031.
Villaschi S. & Nicosia R.F. (1994) Paracrine interactions between fibroblasts and
endothelial cells in a serum-free coculture model -modulation of angiogenesis and
collagen gel contraction. Lab. Invest. 71, 291-299.
Vitola J.V., Forman M.B., Holsinger J.P. et al. (1996) Role of endothelin in a rabbit
model of acute myocardial infarction: Effects of receptor antagonists. J. Cardiovasc.
Pharmacol. 28, 774-783.
Vonlutterotti N., Catanzaro D.F., Sealey J.E. & Laragh J.H. (1994) Renin is not
synthesised by cardiac and extrarenal vascular tissues - a review of experimental
evidence. Circulation 89, 458-470.
Vracko R., Thorning D. & Frederickson R.G. (1989) Connective tissue cells in
healing rat myocardium -a study of cell reactions in rhythmically contracting
environment. Am. J. Pathol. 134, 993-1006.
Wahl G.M., Stern M. & Stark G.R. (1979) Efficient transfer of large DNA fragments
from agarose gels to diazobenzyloxymtehyl paper and rapid hybridisation by using
dextran sulfate. Proc. Natl. Acad. Sci. 76, 3683-3687.
Wahl S.M., McCartney-Francis N., Allen J.B. et al. (1990) Macrophage production
of TGF-beta and regulation by TGF-beta. Ann. New YorkAcc. Sci. 593, 188-196.
Wang D.L., Chen J.J., Shin N.L. et al. (1992) Endothelin stimulates cardiac alpha-




Wang Q.D., Li X.S. & Pernow J. (1994) Characterisation of endothelin-1 -induced
vascular effects in the rat heart by using endothelin receptor antagonists. Eur. J.
Pharmacol. 271, 25-30.
Wang Q.D., Hemsen A., Li X.S. et al. (1995) Local overflow and enhanced tissue
content of endothelin following myocardial ischaemia and reperfusion in the pig -
modulation by L- arginine. Cardiovasc. Res. 29, 44-49.
Wang Y.Z., Pouyssegur J. & Dunn M.J. (1994) Endothelin stimulates mitogen-
activated protein kinase activity in mesangial cells through ET(A). J. Am. Soc. Neph.
5, 1074-1080.
Warford A. (1988) In situ hybridisation -a new tool in pathology. Med. Lab. Sci. 45,
381-394.
Watanabe T., Suzuki N., Shimamoto N., Fujino M. & Imada A. (1991) Contribution
of endogenous endothelin to the extension of myocardial infarct size in rats. Circ.
Res. 69, 370-377.
Weber K.T., Janicki J.S., Shroff S.G. et al. (1988) Collagen remodelling of the
pressure overloaded, hypertrophied non-human primate myocardium. Circ. Res. 62,
757-765.
Weber K.T. & Brilla C.G. (1991) Pathological hypertrophy and cardiac interstitium -
fibrosis and renin-angiotensin-aldosterone system. Circulation 83, 1849-1865.
Weber K.T., Sun Y., Tyagi S.C. & Cleutjens J.P.M. (1994) Collagen network of the
myocardium: Function, structural remodelling and regulatory mechanisms. J. Mol.
Cell. Cardiol. 26, 279-292.
Weber K.T. (1997) Extracellular matrix remodelling in heart failure -A role for de
novo angiotensin II generation. Circulation 96, 4065-4082.
Wei C.M., Heublein D.M., Perrella M.A. et al. (1993) Natriuretic peptide system in
human heart failure. Circulation 88, 1004-1009.
Wei C.M., Lerman A., Rodeheffer R.J. et al. (1994) Endothelin in human congestive
heart failure. Circulation 89, 1580-1586.
Weissberg P.L., Witchell C., Davenport A.P., Hesketh T.R. & Metcalfe J.C. (1990)
The endothelin peptides ET-1, ET-2, ET-3 and sarafotoxin S6b are co-mitogenic
with platelet-derived growth factor for vascular smooth muscle cells. Atherosclerosis
85, 257-262.
Wharton J., Rutherford R.A.D., Gordon L. et al. (1991) Localisation of endothelin
binding sites and endothelin-like immunoreactivity in human fetal heart. J.
Cardiovasc. Pharmacol. 17, S378-S384.
Whittaker P. (1997) Collagen and ventricular remodelling after acute myocardial
infarction: Concepts and hypotheses. Basic Res. Cardiol. 92, 79-81.
236
References
Wieczorek I., Haynes W.G., Webb D.J. et al. (1994) Raised plasma endothelin in
unstable angina and non-q-wave myocardial infarction -relation to cardiovascular
outcome. Br. Heart J. 72, 436-441.
Willingham M.C. (1999) Cytochemical methods for the detection of apoptosis. J.
Histochem. Cytochem. 47, 1101-1109.
Wollert K.C. & Drexler H. (1999) The renin-angiotensin system and experimental
heart failure. Cardiovasc. Res. 43, 838-849.
Xu D., Emoto N., Giaid A., Slaughter C., Kaw S., Dewit D. & Yanagisawa M.
(1994) ECE-1 -a membrane-bound metalloprotease that catalyses the proteolytic
activation of big endothelin-1. Cell 78,473-485.
Yamazaki T., Kudoh S., Zou Y.Z. et al. (1995) Endothelin-1 and angiotensin II
synergistically mediate stretch-induced cardiac hypertrophy. Circulation 90, [suppl
I], A569.
Yanagisawa H., Yanagisawa M. et al. (1998) Dual genetic pathways of endothelin-
mediated intercellular signalling revealed by targeted disruption of endothelin
converting enzyme-1 gene. Development 125, 825-836.
Yanagisawa M., Kurihara H., Kimura S. et al. (1988) A novel potent vasoconstrictor
peptide produced by vascular endothelial cells. Nature 332, 411-415.
Yaoita H., Ogawa K., Maehara K. & Maruyama Y. (2000) Apoptosis in relevant
clinical situations: contribution of apoptosis in myocardial infarction. Cardiovasc.
Res. 45, 630-641.
Yeh Y.C., Burns E.R., Yeh J. & Yeh H.W. (1991) Synergistic effects of endothelin-1
(ET-1) and transforming growth factor-alpha (TGF-alpha) or epidermal growth
factor (EGF) on DNA replication and Gi to S-phase transition. Biosci. Reports 11,
171-180.
Yokokawa K., Tahara H., Kohno M. et al. (1993) Heparin regulates endothelin
production through Endothelium-derived nitric oxide in human endothelial cells. J.
Clin. Invest. 92, 2080-2085.
Yorikane R., Sakai S., Miyauchi T. et al. (1993) Increased production of endothelin-
1 in the hypertrophied rat heart due to pressure overload. Febs Lett. 332, 31-34.
Zeidel ML., Brady HR., Kone B., Gullans SR. & Brenner BM. (1989) Endothelin, a
peptide inhibitor of Na+/K+ ATPase in intact tubular epithelial cells.
Am.J.Physiol.(Heart Circ.Physiol) 257, CI 101-C1107.
Zhang Y., Oliver J.R., & Horowitz J.D. (1998) Endothelin B receptor-mediated




Ziche M., Morbidelli L., Donnini S. et al. (1995) ET(B) receptors promote
proliferation and migration of endothelial cells. J. Cardiovasc. Pharmacol. 26, S284-
S286.
Zile M.R., Tomita M., Ishihara K. et al. (1993) Changes in diastolic function during
development and correction of chronic LV volume overload produced by mitral
regurgitation. Circulation 87, 1378-1388.
Zouki C., Baron C., Founder A. et al. (1999) Endothelin-1 enhances neutrophil
adhesion to human coronary artery endothelial cells: role of ETA receptors and
platelet-activating factor. Br. J. Pharmacol. 127, 969-979.
238
